


**CUMULATIVE
SUPPLEMENT 10
OCTOBER 2015**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs**

2015

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION Cumulative

Supplement 10

October 2015

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement.....	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend.....	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List.....	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List.....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution.....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists.....	A-1
B. Patent and Exclusivity Terms.....	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION CUMULATIVE

**SUPPLEMENT 10
October 2015**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 35th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
AGILA SPECIALTIES PRIVATE LTD (AGILA SPECLTS)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
EXCELLIUM PHARMACEUTICAL INC (EXCELLIUM)	LEADING PHARMA LLC (LEADING PHARMA LLC)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
ONCO THERAPIES LTD (ONCO THERAPIES LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
REDKITT BENCKISER PHARMACEUTICALS INC (RECKITT BENCKISER)	INDIVIOR INC (INDIVIOR INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies

to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2014</u>	<u>MAR 2015</u>	<u>JUN 2015</u>	<u>SEPT 2015</u>	<u>DEC 2015</u>
DRUG PRODUCTS LISTED	16150	16352	16543	16824	
SINGLE SOURCE	2572 (15.9%)	2608 (15.9%)	2586 (15.6%)	2613 (15.5%)	
MULTISOURCE	13578 (84.1%)	13744 (84.1%)	13957 (84.4%)	14211 (84.5%)	
THERAPEUTICALLY EQUIVALENT	13443 (83.2%)	13610 (83.2%)	13832 (83.6%)	14089 (83.7%)	
NOT THERAPEUTICALLY EQUIVALENT	135 (0.8%)	134 (0.8%)	125 (0.8%)	122 (0.7%)	
EXCEPTIONS ¹	77 (0.5%)	75 (0.5%)	75 (0.5%)	75 (0.4%)	
NEW MOLECULAR ENTITIES APPROVED	13	22	12	37	
NUMBER OF APPLICANTS	927	935	957	975	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.

CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN

SOLUTION;IV (INFUSION)
 ACETAMINOPHEN

>A> FRESENIUS KABI USA 1GM/100ML (10MG/ML) N204767 001 Oct 28, 2015 Oct NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN

>A> AA TEDOR PHARMA INC 325MG;50MG A205120 001 Oct 30, 2015 Oct NEWA

BUTAPAP

>D> + MIKART 325MG;50MG A089987 001 Oct 26, 1992 Oct CTEC

>A> AA + 325MG;50MG A089987 001 Oct 26, 1992 Oct CTEC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL

FIORICET

@ ACTAVIS LABS UT INC 325MG;50MG;40MG

A088616 001 Nov 09, 1984 Feb CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

FIORICET W/ CODEINE

AB + ACTAVIS LABS UT INC 325MG;50MG;40MG;30MG N020232 001 Jul 30, 1992 Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA SUN PHARM INDS LTD 300MG;30MG A085868 001 Apr CAHN

AA 300MG;60MG A087083 001 Apr CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA + MIKART 325MG;2.5MG A040846 001 Jun 09, 2010 Feb CTEC

@ SUN PHARM INDS LTD 325MG;10MG A040826 001 Aug 16, 2007 Apr CAHN

NORCO

AA ACTAVIS LABS FL INC 325MG;2.5MG A040148 004 Jul 07, 2014 Feb NEWA

AA 325MG;5MG A040148 005 Jul 07, 2014 Feb NEWA

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

DIAMOX

AB + TEVA BRANDED PHARM 500MG N012945 001 Jun CAHN

ACETOHEXAMIDE

TABLET;ORAL

ACETOHEXAMIDE

@ ANI PHARMS INC 250MG A070869 001 Feb 09, 1987 Jul CAHN

@ 500MG A070870 001 Feb 09, 1987 Jul CAHN

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

AP AKORN INC 6GM/30ML (200MG/ML) A203173 001 Mar 24, 2015 Mar NEWA

AP MYLAN INSTITUTIONAL 6GM/30ML (200MG/ML) A203624 001 Jun 19, 2015 Jun NEWA

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

AN ALVOGEN INC 10% A204674 001 Feb 11, 2014 Sep CAHN

AN 20% A203853 001 Jun 21, 2012 Sep CAHN

ACITRETIN

CAPSULE;ORAL

ACITRETIN

AB MYLAN PHARMS INC 10MG A202148 001 Sep 10, 2015 Aug NEWA

AB 17.5MG A203707 001 Sep 10, 2015 Aug NEWA

AB 22.5MG A203707 002 Sep 10, 2015 Aug NEWA

AB 25MG A202148 002 Sep 10, 2015 Aug NEWA

AB SIGMAPHARM LABS LLC 10MG A204633 001 May 22, 2015 May NEWA

AB 17.5MG A204633 002 May 22, 2015 May NEWA

AB 22.5MG A204633 003 May 22, 2015 May NEWA

	CAPSULE;ORAL							
	ACITRETIN							
AB		25MG		A204633	004	May 22, 2015	May	NEWA
	<u>ACOLIDINIUM BROMIDE</u>							
	POWDER, METERED; INHALATION							
	TUDORZA PRESSAIR							
	+	ASTRAZENECA PHARMS	0.375MG/INH	N202450	001	Jul 23, 2012	Apr	CAHN
	+		0.4MG/INH	N202450	001	Jul 23, 2012	Aug	CPOT
	<u>ACYCLOVIR</u>							
	TABLET;ORAL							
	ACYCLOVIR							
AB		SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998	Apr	CAHN
AB			800MG	A074980	002	Sep 30, 1998	Apr	CAHN
	<u>ADAPALENE; BENZOYL PEROXIDE</u>							
	GEL;TOPICAL							
	ADAPALENE AND BENZOYL PEROXIDE							
AB		ACTAVIS MID ATLANTIC	0.1%;2.5%	A203790	001	Sep 30, 2015	Sep	NEWA
	EPIDUO							
AB	+	GALDERMA LABS LP	0.1%;2.5%	N022320	001	Dec 08, 2008	Sep	CFTG
	EPIDUO FORTE							
	+	GALDERMA LABS	0.3%;2.5%	N207917	001	Jul 15, 2015	Aug	CAHN
	+	GALDERMA R AND D	0.3%;2.5%	N207917	001	Jul 15, 2015	Jul	NEWA
	<u>ADENOSINE</u>							
	INJECTABLE; INJECTION							
	ADENOSINE							
AP		EUROHLTH INTL SARL	3MG/ML	A076500	001	Jun 16, 2004	Jun	CAHN
	@		3MG/ML	A076501	001	Jun 16, 2004	Sep	CAHN
	@	WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009	May	DISC
	<u>ALBENDAZOLE</u>							
	TABLET, CHEWABLE;ORAL							
	ALBENZA							
	+	AMEDRA PHARMS LLC	200MG	N207844	001	Jun 11, 2015	Jun	NEWA
	<u>ALBUTEROL SULFATE</u>							
	POWDER, METERED; INHALATION							
	PROAIR RESPICLICK							
	+	TEVA BRANDED PHARM	EQ 0.090MG BASE/INH	N205636	001	Mar 31, 2015	Mar	NEWA
	SYRUP;ORAL							
	ALBUTEROL SULFATE							
AA		G AND W LABS INC	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Apr	CAHN
	<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>							
	AEROSOL, METERED; INHALATION							
	COMBIVENT							
	@	BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291	001	Oct 24, 1996	May	DISC
	<u>ALFUZOSIN HYDROCHLORIDE</u>							
	TABLET, EXTENDED RELEASE;ORAL							
	ALFUZOSIN HYDROCHLORIDE							
	@	WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012	Feb	DISC
	UROXATRAL							
AB	+	CONCORDIA PHARMS INC	10MG	N021287	001	Jun 12, 2003	Jun	CAHN
	<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE</u>							
	TABLET;ORAL							
	TEKAMLO							
	@	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545	001	Aug 26, 2010	May	DISC
	@		EQ 150MG BASE;EQ 10MG BASE	N022545	002	Aug 26, 2010	May	DISC
	@		EQ 300MG BASE;EQ 5MG BASE	N022545	003	Aug 26, 2010	May	DISC
	@		EQ 300MG BASE;EQ 10MG BASE	N022545	004	Aug 26, 2010	May	DISC

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMTURNIDE

@ NOVARTIS

EQ 150MG BASE;EQ 5MG BASE;12.5MG

N200045 001 Dec 21, 2010 May DISC

@

EQ 300MG BASE;EQ 5MG BASE;12.5MG

N200045 002 Dec 21, 2010 May DISC

@

EQ 300MG BASE;EQ 5MG BASE;25MG

N200045 003 Dec 21, 2010 May DISC

@

EQ 300MG BASE;EQ 10MG BASE;12.5MG

N200045 004 Dec 21, 2010 May DISC

@

EQ 300MG BASE;EQ 10MG BASE;25MG

N200045 005 Dec 21, 2010 May DISC

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

>A> AB MYLAN PHARMS INC

EQ 6.25MG BASE

A205171 001 Nov 09, 2015 Oct NEWA

>A> AB

EQ 12.5MG BASE

A205171 002 Nov 09, 2015 Oct NEWA

AB TEVA PHARMS USA

EQ 6.25MG BASE

A078027 001 Jul 07, 2015 Jun NEWA

AB

EQ 12.5MG BASE

A078027 002 Jul 07, 2015 Jun NEWA

AXERT

AB JANSSEN PHARMS

EQ 6.25MG BASE

N021001 001 May 07, 2001 Jun CFTG

AB +

EQ 12.5MG BASE

N021001 002 May 07, 2001 Jun CFTG

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB ROXANE

EQ 0.5MG BASE

A200652 001 May 04, 2015 Apr NEWA

AB

EQ 1MG BASE

A200652 002 May 04, 2015 Apr NEWA

LOTRONEX

AB PROMETHEUS LABS

EQ 0.5MG BASE

N021107 002 Dec 23, 2003 Apr CFTG

AB +

EQ 1MG BASE

N021107 001 Feb 09, 2000 Apr CFTG

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

@ ANI PHARMS INC

0.25MG

A074085 001 Feb 16, 1994 Jul CAHN

@

0.5MG

A074085 002 Feb 16, 1994 Jul CAHN

@

1MG

A074085 003 Feb 16, 1994 Jul CAHN

@

2MG

A074085 004 Feb 26, 1996 Jul CAHN

AB AUROBINDO PHARMA LTD

0.25MG

A203346 001 Jul 31, 2015 Jul NEWA

AB

0.5MG

A203346 002 Jul 31, 2015 Jul NEWA

AB

1MG

A203346 003 Jul 31, 2015 Jul NEWA

AB

2MG

A203346 004 Jul 31, 2015 Jul NEWA

AB NATCO PHARMA LTD

0.25MG

A200739 001 Apr 15, 2015 Mar NEWA

AB

0.5MG

A200739 002 Apr 15, 2015 Mar NEWA

AB

1MG

A200739 003 Apr 15, 2015 Mar NEWA

AB

2MG

A200739 004 Apr 15, 2015 Mar NEWA

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB HERITAGE PHARMS INC

0.5MG

A078489 001 Oct 17, 2008 Sep CAHN

AB

1MG

A078489 002 Oct 17, 2008 Sep CAHN

AB

2MG

A078489 003 Oct 17, 2008 Sep CAHN

AB

3MG

A078489 004 Oct 17, 2008 Sep CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB BANNER LIFE SCIENCES 100MG

A078720 001 May 29, 2008 Jan CAHN

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

@ G AND W LABS INC

50MG/5ML

A072655 001 Oct 30, 1990 May CAHN

>D> AA + SILARX

50MG/5ML

A076352 001 Sep 10, 2004 Oct DISC

>A>

@

50MG/5ML

A076352 001 Sep 10, 2004 Oct DISC

>D> AA + VINTAGE

50MG/5ML

A077992 001 Dec 12, 2006 Oct DISC

>A>

@

50MG/5ML

A077992 001 Dec 12, 2006 Oct DISC

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@ IGI LABS INC

EQ 50MG BASE/ML

A063167 001 Dec 14, 1995 Mar CAHN

@

EQ 250MG BASE/ML

A063169 001 Dec 14, 1995 Mar CAHN

AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	5MG	A204180	001	Aug 07, 2015	Jul	NEWA
----	----------------------	-----	---------	-----	--------------	-----	------

AMINO ACIDS

INJECTABLE;INJECTION

BRANCHAMIN 4% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 4% (4GM/100ML)

N018684	001	Sep 28, 1984	Feb	DISC
---------	-----	--------------	-----	------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML

N020177	001	Oct 23, 1995	Feb	DISC
---------	-----	--------------	-----	------

AMINOCAPROIC ACID

SYRUP;ORAL

AMINOCAPROIC ACID

AA	VERSAPHARM INC	1.25GM/5ML	A074759	001	Sep 02, 1998	May	CAHN
----	----------------	------------	---------	-----	--------------	-----	------

TABLET;ORAL

AMINOCAPROIC

AB	VERSAPHARM INC	500MG	A075602	001	May 24, 2001	May	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

@ ANI PHARMS INC 10MG

A084910 003

Aug CAHN

@ 25MG

A085031 001

Aug CAHN

@ 50MG

A085032 001

Aug CAHN

@ 75MG

A085030 001

Aug CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

LIMBITROL

@ HERITAGE PHARMS INC EQ 12.5MG BASE;5MG

N016949 001

Jul CAHN

LIMBITROL DS

@ HERITAGE PHARMS INC EQ 25MG BASE;10MG

N016949 002

Jul CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	CHINA RESOURCES	EQ 5MG BASE	A090752	001	Apr 15, 2011	Mar	CAHN
----	-----------------	-------------	---------	-----	--------------	-----	------

AB		EQ 10MG BASE	A090752	002	Apr 15, 2011	Mar	CAHN
----	--	--------------	---------	-----	--------------	-----	------

AB	MYLAN PHARMS INC	EQ 2.5MG BASE	A078224	001	Feb 27, 2008	Sep	CAHN
----	------------------	---------------	---------	-----	--------------	-----	------

AB		EQ 5MG BASE	A078224	002	Feb 27, 2008	Sep	CAHN
----	--	-------------	---------	-----	--------------	-----	------

AB		EQ 10MG BASE	A078224	003	Feb 27, 2008	Sep	CAHN
----	--	--------------	---------	-----	--------------	-----	------

AB	SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015	Jul	NEWA
----	------------------	---------------	---------	-----	--------------	-----	------

AB		EQ 5MG BASE	A204900	002	Jul 23, 2015	Jul	NEWA
----	--	-------------	---------	-----	--------------	-----	------

AB		EQ 10MG BASE	A204900	003	Jul 23, 2015	Jul	NEWA
----	--	--------------	---------	-----	--------------	-----	------

AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007	Apr	CAHN
----	--------------------	---------------	---------	-----	--------------	-----	------

AB		EQ 5MG BASE	A077974	002	Jul 09, 2007	Apr	CAHN
----	--	-------------	---------	-----	--------------	-----	------

AB		EQ 10MG BASE	A077974	003	Jul 09, 2007	Apr	CAHN
----	--	--------------	---------	-----	--------------	-----	------

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	LUPIN LTD	5MG;12.5MG;160MG	A200797	001	Jun 03, 2015	May	NEWA
----	-----------	------------------	---------	-----	--------------	-----	------

AB		5MG;25MG;160MG	A200797	002	Jun 03, 2015	May	NEWA
----	--	----------------	---------	-----	--------------	-----	------

AB		10MG;12.5MG;160MG	A200797	003	Jun 03, 2015	May	NEWA
----	--	-------------------	---------	-----	--------------	-----	------

AB		10MG;25MG;160MG	A200797	004	Jun 03, 2015	May	NEWA
----	--	-----------------	---------	-----	--------------	-----	------

AB		10MG;25MG;320MG	A200797	005	Jun 03, 2015	May	NEWA
----	--	-----------------	---------	-----	--------------	-----	------

AB	PAR PHARM	5MG;12.5MG;160MG	A201087	001	Jun 01, 2015	May	NEWA
----	-----------	------------------	---------	-----	--------------	-----	------

AB		5MG;25MG;160MG	A201087	002	Jun 01, 2015	May	NEWA
----	--	----------------	---------	-----	--------------	-----	------

AB		10MG;12.5MG;160MG	A201087	003	Jun 01, 2015	May	NEWA
----	--	-------------------	---------	-----	--------------	-----	------

AB		10MG;25MG;160MG	A201087	004	Jun 01, 2015	May	NEWA
----	--	-----------------	---------	-----	--------------	-----	------

AB		10MG;25MG;320MG	A201087	005	Jun 01, 2015	May	NEWA
----	--	-----------------	---------	-----	--------------	-----	------

AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	May	CAIN
----	-------------	------------------	---------	-----	--------------	-----	------

AB		5MG;25MG;160MG	A200435	002	Sep 25, 2012	May	CAIN
----	--	----------------	---------	-----	--------------	-----	------

AB		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	May	CAIN
----	--	-------------------	---------	-----	--------------	-----	------

AB		10MG;25MG;160MG	A200435	003	Sep 25, 2012	May	CAIN
----	--	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		10MG;25MG;320MG	A200435	004	Sep 25, 2012	May	CAIN
AB	TORRENT PHARMS LTD	5MG;12.5MG;160MG	A201593	001	Jun 03, 2015	Sep	CMS1
AB		5MG;12.5MG;160MG	A201593	001	Jun 04, 2015	May	NEWA
AB		5MG;25MG;160MG	A201593	002	Jun 03, 2015	Sep	CMS1
AB		5MG;25MG;160MG	A201593	002	Jun 04, 2015	May	NEWA
AB		10MG;12.5MG;160MG	A201593	003	Jun 03, 2015	Sep	CMS1
AB		10MG;12.5MG;160MG	A201593	003	Jun 04, 2015	May	NEWA
AB		10MG;25MG;160MG	A201593	004	Jun 03, 2015	Sep	CMS1
AB		10MG;25MG;160MG	A201593	004	Jun 04, 2015	May	NEWA
AB		10MG;25MG;320MG	A201593	005	Jun 03, 2015	Sep	CMS1
AB		10MG;25MG;320MG	A201593	005	Jun 04, 2015	May	NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET; ORAL

PRESTALIA

	SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Jan	NEWA
		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Jan	NEWA
+		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Jan	NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;160MG	A202713	001	Apr 03, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A202713	003	Apr 03, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A202713	002	Apr 03, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A202713	004	Apr 03, 2015	Mar	NEWA
AB	LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Mar	NEWA
AB	MATRIX LABS LTD	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Apr	CAHN
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Apr	CAHN
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Apr	CAHN
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Apr	CAHN
AB	NOVEL LABS INC	EQ 5MG BASE;160MG	A202829	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A202829	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A202829	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A202829	004	Mar 30, 2015	Mar	NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Mar	NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Mar	NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

>A>	AP	3D IMAGING DRUG	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203779	001	Oct 19, 2015	Oct	NEWA
	AP	BIOMEDCL RES FDN	48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)	A204352	001	May 01, 2015	Apr	NEWA
		CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539	001	Jun 23, 2015	Jun	NEWA
	AP	IBA MOLECULAR N AM	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Apr	NEWA
		NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015	Jan	NEWA
>A>	AP	PETNET	30mCi-300mCi (3.75-37.5mCi/ML)	A204510	001	Nov 02, 2015	Oct	NEWA
		PRECISION NUCLEAR	3.75-260mCi/ML	A204547	001	Aug 14, 2015	Aug	NEWA
	AP	SPECTRON MRC LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr	NEWA

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Apr	CAHN
AB		500MG	A065016	002	Apr 08, 1999	Apr	CAHN

FOR SUSPENSION;ORAL
AMOXICILLIN

	@ SUN PHARM INDS LTD	200MG/5ML	A 065113	001	Nov 29, 2002	Apr CAHN
	@	400MG/5ML	A 065113	002	Nov 29, 2002	Apr CAHN

TABLET;ORAL
AMOXICILLIN

AB	SUN PHARM INDS LTD	500MG	A 065059	001	Nov 24, 2000	Apr CAHN
AB		875MG	A 065059	002	Nov 24, 2000	Apr CAHN

TABLET, CHEWABLE;ORAL
AMOXICILLIN

AB	SUN PHARM INDS LTD	125MG	A 065021	001	Dec 23, 1999	Apr CAHN
	@	200MG	A 065060	001	Nov 29, 2000	Apr CAHN
AB		250MG	A 065021	002	Dec 23, 1999	Apr CAHN
	@	400MG	A 065060	002	Nov 29, 2000	Apr CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A 065132	001	Mar 19, 2003	Apr CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A 065132	002	Mar 19, 2003	Apr CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A 065207	002	Jan 30, 2007	Apr CAHN

TABLET;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

	@ SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A 065109	001	Nov 04, 2002	Apr CAHN
AB		875MG;EQ 125MG BASE	A 065102	001	Sep 17, 2002	Apr CAHN

TABLET, CHEWABLE;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A 065161	001	Dec 03, 2003	Apr CAHN
AB		400MG;EQ 57MG BASE	A 065161	002	Dec 03, 2003	Apr CAHN

AMPHETAMINE

>A>	SUSPENSION, EXTENDED RELEASE;ORAL					
>A>	DYANA VEL XR					
>A>	+ TRIS PHARMA INC	EQ 2.5MG BASE/ML	N 208147	001	Oct 19, 2015	Oct NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	COREPHARMA	1.875MG;1.875MG;1.875MG;1.875MG	A 040444	005	Nov 03, 2014	May NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A 040444	006	Nov 03, 2014	May NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A 040444	007	Nov 03, 2014	May NEWA
>A> AB	MYLAN PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A 206721	001	Nov 10, 2015	Oct NEWA
>A> AB		1.875MG;1.875MG;1.875MG;1.875MG	A 206721	002	Nov 10, 2015	Oct NEWA
>A> AB		2.5MG;2.5MG;2.5MG;2.5MG	A 206721	003	Nov 10, 2015	Oct NEWA
>A> AB		3.125MG;3.125MG;3.125MG;3.125MG	A 206721	004	Nov 10, 2015	Oct NEWA
>A> AB		3.75MG;3.75MG;3.75MG;3.75MG	A 206721	005	Nov 10, 2015	Oct NEWA
>A> AB		5MG;5MG;5MG;5MG	A 206721	006	Nov 10, 2015	Oct NEWA
>A> AB		7.5MG;7.5MG;7.5MG;7.5MG	A 206721	007	Nov 10, 2015	Oct NEWA

AMPHETAMINE SULFATE

TABLET;ORAL
EVEKEO

	ARBOR PHARMS LLC	5MG	A 200166	001	Aug 09, 2012	Mar CTNA
	+	10MG	A 200166	002	Aug 09, 2012	Mar CTNA

AMPICILLIN SODIUM

INJECTABLE;INJECTION
AMPICILLIN SODIUM

AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A 202864	001	Sep 04, 2015	Aug NEWA
AP		EQ 500MG BASE/VIAL	A 202864	002	Sep 04, 2015	Aug NEWA
AP		EQ 1GM BASE/VIAL	A 202864	003	Sep 04, 2015	Aug NEWA
AP		EQ 2GM BASE/VIAL	A 202864	004	Sep 04, 2015	Aug NEWA
AP		EQ 10GM BASE/VIAL	A 202865	001	Sep 04, 2015	Aug NEWA
>A> AP	SAGENT PHARMS	EQ 10GM BASE/VIAL	A 090581	001	Oct 20, 2015	Oct NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL
PROBAMPACIN

	@ G AND W LABS INC	EQ 3.5GM BASE/BOT;1GM/BOT	A 061741	001		Apr CAHN
--	--------------------	---------------------------	----------	-----	--	----------

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

@ KREMERS URBAN PHARMS 1MG

A091331 001 Jan 05, 2011 Mar CAHN

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

AP FRESENIUS KABI USA 250MG/2.5ML (100MG/ML)

N201811 001 Mar 23, 2015 Apr CDFR

AP + PFIZER 250MG/2.5ML (100MG/ML)

N020883 001 Jun 30, 2000 Aug CTNA

INJECTABLE; IV (INFUSION)

ARGATROBAN

AP FRESENIUS KABI USA 250MG/2.5ML (100MG/ML)

N201811 001 Mar 23, 2015 Mar NEWA

ARIPIPIRAZOLE

SOLUTION; ORAL

ARIPIPIRAZOLE

AA AMNEAL PHARMS 1MG/ML

A203906 001 Aug 14, 2015 Aug NEWA

AA APOTEX INC 1MG/ML

A204094 001 Sep 30, 2015 Sep NEWA

AA SILARX PHARMS INC 1MG/ML

A204171 001 Aug 14, 2015 Aug NEWA

TABLET; ORAL

ABILIFY

AB OTSUKA 2MG

N021436 006 Nov 15, 2002 Apr CFTG

AB + 5MG

N021436 005 Nov 15, 2002 Apr CFTG

AB + 10MG

N021436 001 Nov 15, 2002 Apr CFTG

AB 15MG

N021436 002 Nov 15, 2002 Apr CFTG

AB 20MG

N021436 003 Nov 15, 2002 Apr CFTG

AB 30MG

N021436 004 Nov 15, 2002 Apr CFTG

ARIPIPIRAZOLE

AB ALEMBIC PHARMS LTD 2MG

A202101 001 Apr 28, 2015 Apr NEWA

AB 5MG

A202101 002 Apr 28, 2015 Apr NEWA

AB 10MG

A202101 003 Apr 28, 2015 Apr NEWA

AB 15MG

A202101 004 Apr 28, 2015 Apr NEWA

AB 20MG

A202101 005 Apr 28, 2015 Apr NEWA

AB 30MG

A202101 006 Apr 28, 2015 Apr NEWA

AB APOTEX INC 2MG

A078583 001 Jul 24, 2015 Jul NEWA

AB 5MG

A078583 002 Jul 24, 2015 Jul NEWA

AB 10MG

A078583 003 Jul 24, 2015 Jul NEWA

AB 15MG

A078583 004 Jul 24, 2015 Jul NEWA

AB 20MG

A078583 005 Jul 24, 2015 Jul NEWA

AB 30MG

A078583 006 Jul 24, 2015 Jul NEWA

AB AUROBINDO PHARMA LTD 2MG

A203908 001 Oct 08, 2015 Sep NEWA

AB 5MG

A203908 002 Oct 08, 2015 Sep NEWA

AB 10MG

A203908 003 Oct 08, 2015 Sep NEWA

AB 15MG

A203908 004 Oct 08, 2015 Sep NEWA

AB 20MG

A203908 005 Oct 08, 2015 Sep NEWA

AB 30MG

A203908 006 Oct 08, 2015 Sep NEWA

AB HETERO LABS LTD V 2MG

A205064 001 Apr 28, 2015 Apr NEWA

AB 5MG

A205064 002 Apr 28, 2015 Apr NEWA

AB 10MG

A205064 003 Apr 28, 2015 Apr NEWA

AB 15MG

A205064 004 Apr 28, 2015 Apr NEWA

AB 20MG

A205064 005 Apr 28, 2015 Apr NEWA

AB 30MG

A205064 006 Apr 28, 2015 Apr NEWA

AB TEVA PHARMS USA 2MG

A078607 001 Apr 28, 2015 Apr NEWA

AB 5MG

A078607 002 Apr 28, 2015 Apr NEWA

AB 10MG

A078608 001 Apr 28, 2015 Apr NEWA

AB 15MG

A078708 001 Apr 28, 2015 Apr NEWA

AB 20MG

A078708 002 Apr 28, 2015 Apr NEWA

AB 30MG

A078708 003 Apr 28, 2015 Apr NEWA

AB TORRENT PHARMS LTD 2MG

A201519 001 Apr 28, 2015 Apr NEWA

AB 10MG

A201519 003 Apr 28, 2015 Apr NEWA

AB 5MG

A201519 002 Apr 28, 2015 Apr NEWA

AB 15MG

A201519 004 Apr 28, 2015 Apr NEWA

AB 20MG

A201519 005 Apr 28, 2015 Apr NEWA

AB 30MG

A201519 006 Apr 28, 2015 Apr NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

AB + OTSUKA 10MG

N021729 002 Jun 07, 2006 Apr CFTG

AB 15MG

N021729 003 Jun 07, 2006 Apr CFTG

ARIPIPIRAZOLE

AB ALEMBIC PHARMS LTD 10MG

A202102 001 Apr 28, 2015 Apr NEWA

AB 15MG

A202102 002 Apr 28, 2015 Apr NEWA

>A>	<u>ARIPIPIRAZOLE LAUROXIL</u>					
>A>	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR					
>A>	ARISTADA					
>A>	ALKERMES INC	441MG/1.6ML (275.63MG/ML)	N207533	001	Oct 05, 2015	Oct NEWA
>A>		662MG/2.4ML (275.83MG/ML)	N207533	002	Oct 05, 2015	Oct NEWA
>A>	+	882MG/3.2ML (275.63MG/ML)	N207533	003	Oct 05, 2015	Oct NEWA
<u>ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E</u>						
INJECTABLE;INJECTION						
M.V.I.-12 LYOPHILIZED						
	@ IGI LABS INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIA L;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;4 0MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/V IAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985	Jun CAHN
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE</u>						
FOR SOLUTION;ORAL						
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID						
	@ NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM; 7.5GM	A090145	001	Jan 25, 2012	Aug CTNA
<u>ASENAPIINE MALEATE</u>						
TABLET;SUBLINGUAL						
SAPHRIS						
	FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Jun CAHN
	+	EQ 10MG BASE	N022117	002	Aug 13, 2009	Jun CAHN
<u>ASPIRIN</u>						
CAPSULE, EXTENDED RELEASE;ORAL						
DURLAZA						
	+ NEW HAVEN PHARMS	162.5MG	N200671	001	Sep 04, 2015	Sep NEWA
<u>ASPIRIN; BUTALBITAL; CAFFEINE</u>						
CAPSULE;ORAL						
FIORINAL						
AA	+ ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Jan CAHN
TABLET;ORAL						
FIORINAL						
	@ ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan CAHN
<u>ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE</u>						
CAPSULE;ORAL						
BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE						
>A> AB	COASTAL PHARMS	325MG;50MG;40MG;30MG	A203335	001	Oct 30, 2015	Oct NEWA
FIORINAL W/CODEINE						
AB	+ ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	Jan CAHN
<u>ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE</u>						
CAPSULE;ORAL						
SYNALGOS-DC						
	+ SUN PHARM INDS	356.4MG;30MG;16MG	N011483	004	Sep 06, 1983	Aug CAHN
<u>ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE</u>						
TABLET;ORAL						
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE						
	SANDOZ	385MG;30MG;25MG	A074654	001	Dec 31, 1996	Mar CTEC
	+	770MG;60MG;50MG	A074654	002	Dec 31, 1996	Mar CTEC
<u>ASPIRIN; OXYCODONE HYDROCHLORIDE</u>						
TABLET;ORAL						
OXYCODONE AND ASPIRIN						
AA	ACTAVIS LABS FL INC	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar CAHN

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

+	BRISTOL MYERS SQUIBB	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015	Jan NEWA
---	----------------------	---------------------	---------	-----	--------------	----------

ATENOLOL

TABLET;ORAL

ATENOLOL

AB	ALVOGEN IPCO SARL	25MG	A073646	001	Jul 31, 1992	Jul CAHN
AB		50MG	A072303	001	Jul 15, 1988	Jul CAHN
AB		100MG	A072304	001	Jul 15, 1988	Jul CAHN
	@ DAVA PHARMS INC	25MG	A074099	001	Apr 28, 1992	Jun DISC
	TENORMIN					
AB	ALVOGEN IPCO SARL	25MG	N018240	004	Apr 09, 1990	Feb CAHN
AB		50MG	N018240	001		Feb CAHN
AB	+	100MG	N018240	002		Feb CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB	ALVOGEN IPCO SARL	50MG;25MG	A072301	001	May 31, 1990	Jul CAHN	
AB		100MG;25MG	A072302	001	May 31, 1990	Jul CAHN	
	TENORETIC 100						
AB	+	ALVOGEN IPCO SARL	100MG;25MG	N018760	001	Jun 08, 1984	Feb CAHN
	TENORETIC 50						
AB	ALVOGEN IPCO SARL	50MG;25MG	N018760	002	Jun 08, 1984	Feb CAHN	

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	KREMERS URBAN PHARMS	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar CAHN
AB		EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar CAHN
AB		EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar CAHN
AB		EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar CAHN
AB	SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Apr CAHN
AB		EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr CAHN
AB		EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr CAHN
AB		EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LIPTRUZET

@ MERCK SHARP DOHME

@

@

@

EQ 10MG BASE;10MG	N200153	001	May 03, 2013	May DISC
EQ 20MG BASE;10MG	N200153	002	May 03, 2013	May DISC
EQ 40MG BASE;10MG	N200153	003	May 03, 2013	May DISC
EQ 80MG BASE;10MG	N200153	004	May 03, 2013	May DISC

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	GLENMARK GENERICS	62.5MG;25MG	A091211	002	Apr 06, 2015	Mar NEWA
----	-------------------	-------------	---------	-----	--------------	----------

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

AP	AUROBINDO PHARMA LTD	10MG/ML	A206011	001	Apr 08, 2015	Mar NEWA
	ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	AUROBINDO PHARMA LTD	10MG/ML	A206010	001	Apr 08, 2015	Mar NEWA

ATROPINE SULFATE

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

+	AKORN	1%	N206289	001	Jul 18, 2014	May CRLD
---	-------	----	---------	-----	--------------	----------

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL

MOTOFEN

+	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002		Feb CAHN
	MOTOFEN HALF-STRENGTH					
	@ SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001		Feb CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@ ANI PHARMS INC

0.025MG;2.5MG

A 086727 001

Jul CAHN

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)

AVYCAZ

+ CEREXA INC

EQ 0.5GM BASE;2GM/VIAL

N 206494 001 Feb 25, 2015

Feb NEWA

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

FINACEA

+ BAYER HLTHCARE

15%

N 207071 001 Jul 29, 2015

Jul NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AB BRECKENRIDGE PHARMS

EQ 0.125MG BASE/SPRAY

A 090176 001 Jul 28, 2015

Jul NEWA

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB LUPIN LTD

EQ 100MG BASE/5ML

A 065488 001 May 15, 2015

May NEWA

AB LUPIN LTD

EQ 200MG BASE/5ML

A 065488 002 May 15, 2015

May NEWA

INJECTABLE; INJECTION

AZITHROMYCIN

AP AUROBINDO PHARMA LTD

EQ 500MG BASE/VIAL

A 203294 001 Jun 19, 2015

Jun NEWA

TABLET;ORAL

AZITHROMYCIN

AB LUPIN LTD

EQ 250MG BASE

A 065398 001 May 15, 2015

May NEWA

AB LUPIN LTD

EQ 500MG BASE

A 065399 001 May 15, 2015

May NEWA

AB LUPIN LTD

EQ 600MG BASE

A 065400 001 May 15, 2015

May NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL

COLAZAL

AB + VALEANT PHARMS INTL

750MG

N 020610 001 Jul 18, 2000

Jul CAHN

TABLET;ORAL

BALSALAZIDE DISODIUM

AB PAR PHARM INC

1.1GM

A 206336 001 Sep 08, 2015

Aug NEWA

GIAZO

AB + VALEANT PHARMS INTL

1.1GM

N 022205 001 Feb 03, 2012

Aug CFTG

+

1.1GM

N 022205 001 Feb 03, 2012

Jul CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB AMNEAL PHARMS LLC

5MG

A 076820 001 Feb 03, 2006

Jan CAHN

AB AMNEAL PHARMS LLC

10MG

A 076820 002 Feb 03, 2006

Jan CAHN

AB AMNEAL PHARMS LLC

20MG

A 076820 003 Feb 03, 2006

Jan CAHN

AB AMNEAL PHARMS LLC

40MG

A 076820 004 Feb 03, 2006

Jan CAHN

AB SUN PHARM INDS LTD

5MG

A 076344 001 Feb 11, 2004

Apr CAHN

AB SUN PHARM INDS LTD

10MG

A 076344 002 Feb 11, 2004

Apr CAHN

AB SUN PHARM INDS LTD

20MG

A 076344 003 Feb 11, 2004

Apr CAHN

AB SUN PHARM INDS LTD

40MG

A 076344 004 Feb 11, 2004

Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB SUN PHARM INDS LTD

5MG;6.25MG

A 077483 001 Sep 08, 2005

Apr CAHN

AB SUN PHARM INDS LTD

10MG;12.5MG

A 077483 002 Sep 08, 2005

Apr CAHN

AB SUN PHARM INDS LTD

20MG;12.5MG

A 077483 003 Sep 08, 2005

Apr CAHN

AB SUN PHARM INDS LTD

20MG;25MG

A 077483 004 Sep 08, 2005

Apr CAHN

BENZONATATE

CAPSULE;ORAL		BENZONATATE					
AA	APOTEX INC	100MG		A091310	001	Jan 16, 2015	Jan NEWA
AA		200MG		A091310	002	Jan 16, 2015	Jan NEWA
AA	BANNER LIFE SCIENCES	100MG		A081297	001	Jan 29, 1993	Jan CAHN
AA		200MG		A081297	002	Oct 30, 2007	Jan CAHN
AA	CSPC NBP PHARM CO	200MG		A202765	001	Jul 31, 2015	Jul NEWA
AA	STRIDES ARCOLAB LTD	100MG		A091133	001	Jul 30, 2015	Jul NEWA
AA		200MG		A091133	002	Jul 30, 2015	Jul NEWA
AA	STRIDES PHARMA	100MG		A091133	001	Jul 30, 2015	Aug CAHN
AA		200MG		A091133	002	Jul 30, 2015	Aug CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL		ACANYA					
AB	+ DOW PHARM	2.5%;EQ 1.2% BASE		N050819	001	Oct 23, 2008	Jun CFTG
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE							
AB	ACTAVIS LABS UT INC	2.5%;EQ 1.2% BASE		A205128	001	Jun 19, 2015	Jun NEWA
AB	PERRIGO ISRAEL	5%;EQ 1% BASE		A202440	001	Sep 21, 2015	Sep NEWA
ONEXTON							
	+ DOW PHARM	3.75%;EQ 1.2% BASE		N050819	002	Nov 24, 2014	Jan CRLD

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL		ERYTHROMYCIN AND BENZOYL PEROXIDE					
AB	LYNE	5%;3%		A065385	001	Sep 18, 2015	Sep NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL		BENZPHETAMINE HYDROCHLORIDE					
AA	+ KVK TECH	50MG		A090968	001	Jul 20, 2010	Jun CRLD
DIDREX							
	@ PHARMACIA AND UPJOHN	50MG		N012427	002		Jun DISC

BENZTROPINE MESYLATE

TABLET;ORAL		BENZTROPINE MESYLATE					
AA	NUVO PHARM INC	0.5MG		A204713	001	Apr 14, 2015	Mar NEWA
AA		1MG		A204713	002	Apr 14, 2015	Mar NEWA
AA		2MG		A204713	003	Apr 14, 2015	Mar NEWA

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL		BETAMETHASONE DIPROPIONATE					
AB	G AND W LABS INC	EQ 0.05% BASE		A071467	001	Aug 10, 1987	Apr CAHN
	@	EQ 0.05% BASE		A071882	001	Jun 06, 1988	Apr CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

>A>	AEROSOL, FOAM;TOPICAL						
>A>	ENSTILAR						
>A>	+ LEO PHARMA AS	0.064%;0.005%		N207589	001	Oct 16, 2015	Oct NEWA

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL		CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE					
>A>	AB	GLENMARK PHARMS LTD	EQ 0.05% BASE;1%	A202894	001	Oct 30, 2015	Oct NEWA

BETAMETHASONE VALERATE

CREAM;TOPICAL		BETA-VAL					
AB	G AND W LABS INC	EQ 0.1% BASE		N018642	001	Mar 24, 1983	Aug CAHN
LOTION;TOPICAL		BETA-VAL					
AB	G AND W LABS INC	EQ 0.1% BASE		A070072	001	Jun 27, 1985	Apr CAHN
OINTMENT;TOPICAL		BETA-VAL					
>A>	AB	G AND W LABS INC	EQ 0.1% BASE	A070069	001	Dec 19, 1985	Oct CAHN
>D>	@	TEVA	EQ 0.1% BASE	A070069	001	Dec 19, 1985	Oct CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA	HERITAGE PHARMA	5MG	A 091256	001	May 04, 2010	Mar	CAHN
AA		10MG	A 091256	002	May 04, 2010	Mar	CAHN
AA		25MG	A 091256	003	May 04, 2010	Mar	CAHN
AA		50MG	A 091256	004	May 04, 2010	Mar	CAHN
AA	LANNETT HOLDINGS INC	5MG	A 040703	001	Mar 27, 2008	Feb	CMFD
AA		50MG	A 040677	001	Mar 27, 2008	Feb	CMFD

DUVOID

AA	WELLSPRING PHARM	10MG	A 086262	001		Jan	CMFD
AA		25MG	A 086263	001		May	CMFD
AA		50MG	A 085882	003		May	CMFD

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

AB	BANNER LIFE SCIENCES	75MG	A 203174	001	Aug 12, 2014	Jun	CMFD
	@	75MG	A 203174	001	Aug 12, 2014	Jan	CAHN
	TARGETIN						
AB	+ VALEANT LUXEMBOURG	75MG	N 021055	001	Dec 29, 1999	Jun	CTEC

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB	APOTEX INC	50MG	A 200274	001	May 21, 2015	May	NEWA
AB	STASON PHARMS	50MG	A 091011	001	Jun 10, 2015	May	NEWA

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AT	ALCON RES LTD	0.03%	A 202565	001	May 05, 2015	Apr	NEWA
AT	APOTEX INC	0.03%	A 090449	001	Jul 20, 2015	Jul	NEWA
AT	+ LUPIN LTD	0.03%	A 203991	001	Feb 20, 2015	Apr	CTEC
	+	0.03%	A 203991	001	Feb 20, 2015	Mar	CTEC
AT	+	0.03%	A 203991	001	Feb 20, 2015	Feb	NEWA

BIPERIDEN HYDROCHLORIDE

TABLET;ORAL

AKINETON

@ ABBVIE

2MG

N 012003 001 Aug DISC

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE;ORAL

PYLERA

+ FOREST LABS LLC 140MG;125MG;125MG

N 050786 001 Sep 28, 2006 Jul CAHN

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

AP	HOSPIRA INC	250MG/VIAL	A 090811	001	Jul 14, 2015	Jun	NEWA
AP		250MG/VIAL	A 090816	001	Jul 14, 2015	Jun	NEWA

BOSUTINIB MONOHYDRATE

TABLET;ORAL

BOSULIF

+ WYETH PHARMS INC EQ 100MG BASE
EQ 500MG BASEN 203341 001 Sep 04, 2012 Jun CRLD
N 203341 002 Sep 04, 2012 Jun CRLDBREXPIRAZOLE

TABLET;ORAL

REXULTI

	OTSUKA PHARM CO LTD	0.25MG	N 205422	001	Jul 10, 2015	Jul	NEWA
		0.5MG	N 205422	002	Jul 10, 2015	Jul	NEWA
		1MG	N 205422	003	Jul 10, 2015	Jul	NEWA
		2MG	N 205422	004	Jul 10, 2015	Jul	NEWA
		3MG	N 205422	005	Jul 10, 2015	Jul	NEWA
	+	4MG	N 205422	006	Jul 10, 2015	Jul	NEWA

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC		BROMDAY							
	@ BAUSCH AND LOMB INC	EQ 0.09% ACID		N021664	002	Oct 16, 2010	Sep	DISC	
AT2	+	EQ 0.09% ACID		N021664	002	Oct 16, 2010	May	CTEC	
BROMFENAC SODIUM									
AT2	APOTEX INC	EQ 0.09% ACID		A202620	001	Jun 23, 2014	May	CTEC	
AT1	+	COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	May	CRLD	
AT2	HI-TECH PHARMACAL	EQ 0.09% ACID		A203395	001	Jan 22, 2014	May	CTEC	
AT1	PADDOCK LLC	EQ 0.09% ACID		A201941	001	Feb 10, 2015	Jan	NEWA	

BUDESONIDE

AEROSOL, FOAM;RECTAL		UCERIS							
	+ VALEANT PHARMS INTL	2MG/ACTUATION		N205613	001	Oct 07, 2014	Apr	CAHN	
SPRAY, METERED;NASAL		BUDESONIDE							
	APOTEX INC	0.032MG/INH		A078949	001	May 12, 2014	Mar	CTEC	
TABLET, EXTENDED RELEASE;ORAL		UCERIS							
	+ VALEANT PHARMS INTL	9MG		N203634	001	Jan 14, 2013	Aug	CAHN	

BUMETANIDE

INJECTABLE;INJECTION		BUMETANIDE							
AP	EUROHLTH INTL SARL	0.25MG/ML		A079196	001	Apr 30, 2008	Jun	CAHN	
TABLET;ORAL		BUMEX							
>D>	@ VALIDUS PHARMS INC	0.5MG		N018225	002	Feb 28, 1983	Oct	CMFD	
>A>	AB	0.5MG		N018225	002	Feb 28, 1983	Oct	CMFD	
>D>	@	1MG		N018225	001	Feb 28, 1983	Oct	CMFD	
>A>	AB	1MG		N018225	001	Feb 28, 1983	Oct	CMFD	
>D>	@	2MG		N018225	003	Jun 14, 1985	Oct	CMFD	
>A>	AB	2MG		N018225	003	Jun 14, 1985	Oct	CMFD	
>A>	<u>BUPRENORPHINE HYDROCHLORIDE</u>								
>A>	FILM;BUCCAL								
>A>	BELBUCA								
>A>	ENDO PHARMS INC	75MCG		N207932	001	Oct 23, 2015	Oct	NEWA	
>A>		150MCG		N207932	002	Oct 23, 2015	Oct	NEWA	
>A>		300MCG		N207932	003	Oct 23, 2015	Oct	NEWA	
>A>		450MCG		N207932	004	Oct 23, 2015	Oct	NEWA	
>A>		600MCG		N207932	005	Oct 23, 2015	Oct	NEWA	
>A>		750MCG		N207932	006	Oct 23, 2015	Oct	NEWA	
>A>		900MCG		N207932	007	Oct 23, 2015	Oct	NEWA	

INJECTABLE;INJECTION		BUPRENORPHINE HYDROCHLORIDE							
AP	PAR STERILE PRODUCTS	EQ 0.3MG BASE/ML		A206586	001	Jul 28, 2015	Jul	NEWA	
TABLET;SUBLINGUAL		BUPRENORPHINE HYDROCHLORIDE							
AB	ACTAVIS ELIZABETH	EQ 2MG BASE		A090819	001	Feb 19, 2015	Feb	NEWA	
AB		EQ 8MG BASE		A090819	002	Feb 19, 2015	Feb	NEWA	
AB	MYLAN PHARMS INC	EQ 2MG BASE		A201066	001	Mar 06, 2015	Feb	NEWA	
AB		EQ 8MG BASE		A201066	002	Mar 06, 2015	Feb	NEWA	
AB	SANDOZ INC	EQ 2MG BASE		A090279	001	Jun 10, 2015	May	NEWA	
AB		EQ 8MG BASE		A090279	002	Jun 10, 2015	May	NEWA	

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL		SUBOXONE							
	INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE		N022410	001	Aug 30, 2010	Sep	CDFR	
		EQ 4MG BASE;EQ 1MG BASE		N022410	003	Aug 10, 2012	Sep	CDFR	
		EQ 8MG BASE;EQ 2MG BASE		N022410	002	Aug 30, 2010	Sep	CDFR	
	+	EQ 12MG BASE;EQ 3MG BASE		N022410	004	Aug 10, 2012	Sep	CDFR	
TABLET;SUBLINGUAL		BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE							
>A>	AB	ETHYPHARM USA CORP	EQ 2MG BASE;EQ 0.5MG BASE	A204431	001	Oct 16, 2015	Oct	NEWA	
>A>	AB		EQ 8MG BASE;EQ 2MG BASE	A204431	002	Oct 16, 2015	Oct	NEWA	
ZUBSOLV		OREXO AB							
		EQ 2.9MG BASE;EQ 0.71MG BASE		N204242	005	Jun 04, 2015	Jun	NEWA	

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
APLENZIN

	VALEANT PHARMS NORTH	174MG	N022108	001	Apr 23, 2008	Feb CAHN
		348MG	N022108	002	Apr 23, 2008	Feb CAHN
+		522MG	N022108	003	Apr 23, 2008	Feb CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

AB1	PRINSTON INC	100MG	A202304	001	May 26, 2015	May NEWA
AB1		150MG	A202304	002	May 26, 2015	May NEWA
AB1		200MG	A202304	003	May 26, 2015	May NEWA
AB2	SANDOZ INC	150MG	A077475	001	Mar 12, 2008	Mar CAHN
	@ WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012	May DISC
	@	150MG	A201331	002	Aug 30, 2012	May DISC
	@	200MG	A201331	003	Aug 30, 2012	May DISC

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

AB	EMCURE PHARMS USA	5MG	A204582	001	Sep 18, 2015	Sep NEWA
AB		10MG	A204582	002	Sep 18, 2015	Sep NEWA
AB		15MG	A204582	003	Sep 18, 2015	Sep NEWA
AB		30MG	A204582	004	Sep 18, 2015	Sep NEWA

BUTABARBITAL SODIUM

ELIXIR;ORAL

BUTISOL SODIUM

@	MEDA PHARMS	30MG/5ML	A085380	001		Jul DISC
---	-------------	----------	---------	-----	--	----------

TABLET;ORAL

BUTISOL SODIUM

@	MEDA PHARMS	50MG	N000793	003		May DISC
---	-------------	------	---------	-----	--	----------

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

@	ELAN PHARMA INTL LTD	2%	N019881	001	Feb 07, 1997	May CTNA
---	----------------------	----	---------	-----	--------------	----------

GYNAZOLE-1

+	PERRIGO ISRAEL	2%	A200923	001	May 18, 2012	Jun CTNA
---	----------------	----	---------	-----	--------------	----------

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAFFEINE CITRATE

AP	AUROBINDO PHARMA LTD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A205013	001	Sep 22, 2015	Sep NEWA
----	----------------------	------------------------------------	---------	-----	--------------	----------

CALCIPOTRIENE

CREAM;TOPICAL

CALCIPOTRIENE

AB	GLENMARK PHARMS LTD	0.005%	A205772	001	Jun 09, 2015	May NEWA
----	---------------------	--------	---------	-----	--------------	----------

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCITONIN-SALMON

@	IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995	Mar CAHN
---	--------------	-----------	---------	-----	--------------	----------

MIACALCIN

@	MYLAN IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986	Aug CAHN
---	-------------------	-----------	---------	-----	--------------	----------

+		200 IU/ML	N017808	002	Mar 29, 1991	Aug CAHN
---	--	-----------	---------	-----	--------------	----------

SPRAY, METERED;NASAL

MIACALCIN

AB	+	MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Aug CAHN
----	---	-------------------	--------------	---------	-----	--------------	----------

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB	BANNER LIFE SCIENCES	0.25MCG	A091174	001	May 24, 2013	Jan CAHN
----	----------------------	---------	---------	-----	--------------	----------

AB		0.5MCG	A091174	002	May 24, 2013	Jan CAHN
----	--	--------	---------	-----	--------------	----------

AB	STRIDES PHARMA	0.25MCG	A091356	001	Dec 12, 2014	Jan CAHN
----	----------------	---------	---------	-----	--------------	----------

AB		0.5MCG	A091356	002	Dec 12, 2014	Jan CAHN
----	--	--------	---------	-----	--------------	----------

INJECTABLE; INJECTION

CALCIJEX

@	ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986	Jun	DISC
@		0.002MG/ML	N018874	002	Sep 25, 1986	Jun	DISC
CALCITRIOL							
@	AKORN	0.002MG/ML	A078066	002	Jan 29, 2008	Jun	DISC
@	FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002	Jun	DISC
@		0.002MG/ML	A075836	002	Dec 31, 2002	Jun	DISC
@	FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003	Jun	DISC
@		0.002MG/ML	A075766	002	Feb 20, 2003	Jun	DISC
@	LUITPOLD	0.001MG/ML	A075746	001	Sep 26, 2003	Jun	DISC
@		0.002MG/ML	A075746	002	Sep 26, 2003	Jun	DISC
@	SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006	Jun	DISC

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB	HERITAGE PHARMS INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Sep	CAHN	
AB	LUPIN LTD	EQ 169MG CALCIUM	A202127	001	Jul 09, 2015	Jun	NEWA	
>A>	AB	NOSTRUM LABS INC	EQ 169MG CALCIUM	A203179	001	Oct 26, 2015	Oct	NEWA
AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Jun	NEWA	

TABLET; ORAL

CALCIUM ACETATE

AB	HERITAGE PHARMS INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Sep	CAHN
AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Jan	NEWA

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Oct	CAHN
>D>	+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Oct	CAHN
	+		N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jan	CPOT
PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER								
>A>	@	BAXTER HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Oct	CAHN
>D>	@	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Oct	CAHN
	@		3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Jan	CPOT
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER								
>A>	+	BAXTER HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Oct	CAHN
>D>	+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Oct	CAHN
	+		N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Jan	CPOT
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER								
>A>	+	BAXTER HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Oct	CAHN
>D>	+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Oct	CAHN

INJECTABLE; INJECTION

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

	+		3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jan CPOT
--	---	--	--	---------	-----	--------------	----------

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Oct CAHN
-----	---	-----------------	--	---------	-----	--------------	----------

>D>	+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Oct CAHN
-----	---	--------------------	--	---------	-----	--------------	----------

	+		3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Jan CPOT
--	---	--	--	---------	-----	--------------	----------

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Oct CAHN
-----	---	-----------------	---	---------	-----	--------------	----------

>D>	+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Oct CAHN
-----	---	--------------------	---	---------	-----	--------------	----------

	+		N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Jan CPOT
--	---	--	---	---------	-----	--------------	----------

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Oct CAHN
-----	---	-----------------	--	---------	-----	--------------	----------

>D>	+	GAMBRO RENAL PRODS	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Oct CAHN
-----	---	--------------------	--	---------	-----	--------------	----------

	+		5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Jan CPOT
--	---	--	--	---------	-----	--------------	----------

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

>A>	@	BAXTER HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Oct CAHN
-----	---	-----------------	---	---------	-----	--------------	----------

>D>	@	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Oct CAHN
-----	---	--------------------	---	---------	-----	--------------	----------

	@		N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Jan CPOT
--	---	--	---	---------	-----	--------------	----------

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Oct CAHN
-----	---	-----------------	---	---------	-----	--------------	----------

>D>	+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Oct CAHN
-----	---	--------------------	---	---------	-----	--------------	----------

	+		N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Jan CPOT
--	---	--	---	---------	-----	--------------	----------

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Oct CAHN
-----	---	-----------------	--	---------	-----	--------------	----------

>D>	+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Oct CAHN
-----	---	--------------------	--	---------	-----	--------------	----------

INJECTABLE; INJECTION

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+		3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Jan CPOT
---	--	--	---------	-----	--------------	----------

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

>A>	@ BAXTER HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Oct CAHN
-----	-------------------	--	---------	-----	--------------	----------

>D>	@ GAMBRO RENAL PRODS	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Oct CAHN
-----	----------------------	--	---------	-----	--------------	----------

	@	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Jan CPOT
--	---	--	---------	-----	--------------	----------

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

>A>	@ BAXTER HLTHCARE	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Oct CAHN
-----	-------------------	--	---------	-----	--------------	----------

>D>	@ GAMBRO RENAL PRODS	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Oct CAHN
-----	----------------------	--	---------	-----	--------------	----------

	@	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Jan CPOT
--	---	--	---------	-----	--------------	----------

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

>A>	+ BAXTER HLTHCARE	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Oct CAHN
-----	-------------------	--	---------	-----	--------------	----------

>D>	+ GAMBRO RENAL PRODS	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Oct CAHN
-----	----------------------	--	---------	-----	--------------	----------

	+	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Jan CPOT
--	---	--	---------	-----	--------------	----------

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

>A>	+ BAXTER HLTHCARE	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Oct CAHN
-----	-------------------	---	---------	-----	--------------	----------

>D>	+ GAMBRO RENAL PRODS	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Oct CAHN
-----	----------------------	---	---------	-----	--------------	----------

	+	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jan CPOT
--	---	---	---------	-----	--------------	----------

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

>A>	@ BAXTER HLTHCARE	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Oct CAHN
-----	-------------------	---	---------	-----	--------------	----------

>D>	@ GAMBRO RENAL PRODS	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Oct CAHN
-----	----------------------	---	---------	-----	--------------	----------

	@	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Jan CPOT
--	---	---	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	N/A/1000ML; N/A/1000ML; N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Jan NEWA
---	---------------	--	---------	-----	--------------	----------

INJECTABLE; INJECTION

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	3.68GM/1000ML; N/A/1000ML; N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.34GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	001	Jan 13, 2015	Jan	NEWA
---	---------------	---	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

NAVSTEL

@	ALCON PHARMS LTD	0.154MG/ML; 0.92MG/ML; 0.2MG/ML; 0.184MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML	N022193	001	Jul 24, 2008	Jun	DISC
---	------------------	--	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	37MG/100ML; 5GM/100ML; 30MG/100ML; 119MG/100ML; 161MG/100ML; 94MG/100ML; 138MG/100ML	N017390	001		Mar	DISC
---	-----------------	--	---------	-----	--	-----	------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	36.8MG/100ML; 30.5MG/100ML; 74.6MG/100ML; 640MG/100ML; 496MG/100ML; 89.6MG/100ML	N017438	001		Mar	DISC
---	-----------------	--	---------	-----	--	-----	------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Oct	CAHN
>D>	+	GAMBRO LUNDIA	N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Oct	CAHN
	+		N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Feb	CAIN
>A>	+	BAXTER HLTHCARE	3.68GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.34GM/1000ML; 0.187GM/1000ML	N207026	001	Jan 13, 2015	Oct	CAHN
>D>	+	GAMBRO LUNDIA	3.68GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.34GM/1000ML; 0.187GM/1000ML	N207026	001	Jan 13, 2015	Oct	CAHN
	+		3.68GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.34GM/1000ML; 0.187GM/1000ML	N207026	001	Jan 13, 2015	Feb	CAIN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019933	001	Aug 29, 1989	Sep	DISC
---	-----------------	--	---------	-----	--------------	-----	------

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	MACLEODS PHARMS LTD	16MG; 12.5MG	A204100	001	Feb 27, 2015	Feb	NEWA
AB		32MG; 12.5MG	A204100	002	Feb 27, 2015	Feb	NEWA
AB		32MG; 25MG	A204100	003	Feb 27, 2015	Feb	NEWA

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB	ACCORD HLTHCARE	150MG	A202593	001	Apr 23, 2015	Apr	NEWA
AB		500MG	A202593	002	Apr 23, 2015	Apr	NEWA

CAPTOPRIL

TABLET;ORAL		CAPTOPRIL							
	@	G AND W LABS INC	12.5MG	A 074433	001	Feb 13, 1996	Jul	CAHN	
	@		12.5MG	A 074462	001	Feb 13, 1996	Apr	CAHN	
	@		12.5MG	A 074483	001	Feb 13, 1996	Jul	CAHN	
	@		12.5MG	A 074590	004	Aug 30, 1996	Apr	CAHN	
	@		25MG	A 074433	002	Feb 13, 1996	Jul	CAHN	
	@		25MG	A 074462	002	Feb 13, 1996	Apr	CAHN	
	@		25MG	A 074483	002	Feb 13, 1996	Jul	CAHN	
	@		25MG	A 074590	002	Aug 30, 1996	Apr	CAHN	
	@		50MG	A 074433	003	Feb 13, 1996	Jul	CAHN	
	@		50MG	A 074462	003	Feb 13, 1996	Apr	CAHN	
	@		50MG	A 074483	003	Feb 13, 1996	Jul	CAHN	
	@		50MG	A 074590	001	Aug 30, 1996	Apr	CAHN	
	@		100MG	A 074433	004	Feb 13, 1996	Jul	CAHN	
	@		100MG	A 074462	004	Feb 13, 1996	Apr	CAHN	
	@		100MG	A 074483	004	Feb 13, 1996	Jul	CAHN	
	@		100MG	A 074590	003	Aug 30, 1996	Apr	CAHN	
AB	+	MYLAN	100MG	A 074434	004	Feb 13, 1996	May	CRLD	

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL		CAPTOPRIL AND HYDROCHLOROTHIAZIDE							
AB		G AND W LABS INC	25MG;15MG	A 074827	001	Dec 29, 1997	Apr	CAHN	
AB			25MG;25MG	A 074827	002	Dec 29, 1997	Apr	CAHN	
AB			50MG;15MG	A 074827	004	Dec 29, 1997	Apr	CAHN	
AB			50MG;25MG	A 074827	003	Dec 29, 1997	Apr	CAHN	

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL		CARBAMAZEPINE							
AB		MYLAN PHARMS INC	100MG	A 076697	001	May 20, 2011	May	CAHN	
AB			200MG	A 076697	002	May 20, 2011	May	CAHN	
AB			300MG	A 076697	003	May 20, 2011	May	CAHN	

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE;ORAL		RYTARY							
		IMPAX LABS INC	23.75MG;95MG	N 203312	001	Jan 07, 2015	Jan	NEWA	
			36.25MG;145MG	N 203312	002	Jan 07, 2015	Jan	NEWA	
			48.75MG;195MG	N 203312	003	Jan 07, 2015	Jan	NEWA	
	+		61.25MG;245MG	N 203312	004	Jan 07, 2015	Jan	NEWA	
	+	ABBVIE INC	4.63MG/ML;20MG/ML	N 203952	001	Jan 09, 2015	Jan	NEWA	

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL		VRAYLAR							
		FOREST RES INST INC	EQ 1.5MG BASE	N 204370	001	Sep 17, 2015	Sep	NEWA	
			EQ 3MG BASE	N 204370	002	Sep 17, 2015	Sep	NEWA	
			EQ 4.5MG BASE	N 204370	003	Sep 17, 2015	Sep	NEWA	
	+		EQ 6MG BASE	N 204370	004	Sep 17, 2015	Sep	NEWA	

CARISOPRODOL

TABLET;ORAL		CARISOPRODOL							
AB		INDICUS PHARMA	250MG	A 205126	001	Jul 08, 2015	Jun	NEWA	
AA			350MG	A 205126	002	Jul 08, 2015	Jun	NEWA	
>A>	AB	SHASUN PHARMS LTD	250MG	A 205513	001	Nov 12, 2015	Oct	NEWA	
>A>	AA		350MG	A 205513	002	Nov 12, 2015	Oct	NEWA	
	+	MEDA PHARMS	250MG	N 011792	004	Sep 13, 2007	Jun	CTEC	

CARVEDILOL

TABLET;ORAL		CARVEDILOL							
	@	HIKMA	3.125MG	A 077887	001	Sep 07, 2007	Jun	DISC	
	@		6.25MG	A 077887	002	Sep 07, 2007	Jun	DISC	
	@		12.5MG	A 077887	003	Sep 07, 2007	Jun	DISC	

TABLET; ORAL
CARVEDILOL

	@	25MG		A077887	004	Sep 07, 2007	Jun	DISC
AB	SUN PHARM INDS LTD	3.125MG		A076989	001	Sep 05, 2007	Apr	CAHN
AB		6.25MG		A076989	002	Sep 05, 2007	Apr	CAHN
AB		12.5MG		A076989	003	Sep 05, 2007	Apr	CAHN
AB		25MG		A076989	004	Sep 05, 2007	Apr	CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL
CEFADROXIL

	SUN PHARM INDS LTD	EQ 125MG BASE/5ML		A065115	001	Mar 26, 2003	Apr	CAHN
AB		EQ 250MG BASE/5ML		A065115	002	Mar 26, 2003	Apr	CAHN
AB		EQ 500MG BASE/5ML		A065115	003	Mar 26, 2003	Apr	CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	FACTA FARMA	EQ 500MG BASE/VIAL		A063214	001	Dec 27, 1991	Jan	CAHN
AP		EQ 1GM BASE/VIAL		A063207	001	Dec 27, 1991	Jan	CAHN
AP		EQ 10GM BASE/VIAL		A063209	001	Dec 27, 1991	Jan	CAHN
AP	+	EQ 20GM BASE/VIAL		A063209	002	Apr 30, 1999	Jan	CAHN

SOLUTION; INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

	BAXTER HLTHCARE	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)		N207131	001	Aug 07, 2015	Sep	CAHN
	CELERITY PHARMS	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)		N207131	001	Aug 07, 2015	Aug	NEWA

CEFIXIME

FOR SUSPENSION; ORAL
CEFIXIME

AB	AUROBINDO PHARMA LTD	100MG/5ML		A204835	001	Apr 14, 2015	Apr	NEWA
AB		200MG/5ML		A204835	002	Apr 14, 2015	Apr	NEWA
	SUPRAX							
AB	LUPIN PHARMS	100MG/5ML		A065129	001	Feb 23, 2004	Apr	CFTG
AB		200MG/5ML		A065355	001	Apr 10, 2007	Apr	CFTG

CEFOTETAN DISODIUM

INJECTABLE; INJECTION
CEFOTAN

	@ IGI LABS INC	EQ 1GM BASE/VIAL		A063293	001	Apr 29, 1993	May	CAHN
	@	EQ 1GM BASE/VIAL		N050588	001	Dec 27, 1985	Mar	CAHN
	@	EQ 2GM BASE/VIAL		A063293	002	Apr 29, 1993	May	CAHN
	@	EQ 2GM BASE/VIAL		N050588	002	Dec 27, 1985	Mar	CAHN
	@	EQ 10GM BASE/VIAL		N050588	003	Apr 25, 1988	Mar	CAHN

CEFOTAN IN PLASTIC CONTAINER

	@ IGI LABS INC	EQ 20MG BASE/ML		N050694	002	Jul 30, 1993	Mar	CAHN
	@	EQ 40MG BASE/ML		N050694	001	Jul 30, 1993	Mar	CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL
CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 50MG BASE/5ML		A065082	001	May 31, 2002	Apr	CAHN
AB		EQ 100MG BASE/5ML		A065082	002	May 31, 2002	Apr	CAHN

TABLET; ORAL

CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 100MG BASE		A065083	001	Aug 20, 2003	Apr	CAHN
AB		EQ 200MG BASE		A065083	002	Aug 20, 2003	Apr	CAHN

CEFTAZIDIME

INJECTABLE; INJECTION
FORTAZ

>D>	AP	+	CONCORDIA PHARMS INC	500MG/VIAL		N050578	001	Jul 19, 1985	Oct	CAHN
	AP	+		500MG/VIAL		N050578	001	Jul 19, 1985	Jun	CAHN
>D>	AP	+		1GM/VIAL		N050578	002	Jul 19, 1985	Oct	CAHN
	AP	+		1GM/VIAL		N050578	002	Jul 19, 1985	Jun	CAHN
>D>	AP	+		2GM/VIAL		N050578	003	Jul 19, 1985	Oct	CAHN
	AP	+		2GM/VIAL		N050578	003	Jul 19, 1985	Jun	CAHN
>D>	AP	+		6GM/VIAL		N050578	004	Jul 19, 1985	Oct	CAHN
	AP	+		6GM/VIAL		N050578	004	Jul 19, 1985	Jun	CAHN
>A>	AP	+	IGI LABS INC	500MG/VIAL		N050578	001	Jul 19, 1985	Oct	CAHN

INJECTABLE; INJECTION
FORTAZ

>A>	AP	+	1GM/VIAL	N050578	002	Jul 19, 1985	Oct	CAHN
>A>	AP	+	2GM/VIAL	N050578	003	Jul 19, 1985	Oct	CAHN
>A>	AP	+	6GM/VIAL	N050578	004	Jul 19, 1985	Oct	CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
FORTAZ IN PLASTIC CONTAINER

>D>			EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Oct	CAHN
		@	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Jun	CAHN
>D>		+	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Oct	CAHN
		+	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Jun	CAHN
>D>		+	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Oct	CAHN
		+	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Jun	CAHN
>A>		@	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Oct	CAHN
>A>		+	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Oct	CAHN
>A>		+	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Oct	CAHN

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER; IV (INFUSION)
ZERBAXA

+	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL; EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014	Aug	CAHN
---	-------------------	--------------------------------------	---------	-----	--------------	-----	------

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION
CEFTRIAZONE

AP			EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Jan	CAHN
			INJECTABLE; INTRAMUSCULAR, INTRAVENOUS					
			CEFTRIAZONE					
		@	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Jan	CAHN
		@	EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Jan	CAHN
		@	EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006	Jul	DISC

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL
CEFUROXIME AXETIL

AB			EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Apr	CAHN
AB			EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Apr	CAHN

TABLET; ORAL

CEFUROXIME AXETIL

AB			EQ 250MG BASE	A065190	001	Oct 18, 2004	Jul	CAHN
AB			EQ 500MG BASE	A065190	002	Oct 18, 2004	Jul	CAHN
AB			EQ 125MG BASE	A065118	001	Apr 25, 2003	Apr	CAHN
AB			EQ 250MG BASE	A065118	002	Apr 25, 2003	Apr	CAHN
AB			EQ 500MG BASE	A065118	003	Apr 25, 2003	Apr	CAHN

CEFUROXIME SODIUM

INJECTABLE; INJECTION
CEFUROXIME SODIUM

AP			EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Jan	CAHN
AP			EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jan	CAHN
			ZINACEF					
AP		+	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun	CAHN
AP		+	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun	CAHN
			ZINACEF IN PLASTIC CONTAINER					
		@	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jun	CAHN
		+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jun	CAHN
			INJECTABLE; INTRAMUSCULAR, INTRAVENOUS					
			CEFUROXIME SODIUM					
AB			EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Jan	CAHN
			ZINACEF					
AB		+	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun	CAHN

CELECOXIB

CAPSULE; ORAL
CELECOXIB

AB			50MG	A204519	001	Aug 21, 2015	Aug	NEWA
AB			100MG	A204519	002	Aug 21, 2015	Aug	NEWA
AB			200MG	A204519	003	Aug 21, 2015	Aug	NEWA
AB			400MG	A204519	004	Aug 21, 2015	Aug	NEWA

<u>CAPSULE;ORAL</u>						
<u>CELECOXIB</u>						
AB	APOTEX INC	50MG	A204197	001	Jun 02, 2015	May NEWA
AB		100MG	A204197	002	Jun 02, 2015	May NEWA
AB		200MG	A204197	003	Jun 02, 2015	May NEWA
AB	CIPLA LTD	50MG	A207446	001	Sep 23, 2015	Sep NEWA
AB		100MG	A207446	002	Sep 23, 2015	Sep NEWA
AB		200MG	A207446	003	Sep 23, 2015	Sep NEWA
AB		400MG	A207446	004	Sep 23, 2015	Sep NEWA
AB	LUPIN LTD	100MG	A202240	002	Jun 09, 2015	May NEWA
AB		200MG	A202240	003	Jun 09, 2015	May NEWA
AB		400MG	A202240	004	Jun 09, 2015	May NEWA
AB	MYLAN PHARMS INC	100MG	A078857	002	Feb 11, 2015	Jan NEWA
AB		200MG	A078857	003	Feb 11, 2015	Jan NEWA
AB		400MG	A078857	004	Feb 11, 2015	Jan NEWA
AB	WATSON LABS INC	50MG	A200562	001	Feb 11, 2015	Jan NEWA
AB		100MG	A200562	002	Feb 11, 2015	Jan NEWA
AB		200MG	A200562	003	Feb 11, 2015	Jan NEWA
AB		400MG	A200562	004	Feb 11, 2015	Jan NEWA
<u>CEPHALEXIN</u>						
<u>CAPSULE;ORAL</u>						
<u>CEPHALEXIN</u>						
AB	SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Apr CAHN
AB		EQ 500MG BASE	A065007	002	Sep 16, 1999	Apr CAHN
<u>FOR SUSPENSION;ORAL</u>						
<u>CEPHALEXIN</u>						
	@ SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Apr CAHN
	@	EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Apr CAHN
<u>CETIRIZINE HYDROCHLORIDE</u>						
<u>SYRUP;ORAL</u>						
<u>ZYRTEC</u>						
AA	+ J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Aug CAHN
<u>CHLOROTHIAZIDE SODIUM</u>						
<u>INJECTABLE;INJECTION</u>						
<u>CHLOROTHIAZIDE SODIUM</u>						
AP	SAGENT PHARMS	EQ 500MG BASE/VIAL	A202462	001	May 29, 2015	May NEWA
<u>CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE</u>						
<u>TABLET, EXTENDED RELEASE;ORAL</u>						
<u>CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE</u>						
	SPRIASO LLC	8MG;54.3MG	N206323	001	Jun 22, 2015	Jun NEWA
<u>CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE</u>						
<u>SOLUTION;ORAL</u>						
<u>HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE</u>						
AA	TRIS PHARMA INC	4MG/5ML;5MG/5ML	A206438	001	Jan 27, 2015	Jan NEWA
<u>VITUZ</u>						
AA	+ CYPRESS PHARM	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013	Jan CFTG
<u>CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>						
<u>SOLUTION;ORAL</u>						
<u>HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE</u>						
AA	COASTAL PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015	Jul NEWA
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX</u>						
<u>SUSPENSION, EXTENDED RELEASE;ORAL</u>						
<u>TUZISTRA XR</u>						
	+ TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Apr NEWA
	+ VERNALIS R AND D LTD	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun CAHN
<u>CHLORPROMAZINE HYDROCHLORIDE</u>						
<u>CONCENTRATE;ORAL</u>						
<u>CHLORPROMAZINE HYDROCHLORIDE INTENSOL</u>						
	@ CYCLE PHARMS LTD	30MG/ML	A088157	001	Apr 27, 1983	Jun CAHN
	@	100MG/ML	A088158	001	Apr 27, 1983	Jun CAHN

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

+ EUROHLTH INTL SARL 25MG/ML A 083329 001 Feb CAHN

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

@ CYCLE PHARMS LTD 10MG A 085331 001 Jun CAHN

@ 25MG A 085331 002 Jun CAHN

@ 50MG A 085331 003 Jun CAHN

@ 100MG A 085331 004 Jun CAHN

@ 200MG A 085331 005 Jun CAHN

@ SANDOZ 10MG A 080439 001 May DISC

@ 25MG A 080439 002 May DISC

@ 50MG A 080439 003 May DISC

@ 100MG A 080439 004 May DISC

@ 200MG A 080439 005 May DISC

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

@ G AND W LABS INC 50MG A 088651 001 May 30, 1985 Apr CAHN

AB MUTUAL PHARM 50MG A 089286 001 Jul 21, 1986 Mar CMFD

AB + MYLAN 50MG A 086831 001 Jun CTEC

THALITONE

@ CITRON PHARMA LLC 15MG N 019574 001 Dec 20, 1988 Jun DISC

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

@ ANI PHARMS INC EQ 4GM RESIN/PACKET A 074554 001 Oct 02, 1996 Aug CAHN

@ EQ 4GM RESIN/SCOOPFUL A 074554 002 Oct 02, 1996 Aug CAHN

CHOLIC ACID

CAPSULE; ORAL

CHOLBAM

ASKLEPION PHARMS LLC 50MG N 205750 001 Mar 17, 2015 Mar NEWA

+ 250MG N 205750 002 Mar 17, 2015 Mar NEWA

RTRX 50MG N 205750 001 Mar 17, 2015 Apr CAHN

+ 250MG N 205750 002 Mar 17, 2015 Apr CAHN

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

>D> + MCPRF 4-33.1mCi/ML N 203155 001 Sep 12, 2012 Oct CFTG

>A> AP + 4-33.1mCi/ML N 203155 001 Sep 12, 2012 Oct CFTG

>A> AP UNIV TX MD ANDERSON 4-33.1mCi/ML A 205690 001 Oct 29, 2015 Oct NEWA

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB ACTAVIS ELIZABETH EQ 45MG FENOFIBRIC ACID A 200920 001 Oct 07, 2015 Sep NEWA

AB EQ 135MG FENOFIBRIC ACID A 200920 002 Oct 07, 2015 Sep NEWA

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

AT APOTEX INC 8% A 078172 001 Sep 18, 2007 Sep CMFD

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

AP + MYLAN INSTITUTIONAL EQ 75MG BASE/ML A 201276 001 Jun 27, 2012 May CRLD

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@ G AND W LABS INC EQ 300MG BASE/5ML A 074176 001 Jun 01, 1994 Apr CAHN

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

AP	CLARIS PHARMASERVICE	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Apr	CAHN
AP		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Apr	CAHN
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	CLARIS PHARMASERVICE	200MG/100ML	A078024	001	Mar 18, 2008	Apr	CAHN
AP		400MG/200ML	A078024	002	Mar 18, 2008	Apr	CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

>D>	AT	NEXUS PHARMS	EQ 0.3% BASE	A077689	001	Dec 13, 2006	Oct	CAHN
>A>	AT	RISING PHARMS INC	EQ 0.3% BASE	A077689	001	Dec 13, 2006	Oct	CAHN

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 250MG BASE	A075747	001	Jun 09, 2004	Apr	CAHN
AB		EQ 500MG BASE	A075747	002	Jun 09, 2004	Apr	CAHN
AB		EQ 750MG BASE	A075747	003	Jun 09, 2004	Apr	CAHN

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP	FRESENIUS KABI USA	EQ 2MG BASE/ML	A203183	001	Feb 26, 2015	Feb	NEWA
CISATRACURIUM BESYLATE PRESERVATIVE FREE							
AP	FRESENIUS KABI USA	EQ 2MG BASE/ML	A203182	001	Feb 26, 2015	Feb	NEWA
AP		EQ 10MG BASE/ML	A203182	002	Feb 26, 2015	Feb	NEWA

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

AP	ACCORD HLTHCARE	1MG/ML	A206774	001	Aug 18, 2015	Aug	NEWA
----	-----------------	--------	---------	-----	--------------	-----	------

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	G AND W LABS INC	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr	CAHN
AB		EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr	CAHN
AB		EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr	CAHN

CLARITHROMYCIN

FOR SUSPENSION; ORAL

CLARITHROMYCIN

AB	SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007	Apr	CAHN
AB		250MG/5ML	A065382	002	Aug 30, 2007	Apr	CAHN

TABLET; ORAL

CLARITHROMYCIN

AB	HEC PHARM USA INC	250MG	A203584	001	Sep 28, 2015	Sep	NEWA
AB		500MG	A203584	002	Sep 28, 2015	Sep	NEWA
AB	SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004	Apr	CAHN
AB		500MG	A065174	002	Sep 24, 2004	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

AB	LUPIN LTD	500MG	A202532	001	Sep 15, 2015	Aug	NEWA
AB	+ TEVA	500MG	A065154	001	May 18, 2005	Jan	CRLD

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TIMENTIN

@	GLAXOSMITHKLINE	EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986	May	DISC
@		EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985	May	DISC
@		EQ 200MG BASE/VIAL; EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985	May	DISC
@		EQ 1GM BASE/VIAL; EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987	May	DISC
TIMENTIN IN PLASTIC CONTAINER							
@	GLAXOSMITHKLINE	EQ 100MG BASE/100ML; EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989	May	DISC

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

@ ANI PHARMS INC

1.34MG

A073282 001 Jan 31, 1992 Jul CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB G AND W LABS INC EQ 150MG BASE

A063029 001 Sep 20, 1989 Apr CAHN

AB EQ 300MG BASE

A063029 002 Aug 05, 2005 Apr CAHN

AB SUN PHARM INDS LTD EQ 150MG BASE

A065061 001 Feb 02, 2001 Apr CAHN

AB EQ 300MG BASE

A065061 002 Feb 02, 2001 Apr CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

AP ALVOGEN INC EQ 150MG BASE/ML

A062800 001 Jul 24, 1987 Sep CAHN

AP EQ 150MG BASE/ML

A062801 001 Jul 24, 1987 Sep CAHN

AP EQ 150MG BASE/ML

A062943 001 Sep 29, 1988 Sep CAHN

@ IGI LABS INC

EQ 150MG BASE/ML

A062928 001 Feb 13, 1989 Mar CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

@ BOCA PHARMA LLC EQ 1% BASE

A062944 001 Jan 11, 1989 Jan CAHN

AT VINTAGE PHARMS EQ 1% BASE

A203343 001 May 29, 2015 May NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB ACTAVIS MID ATLANTIC 1.2%;0.025%

A202564 001 Jun 12, 2015 Jun NEWA

ZIANA

AB + MEDICIS 1.2%;0.025%

N050802 001 Nov 07, 2006 Jun CTEC

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2 + FOUGERA PHARMS 0.05%

A075430 001 May 26, 1999 May CRLD

CORMAX

AB1 + HI TECH PHARMA 0.05%

A074220 001 May 16, 1997 Jun CRLD

GEL;TOPICAL

CLOBETASOL PROPIONATE

AB + FOUGERA PHARMS 0.05%

A075368 001 Feb 15, 2000 May CRLD

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB G AND W LABS INC 0.05%

A074089 001 Feb 16, 1994 Feb CAHN

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

AT G AND W LABS INC 0.05%

A074331 001 Dec 15, 1995 Mar CMFD

CLOMIPHENE CITRATE

TABLET;ORAL

SEROPHENE

@ EMD SERONO

50MG

N018361 001 Mar 22, 1982 Jun DISC

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CLONIDINE

AB ACTAVIS LABS UT INC 0.1MG/24HR

A090873 001 May 06, 2014 Mar CAHN

AB 0.2MG/24HR

A090873 002 May 06, 2014 Mar CAHN

AB 0.3MG/24HR

A090873 003 May 06, 2014 Mar CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

@ DAVA PHARMS INC

0.1MG

A071783 001 Apr 05, 1988 May DISC

@

0.2MG

A071784 001 Apr 05, 1988 May DISC

@

0.3MG

A071785 001 Apr 05, 1988 May DISC

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB2 ACTAVIS ELIZABETH 0.1MG

A202792 001 May 15, 2015 May NEWA

AB1 0.1MG

A203320 001 May 15, 2015 May NEWA

<u>TABLET, EXTENDED RELEASE;ORAL</u>									
CLONIDINE HYDROCHLORIDE									
	@		0.2MG		A202792	002	May 15, 2015	Aug	DISC
AB2			0.2MG		A202792	002	May 15, 2015	May	NEWA
	@		0.2MG		A203320	002	May 15, 2015	Aug	DISC
AB1			0.2MG		A203320	002	May 15, 2015	May	NEWA
	@	ANCHEN PHARMS	0.1MG		A202983	001	Apr 02, 2014	Aug	DISC
AB2			0.1MG		A202983	001	Apr 02, 2014	May	CTEC
	@		0.2MG		A202983	002	Apr 02, 2014	Aug	DISC
AB2			0.2MG		A202983	002	Apr 02, 2014	May	CTEC
CLONIDINE HYDROCHLORIDE									
AB1		ANCHEN PHARMS	0.1MG		A202984	001	Sep 30, 2013	May	CTEC
	@		0.2MG		A202984	002	Sep 30, 2013	Aug	DISC
AB1			0.2MG		A202984	002	Sep 30, 2013	May	CTEC
KAPVAY									
AB1	+	CONCORDIA PHARMS INC	0.1MG		N022331	003	Sep 28, 2010	Aug	CRLD
AB1			0.1MG		N022331	003	Sep 28, 2010	Jun	CRLD
AB1	+		0.1MG		N022331	003	Sep 28, 2010	May	CTEC
	@		0.2MG		N022331	004	Sep 28, 2010	Aug	DISC
AB1	+		0.2MG		N022331	004	Sep 28, 2010	Jun	CRLD
AB1			0.2MG		N022331	004	Sep 28, 2010	May	CTEC
<u>CLORAZEPATE DIPOTASSIUM</u>									
TABLET;ORAL									
CLORAZEPATE DIPOTASSIUM									
AB		SUN PHARM INDS LTD	3.75MG		A076911	001	Sep 29, 2004	Apr	CAHN
AB			7.5MG		A076911	002	Sep 29, 2004	Apr	CAHN
AB			15MG		A076911	003	Sep 29, 2004	Apr	CAHN
<u>CLOZAPINE</u>									
TABLET;ORAL									
CLOZAPINE									
AB		ACTAVIS LABS FL INC	25MG		A203807	001	Sep 17, 2015	Sep	NEWA
AB			100MG		A203807	002	Sep 17, 2015	Sep	NEWA
CLOZARIL									
AB		HERITAGE LIFE	25MG		N019758	001	Sep 26, 1989	Aug	CAHN
AB	+		100MG		N019758	002	Sep 26, 1989	Aug	CAHN
TABLET, ORALLY DISINTEGRATING;ORAL									
CLOZAPINE									
AB		MYLAN PHARMS INC	25MG		A201824	002	Sep 15, 2015	Aug	NEWA
AB			100MG		A201824	003	Sep 15, 2015	Aug	NEWA
FAZACLO ODT									
AB		JAZZ PHARMS III	25MG		N021590	001	Feb 10, 2004	Aug	CFTG
AB	+		100MG		N021590	002	Feb 10, 2004	Aug	CFTG
<u>COBICISTAT; DARUNAVIR ETHANOLATE</u>									
TABLET;ORAL									
PREZCOBIX									
	+	JANSSEN PRODS	150MG;EQ 800MG BASE		N205395	001	Jan 29, 2015	Jan	NEWA
<u>CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE</u>									
SYRUP;ORAL									
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE									
AA		AMNEAL PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML		A200963	001	Aug 26, 2015	Aug	NEWA
<u>CODEINE SULFATE</u>									
SOLUTION;ORAL									
CODEINE SULFATE									
	@	ROXANE	30MG/5ML		N202245	001	Jun 30, 2011	Jan	DISC
<u>COLCHICINE</u>									
CAPSULE;ORAL									
MITIGARE									
		HIKMA INTL PHARMS	0.6MG		N204820	001	Sep 26, 2014	Jan	CAHN
<u>COLCHICINE; PROBENECID</u>									
TABLET;ORAL									
PROBENECID AND COLCHICINE									
	@	ANI PHARMS INC	0.5MG;500MG		A083734	001		Aug	CAHN

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION
 COLISTIMETHATE SODIUM
 AP XELLIA PHARMS APS EQ 150MG BASE/VIAL A205356 001 May 29, 2015 May NEWA

CORTICOTROPIN

INJECTABLE; INJECTION
 H.P. ACTHAR GEL
 @ MALLINCKRODT ARD 40 UNITS/ML N008372 006 Aug CAHN
 + 80 UNITS/ML N008372 008 Aug CAHN

CYANOCOBALAMIN

INJECTABLE; INJECTION
 CYANOCOBALAMIN
 @ EUROHLTH INTL SARL 1MG/ML A080515 002 Feb CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
 CYCLOBENZAPRINE HYDROCHLORIDE
 AB ORIT LABS LLC 5MG A078218 002 Jun 19, 2015 Jun NEWA
 AB SUN PHARM INDS LTD 5MG A078722 001 May 12, 2008 Apr CAHN
 AB 7.5MG A078722 002 May 12, 2008 Apr CAHN
 AB 10MG A078722 003 May 12, 2008 Apr CAHN

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
 CYPROHEPTADINE HYDROCHLORIDE
 AA MIRROR PHARMS LLC 4MG A205087 001 Sep 23, 2015 Sep NEWA

DABRAFENIB MESYLATE

CAPSULE; ORAL
 TAFINLAR
 NOVARTIS PHARMS CORP EQ 50MG BASE N202806 001 May 29, 2013 Mar CAHN
 + EQ 75MG BASE N202806 002 May 29, 2013 Mar CAHN

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL
 DAKLINZA
 BRISTOL-MYERS SQUIBB EQ 30MG BASE N206843 001 Jul 24, 2015 Jul NEWA
 + EQ 60MG BASE N206843 002 Jul 24, 2015 Jul NEWA

DALTEPARIN SODIUM

INJECTABLE; INJECTION
 FRAGMIN
 @ PFIZER INC 7,500 IU/0.75ML N020287 008 Apr 04, 2002 Jun CAHN
 @ PHARMACIA AND UPJOHN 7,500 IU/0.75ML N020287 008 Apr 04, 2002 Apr CAHN
 INJECTABLE; SUBCUTANEOUS
 FRAGMIN
 PFIZER INC 2,500IU/0.2ML (12,500IU/ML) N020287 001 Dec 22, 1994 Jun CAHN
 5,000IU/0.2ML (25,000IU/ML) N020287 003 Mar 18, 1996 Jun CAHN
 7,500IU/0.3ML (25,000IU/ML) N020287 005 Apr 04, 2002 Jun CAHN
 @ 10,000IU/0.4ML (10,000IU/ML) N020287 002 May 01, 2007 Jun CAHN
 10,000IU/ML (10,000IU/ML) N020287 004 Jan 30, 1998 Jun CAHN
 12,500IU/0.5ML (25,000IU/ML) N020287 009 May 01, 2007 Jun CAHN
 15,000IU/0.6ML (25,000IU/ML) N020287 010 May 01, 2007 Jun CAHN
 18,000IU/0.72ML (25,000IU/ML) N020287 011 May 01, 2007 Jun CAHN
 + 95,000IU/3.8ML (25,000IU/ML) N020287 006 Apr 04, 2002 Jun CAHN
 @ 95,000IU/9.5ML (10,000IU/ML) N020287 007 Apr 04, 2002 Jun CAHN
 PHARMACIA AND UPJOHN 2,500IU/0.2ML (12,500IU/ML) N020287 001 Dec 22, 1994 Apr CAHN
 5,000IU/0.2ML (25,000IU/ML) N020287 003 Mar 18, 1996 Apr CAHN
 7,500IU/0.3ML (25,000IU/ML) N020287 005 Apr 04, 2002 Apr CAHN
 @ 10,000IU/0.4ML (25,000IU/ML) N020287 002 May 01, 2007 Apr CAHN
 10,000IU/ML (10,000IU/ML) N020287 004 Jan 30, 1998 Apr CAHN
 12,500IU/0.5ML (25,000IU/ML) N020287 009 May 01, 2007 Apr CAHN
 15,000IU/0.6ML (25,000IU/ML) N020287 010 May 01, 2007 Apr CAHN
 18,000IU/0.72ML (25,000IU/ML) N020287 011 May 01, 2007 Apr CAHN
 + 95,000IU/3.8ML (25,000IU/ML) N020287 006 Apr 04, 2002 Apr CAHN
 @ 95,000IU/9.5ML (10,000IU/ML) N020287 007 Apr 04, 2002 Apr CAHN

DANTROLENE SODIUM

CAPSULE;ORAL

DANTROLENE SODIUM

AB	ELITE LABS INC	25MG	A076686	001	Oct 24, 2005	May	CAHN
AB		50MG	A076686	002	Oct 24, 2005	May	CAHN
AB		100MG	A076686	003	Oct 24, 2005	May	CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN HYDROBROMIDE

AB	ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Mar	NEWA
AB		EQ 15MG BASE	A091190	002	Mar 13, 2015	Mar	NEWA
	ENABLEX						
AB	WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Mar	CFTG
AB	+	EQ 15MG BASE	N021513	002	Dec 22, 2004	Mar	CFTG

DASATINIB

TABLET;ORAL

SPRYCEL

+ BRISTOL MYERS SQUIBB

		100MG	N021986	004	May 30, 2008	Sep	CRLD
		140MG	N021986	006	Oct 28, 2010	Sep	CRLD

DECITABINE

INJECTABLE;INTRAVENOUS

DACOGEN

AP	+	OTSUKA PHARM CO LTD	50MG/VIAL	N021790	001	May 02, 2006	Jan	CAHN
----	---	---------------------	-----------	---------	-----	--------------	-----	------

DEFERASIROX

TABLET;ORAL

JADENU

NOVARTIS PHARMS CORP

		90MG	N206910	001	Mar 30, 2015	Mar	NEWA
		180MG	N206910	002	Mar 30, 2015	Mar	NEWA
	+	360MG	N206910	003	Mar 30, 2015	Mar	NEWA

DEFERIPRONE

SOLUTION;ORAL

FERRIPROX

+ APOPHARMA INC

		100MG/ML	N208030	001	Sep 09, 2015	Sep	NEWA
--	--	----------	---------	-----	--------------	-----	------

DEMECLOCYCLINE HYDROCHLORIDE

TABLET;ORAL

DEMECLOCYCLINE HYDROCHLORIDE

AB	EPIC PHARMA LLC	150MG	A065447	001	Aug 18, 2015	Aug	NEWA
AB		300MG	A065447	002	Aug 18, 2015	Aug	NEWA

DEOXYCHOLIC ACID

SOLUTION;SUBCUTANEOUS

KYBELLA

+ KYTHERA BIOPHARMS

		20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Apr	NEWA
--	--	--------------------	---------	-----	--------------	-----	------

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

ANI PHARMS INC

		25MG	A071803	002	Dec 08, 1987	Sep	CMS1
		50MG	A071803	003	Dec 08, 1987	Sep	CMS1
		75MG	A071803	004	Dec 08, 1987	Sep	CMS1
		150MG	A071803	005	May 29, 1997	Sep	CMS1

DESIRUDIN RECOMBINANT

INJECTABLE;SUBCUTANEOUS

IPRIVASK

+ VALEANT PHARMS NORTH

		15MG/VIAL	N021271	001	Apr 04, 2003	May	CAHN
--	--	-----------	---------	-----	--------------	-----	------

DESLORATADINE

SOLUTION;ORAL

CLARINEX

AA	+	MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004	Jun	CFTG
		DESLORATADINE						
AA		TARO PHARM INDS	0.5MG/ML	A202592	001	Jun 30, 2015	Jun	NEWA

DESMOPRESSIN ACETATE

TABLET; ORAL

DDAVP

AB	FERRING PHARMS INC	0.1MG	N019955	001	Sep 06, 1995	Jan	CAHN
AB	+ DESMOPRESSIN ACETATE	0.2MG	N019955	002	Sep 06, 1995	Jan	CAHN
AB	GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May	NEWA
AB		0.2MG	A201831	002	May 28, 2015	May	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

BEKYREE

AB	LUPIN LTD	0.15MG, N/A; 0.02MG, 0.01MG	A202226	001	Aug 12, 2015	Jul	NEWA
AB	+ ASPEN GLOBAL INC	0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG	N021090	001	Dec 20, 2000	Aug	CAHN
AB	ISIBLOOM SANDOZ INC	0.15MG; 0.03MG	A202789	001	Aug 12, 2015	Jul	NEWA
AB	+ KARIVA BARR	0.15MG, N/A; 0.02MG, 0.01MG	A075863	001	Apr 05, 2002	Apr	CTEC
AB	KIMIDESS VINTAGE PHARMS	0.15MG, N/A; 0.02MG, 0.01MG	A076681	001	Apr 30, 2015	Apr	NEWA

DESONIDE

CREAM; TOPICAL

DESONIDE

AB	TEVA PHARMS	0.05%	A074027	001	Sep 28, 1992	May	CMFD
----	-------------	-------	---------	-----	--------------	-----	------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB	ACTAVIS MID ATLANTIC	0.25%	A205082	001	Sep 04, 2015	Aug	NEWA
AB	VERSAPHARM INC	0.25%	A203234	001	Jun 12, 2015	Jun	NEWA

OINTMENT; TOPICAL

DESOXIMETASONE

AB	PERRIGO NEW YORK	0.25%	A077770	001	Apr 20, 2015	Apr	NEWA
----	------------------	-------	---------	-----	--------------	-----	------

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

AB	ALEMBIC PHARMS LTD	EQ 50MG BASE	A204003	001	Jun 29, 2015	Jun	NEWA
AB		EQ 100MG BASE	A204003	002	Jun 29, 2015	Jun	NEWA
AB	LUPIN LTD	EQ 50MG BASE	A204172	001	Jun 29, 2015	Jun	NEWA
AB		EQ 100MG BASE	A204172	002	Jun 29, 2015	Jun	NEWA
AB	MYLAN PHARMS INC	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun	NEWA
AB		EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun	NEWA
AB	SANDOZ INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Jun	NEWA
AB		EQ 100MG BASE	A204028	002	Jun 29, 2015	Jun	NEWA
AB	PRISTIQ						
AB	+ WYETH PHARMS INC	EQ 50MG BASE	N021992	001	Feb 29, 2008	Jun	CFTG
AB	+	EQ 100MG BASE	N021992	002	Feb 29, 2008	Jun	CFTG

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	BD RX	EQ 4MG PHOSPHATE/ML	A203129	001	Sep 30, 2015	Sep	NEWA
AP	@ EUROHLTH INTL SARL	EQ 4MG PHOSPHATE/ML	A084282	001		Mar	CAHN
AP	+	EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Feb	CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

MAXITROL

AT	+ ALCON LABS INC	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N050065	002		Mar	CAHN
AT	+ ALCON LABS INC	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N050023	002		Mar	CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A201072	001	Sep 18, 2015	Sep NEWA
AP	SUN PHARM INDS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202126	001	Aug 20, 2015	Aug NEWA
	PRECEDEX					
	HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Jan NEWA

>A> SOLUTION; IV (INFUSION)

DEXMEDETOMIDINE HYDROCHLORIDE

>A>	+ HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628	002	Oct 21, 2015	Oct NEWA
>A>		EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628	001	Oct 21, 2015	Oct NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	MYLAN PHARMS INC	5MG	A204266	001	Aug 25, 2015	Aug NEWA
AB		10MG	A204266	002	Aug 25, 2015	Aug NEWA
AB		15MG	A204266	003	Aug 25, 2015	Aug NEWA
AB		40MG	A204266	007	Aug 25, 2015	Aug NEWA
AB	WATSON LABS INC	5MG	A079108	001	Aug 05, 2015	Jul NEWA
AB		10MG	A079108	002	Aug 05, 2015	Jul NEWA

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	2.5MG	A201231	001	Sep 24, 2015	Sep NEWA
AB		5MG	A201231	002	Sep 24, 2015	Sep NEWA
AB		10MG	A201231	003	Sep 24, 2015	Sep NEWA

DEXTOSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	5GM/100ML; 30MG/100ML; 37MG/100ML; 36 8MG/100ML; 526MG/100ML; 502MG/100ML	N017451	001			Mar DISC
-------------------	---	---------	-----	--	--	----------

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-76R

AP	+ LIEBEL-FLARSHEIM	66%; 10%	N019292	001	Sep 29, 1989	Feb CAHN
	SOLUTION; ORAL, RECTAL					
	MD-GASTROVIEW					
AA	LIEBEL-FLARSHEIM	66%; 10%	A087388	001		Jan CAHN

DICHLORPHENAMIDE

TABLET; ORAL

KEVEYIS

TARO	50MG	N011366	002	Aug 07, 2015	Aug NEWA
------	------	---------	-----	--------------	----------

DICLOFENAC SODIUM

GEL; TOPICAL

VOLTAREN

+ GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Aug CAHN
------------------------	----	---------	-----	--------------	----------

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AT	IGI LABS INC	1.5%	A202769	001	Jul 08, 2015	Jun NEWA
AT	LUPIN LTD	1.5%	A204132	001	Aug 20, 2015	Aug NEWA

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

>D>	AB	VALEANT INTL	100MG	A075492	001	Feb 11, 2000	Oct CAHN
>A>	AB	VPNA	100MG	A075492	001	Feb 11, 2000	Oct CAHN

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

TENUATE

AA	+ ACTAVIS LABS UT INC	25MG	N011722	002		Mar CAHN
----	-----------------------	------	---------	-----	--	----------

		TABLET, EXTENDED RELEASE;ORAL							
		TENUATE DOSPAN							
AB	+	ACTAVIS LABS UT INC	75MG	N012546	001			Mar	CAHN
<u>DIFLORASONE DIACETATE</u>									
		OINTMENT;TOPICAL							
		DIFLORASONE DIACETATE							
AB		VERSAPHARM INC	0.05%	A206572	001	Jul 24, 2015		Jul	NEWA
<u>DIFLUNISAL</u>									
		TABLET;ORAL							
		DIFLUNISAL							
AB		HERITAGE PHARMA	500MG	A202845	001	Mar 08, 2012		Mar	CAHN
<u>DIGOXIN</u>									
		INJECTABLE;INJECTION							
		DIGOXIN							
AP		EUROHLTH INTL SARL	0.25MG/ML	A083391	001			Feb	CAHN
		TABLET;ORAL							
		DIGOXIN							
AB		MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999		Jan	CTEC
AB			0.25MG	A040282	002	Dec 23, 1999		Jan	CTEC
AB		SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003		Feb	CMFD
AB			0.25MG	A076363	002	Jan 31, 2003		Feb	CMFD
		LANOXIN							
		CONCORDIA PHARMS INC							
AB			0.0625MG	N020405	001	Sep 30, 1997		Apr	CAHN
			0.125MG	N020405	002	Sep 30, 1997		Apr	CAHN
			0.1875MG	N020405	003	Sep 30, 1997		Apr	CAHN
AB	+		0.25MG	N020405	004	Sep 30, 1997		Apr	CAHN
	@		0.375MG	N020405	005	Sep 30, 1997		Apr	CAHN
	@		0.5MG	N020405	006	Sep 30, 1997		Apr	CAHN
<u>DILTIAZEM HYDROCHLORIDE</u>									
		CAPSULE, EXTENDED RELEASE;ORAL							
>D>		DILT-CD							
>D>	AB3	APOTEX	120MG	A076151	001	May 20, 2004		Oct	DISC
>A>		@	120MG	A076151	001	May 20, 2004		Oct	DISC
>D>	AB3		180MG	A076151	002	May 20, 2004		Oct	DISC
>A>		@	180MG	A076151	002	May 20, 2004		Oct	DISC
>D>	AB3		240MG	A076151	003	May 20, 2004		Oct	DISC
>A>		@	240MG	A076151	003	May 20, 2004		Oct	DISC
>D>	AB3		300MG	A076151	004	May 20, 2004		Oct	DISC
>A>		@	300MG	A076151	004	May 20, 2004		Oct	DISC
		DILTIAZEM HYDROCHLORIDE							
AB2	+	MYLAN	240MG	A075124	001	Mar 18, 1998		Feb	CRLD
		TIAZAC							
AB4		VALEANT PHARMS NORTH	120MG	N020401	001	Sep 11, 1995		Feb	CAHN
AB4			180MG	N020401	002	Sep 11, 1995		Feb	CAHN
AB4			240MG	N020401	003	Sep 11, 1995		Feb	CAHN
AB4			300MG	N020401	004	Sep 11, 1995		Feb	CAHN
AB4			360MG	N020401	005	Sep 11, 1995		Feb	CAHN
AB4	+		420MG	N020401	006	Oct 16, 1998		Feb	CAHN
		INJECTABLE;INJECTION							
		DILTIAZEM HYDROCHLORIDE							
AP		EUROHLTH INTL SARL	5MG/ML	A078538	001	Dec 17, 2008		Jun	CAHN
<u>DIPHENHYDRAMINE HYDROCHLORIDE</u>									
		INJECTABLE;INJECTION							
		DIPHENHYDRAMINE HYDROCHLORIDE							
AP	+	EUROHLTH INTL SARL	50MG/ML	A080817	002			Jun	CAHN
<u>DIPYRIDAMOLE</u>									
		INJECTABLE;INJECTION							
		DIPYRIDAMOLE							
AP		EUROHLTH INTL SARL	5MG/ML	A074521	001	Oct 18, 1996		Jun	CAHN

DISULFIRAMTABLET; ORAL
DISULFIRAM

AB	MYLAN PHARMS INC	250MG	A203916	001	Mar 04, 2015	Feb	NEWA
AB		500MG	A203916	002	Mar 04, 2015	Feb	NEWA

DIVALPROEX SODIUMTABLET, EXTENDED RELEASE; ORAL
DIVALPROEX SODIUM

AB	AMNEAL PHARMS	EQ 250MG VALPROIC ACID	A203730	001	May 29, 2015	May	NEWA
AB		EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015	May	NEWA
	@ G AND W LABS INC	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009	Jul	CAHN

DOBUTAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DOBUTAMINE HYDROCHLORIDE

	@ IGI LABS INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Mar	CAHN
--	----------------	-------------------	---------	-----	--------------	-----	------

DOCETAXELINJECTABLE; INJECTION
DOCETAXEL

AP	TEVA PHARMS USA	20MG/ML (20MG/ML)	A203877	001	Sep 16, 2015	Aug	NEWA
AP		80MG/4ML (20MG/ML)	A203877	002	Sep 16, 2015	Aug	NEWA

DONEPEZIL HYDROCHLORIDETABLET; ORAL
DONEPEZIL HYDROCHLORIDE

AB	HETERO LABS LTD V	5MG	A203034	001	Jan 30, 2015	Jan	NEWA
AB		10MG	A203034	002	Jan 30, 2015	Jan	NEWA
>A>	AB LUPIN LTD	23MG	A202782	001	Oct 30, 2015	Oct	NEWA
>A>	AB MYLAN PHARMS INC	23MG	A202656	001	Oct 22, 2015	Oct	NEWA
AB	SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010	Apr	CAHN
AB		10MG	A076786	002	Nov 26, 2010	Apr	CAHN
AB		23MG	A204293	001	Jun 05, 2015	May	NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
NAMZARIC

	FOREST LABS LLC	10MG; 14MG	N206439	001	Dec 23, 2014	Mar	CAHN
+		10MG; 28MG	N206439	002	Dec 23, 2014	Mar	CAHN

DOPAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DOPAMINE HYDROCHLORIDE

	@ IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985	Mar	CAHN
	@	40MG/ML	N018656	001	Jun 28, 1983	Mar	CAHN
	@	80MG/ML	A070089	001	Oct 23, 1985	Mar	CAHN
	@	80MG/ML	A070090	001	Oct 23, 1985	Mar	CAHN
	@	80MG/ML	A070091	001	Oct 23, 1985	Mar	CAHN
	@	160MG/ML	A070092	001	Oct 23, 1985	Mar	CAHN
	@	160MG/ML	A070093	001	Oct 23, 1985	Mar	CAHN
	@	160MG/ML	A070094	001	Oct 23, 1985	Mar	CAHN

DOXAPRAM HYDROCHLORIDEINJECTABLE; INJECTION
DOPRAM

AP	+ EUROHLTH INTL SARL	20MG/ML	N014879	001		Jun	CAHN
----	----------------------	---------	---------	-----	--	-----	------

DOXEPIIN HYDROCHLORIDECAPSULE; ORAL
DOXEPIIN HYDROCHLORIDE

AB	+ MYLAN PHARMS INC	EQ 100MG BASE	A070791	005	May 13, 1986	Jan	CRLD
	+ PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987	Jan	CRLD

CREAM; TOPICAL
ZONALON

+	DELCOR ASSET CORP	5%	N020126	001	Apr 01, 1994	Mar	CAHN
---	-------------------	----	---------	-----	--------------	-----	------

DOXERCALCIFEROL

INJECTABLE; INJECTION
DOXERCALCIFEROL

AP AKORN INC 4MCG/2ML (2MCG/ML) A203929 001 May 07, 2015 Apr NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
ADRIAMYCIN PFS

>D> @ PHARMACIA AND UPJOHN 2MG/ML N050629 001 Dec 23, 1987 Oct CTNA
 >D> @ 200MG/100ML N050629 002 May 03, 1988 Oct CTNA
 >D> ADRIAMYCIN RDF
 >D> @ PHARMACIA AND UPJOHN 10MG/VIAL N050467 001 Oct CTNA
 >D> @ 20MG/VIAL N050467 003 May 20, 1985 Oct CTNA
 >D> @ 50MG/VIAL N050467 002 Oct CTNA
 >D> @ 150MG/VIAL N050467 004 Jul 22, 1987 Oct CTNA

DOXORUBICIN HYDROCHLORIDE

>A> AP + PHARMACIA AND UPJOHN 2MG/ML N050629 001 Dec 23, 1987 Oct CMFD
 >A> @ 2MG/ML N050629 001 Dec 23, 1987 Oct CTNA
 >A> @ 10MG/VIAL N050467 001 Oct CTNA
 >A> @ 20MG/VIAL N050467 003 May 20, 1985 Oct CTNA
 >A> @ 50MG/VIAL N050467 002 Oct CTNA
 >A> @ 150MG/VIAL N050467 004 Jul 22, 1987 Oct CTNA
 >A> 150MG/75ML N050629 003 Mar 28, 2011 Oct NEWA
 >A> AP + 200MG/100ML N050629 002 May 03, 1988 Oct CMFD
 >A> @ 200MG/100ML N050629 002 May 03, 1988 Oct CTNA

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

AB NOVEL LABS INC EQ 50MG BASE A204446 001 May 28, 2015 May NEWA
 AB EQ 75MG BASE A204446 002 May 28, 2015 May NEWA
 AB EQ 100MG BASE A204446 003 May 28, 2015 May NEWA
 AB SUN PHARM INDS LTD EQ 50MG BASE A065053 001 Nov 22, 2000 Apr CAHN
 AB EQ 75MG BASE A065053 003 Sep 10, 2003 Apr CAHN
 AB EQ 100MG BASE A065053 002 Nov 22, 2000 Apr CAHN

TABLET; ORAL

DOXYCYCLINE

AB SUN PHARM INDS LTD EQ 50MG BASE A065356 001 May 31, 2006 Apr CAHN
 AB EQ 75MG BASE A065356 002 May 31, 2006 Apr CAHN
 AB EQ 100MG BASE A065356 003 May 31, 2006 Apr CAHN

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION
DOXYCYCLINE

@ EUROHLTH INTL SARL EQ 100MG BASE/VIAL A062450 001 Oct 27, 1983 Jun CAHN
 @ EQ 200MG BASE/VIAL A062450 002 Oct 27, 1983 Jun CAHN

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

@ IGI LABS INC 2.5MG/ML A072019 001 Oct 19, 1988 Mar CAHN
 @ 2.5MG/ML A072020 001 Oct 19, 1988 Mar CAHN
 @ 2.5MG/ML A072021 001 Oct 19, 1988 Mar CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB GLENMARK PHARMS LTD 3MG;0.02MG A204296 001 Aug 17, 2015 Aug NEWA
 >A> AB JAI PHARMA LTD 3MG;0.02MG A202594 001 Oct 22, 2015 Oct NEWA

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL
DULOXETINE HYDROCHLORIDE

AB ALKEM LABS LTD EQ 20MG BASE A203197 001 Aug 26, 2015 Aug NEWA
 AB EQ 30MG BASE A203197 002 Aug 26, 2015 Aug NEWA
 AB EQ 60MG BASE A203197 003 Aug 26, 2015 Aug NEWA
 >A> AB ANCHEN PHARMS EQ 20MG BASE A090780 001 Oct 28, 2015 Oct NEWA
 >A> AB EQ 30MG BASE A090780 002 Oct 28, 2015 Oct NEWA
 >A> AB EQ 60MG BASE A090780 003 Oct 28, 2015 Oct NEWA
 >A> AB INVENTIA HLTHCARE EQ 20MG BASE A202336 001 Oct 28, 2015 Oct NEWA
 >A> AB EQ 30MG BASE A202336 002 Oct 28, 2015 Oct NEWA

CAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

>A> AB	EQ 60MG BASE	A202336	003	Oct 28, 2015	Oct	NEWA
--------	--------------	---------	-----	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

AB	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Mar	CRLD
AB	+ PERRIGO NEW YORK	1%	A076479	001	Jun 23, 2004	Mar	CRLD

EDOXABAN TOSYLATE

TABLET; ORAL

SAVAYSA

	DAIICHI SANKYO	EQ 15MG BASE	N206316	001	Jan 08, 2015	Jan	NEWA
		EQ 30MG BASE	N206316	002	Jan 08, 2015	Jan	NEWA
+		EQ 60MG BASE	N206316	003	Jan 08, 2015	Jan	NEWA

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON

+	MYLAN INSTITUTIONAL	10MG/ML	A088873	001	Aug 06, 1985	Mar	CRLD
---	---------------------	---------	---------	-----	--------------	-----	------

ELTROMBOFAG OLAMINE

FOR SUSPENSION; ORAL

PROMACTA

+	NOVARTIS PHARMS CORP	EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015	Aug	NEWA
---	----------------------	---------------------	---------	-----	--------------	-----	------

TABLET; ORAL

PROMACTA

	NOVARTIS PHARMS CORP	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Mar	CAHN
		EQ 25MG ACID	N022291	001	Nov 20, 2008	Mar	CAHN
		EQ 50MG ACID	N022291	002	Nov 20, 2008	May	CRLD
+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Mar	CAHN
+		EQ 75MG ACID	N022291	003	Sep 08, 2009	May	CRLD
		EQ 75MG ACID	N022291	003	Sep 08, 2009	Mar	CAHN
+		EQ 100MG ACID	N022291	005	Nov 16, 2012	May	CRLD
		EQ 100MG ACID	N022291	005	Nov 16, 2012	Mar	CAHN

ELUXADOLINE

TABLET; ORAL

VIBERZI

	FOREST TOSARA LTD	75MG	N206940	001	May 27, 2015	Jul	CAHN
+		100MG	N206940	002	May 27, 2015	Jul	CAHN
	FURIEX PHARMS	75MG	N206940	001	May 27, 2015	May	NEWA
+		100MG	N206940	002	May 27, 2015	May	NEWA

EMPAGLIFLOZIN; LINAGLIPTIN

TABLET; ORAL

GLYXAMBI

	BOEHRINGER INGELHEIM	10MG; 5MG	N206073	001	Jan 30, 2015	Jan	NEWA
+		25MG; 5MG	N206073	002	Jan 30, 2015	Jan	NEWA

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

SYNJARDY

	BOEHRINGER INGELHEIM	5MG; 500MG	N206111	001	Aug 26, 2015	Aug	NEWA
		5MG; 1GM	N206111	002	Aug 26, 2015	Aug	NEWA
		12.5MG; 500MG	N206111	003	Aug 26, 2015	Aug	NEWA
+		12.5MG; 1GM	N206111	004	Aug 26, 2015	Aug	NEWA

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

AB	SANDOZ INC	2.5MG	A075496	001	Aug 22, 2000	Mar	CMFD
AB		5MG	A075496	002	Aug 22, 2000	Mar	CMFD
AB		10MG	A075459	001	Aug 22, 2000	Mar	CMFD
AB		20MG	A075459	002	Aug 22, 2000	Mar	CMFD
	@ SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000	Apr	CAHN
	@	5MG	A075556	002	Aug 22, 2000	Apr	CAHN
	@	10MG	A075556	003	Aug 22, 2000	Apr	CAHN
	@	20MG	A075556	004	Aug 22, 2000	Apr	CAHN
	VASOTEC						
AB	VALEANT PHARMS NORTH	2.5MG	N018998	005	Jul 26, 1988	Apr	CAHN

TABLET;ORAL
VASOTEC

AB		5MG	N018998	001	Dec 24, 1985	Apr	CAHN
AB		10MG	N018998	002	Dec 24, 1985	Apr	CAHN
AB	+	20MG	N018998	003	Dec 24, 1985	Apr	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	G AND W LABS INC	5MG;12.5MG	A075727	001	Sep 18, 2001	Apr	CAHN
AB		10MG;25MG	A075727	002	Sep 18, 2001	Apr	CAHN

ENTACAPONE

TABLET;ORAL
ENTACAPONE

AB	AUROBINDO PHARMA LTD	200MG	A203437	001	Jun 19, 2015	Jun	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

ENTECAVIR

TABLET;ORAL
ENTECAVIR

>A>	AB	AMNEAL PHARMS	0.5MG	A206652	001	Nov 12, 2015	Oct	NEWA
>A>	AB		1MG	A206652	002	Nov 12, 2015	Oct	NEWA
	AB	AUROBINDO PHARMA LTD	0.5MG	A206217	001	Aug 26, 2015	Aug	NEWA
	AB		1MG	A206217	002	Aug 26, 2015	Aug	NEWA
	AB	HETERO LABS LTD V	0.5MG	A205740	001	Aug 21, 2015	Aug	NEWA
	AB		1MG	A205740	002	Aug 21, 2015	Aug	NEWA

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS
ADRENALIN

+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jul	CAIN
		INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS ADRENALIN					
+	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jul	CAIN

EPINEPHRINE HYDROCHLORIDE

>D>		SOLUTION;IV (INFUSION) EPINEPHRINE						
>D>		BELCHER PHARMS LLC	EQ 1MG BASE/ML	N205029	001	Jul 29, 2014	Oct	CDFR
>A>		SOLUTION;IV (INFUSION), INTRAOCULAR EPINEPHRINE						
>A>		BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Oct	CDFR

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE
@ EUROHLTH INTL SARL 0.01MG/ML;1%
@ 0.01MG/ML;2%

A080406	001		Sep	CAHN
A080406	002		Sep	CAHN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
TEVETEN HCT

@	ABBVIE	600MG;12.5MG	N021268	001	Nov 01, 2001	Jun	DISC
@		600MG;25MG	N021268	002	Nov 01, 2001	Jun	DISC

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

AP	TEVA PHARMS USA	2MG/ML	A090854	001	Jun 12, 2015	Jun	NEWA	
AP		75MG/100ML	A091555	001	Jun 05, 2015	May	NEWA	
		INTEGRILIN						
AP	+	SCHERING	2MG/ML	N020718	001	May 18, 1998	Jun	CTEC
AP	+		75MG/100ML	N020718	002	May 18, 1998	May	CFTG

ERGOCALCIFEROL

CAPSULE;ORAL
VITAMIN D

AA	BANNER LIFE SCIENCES	50,000 IU	A080704	001		Jan	CAHN
----	----------------------	-----------	---------	-----	--	-----	------

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL

ERGOSTAT

@ WATSON LABS INC

2MG

A 088337 001 Jun 08, 1984 Aug CAHN

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

@ MYLAN PHARMS INC

EQ 25MG BASE

A 091002 001 Jun 11, 2014 Sep DISC

@

EQ 100MG BASE

A 091002 002 Jun 11, 2014 Sep DISC

@

EQ 150MG BASE

A 091002 003 Jun 11, 2014 Sep DISC

>D> AB TEVA PHARMS USA

EQ 100MG BASE

A 091059 002 Aug 28, 2015 Oct DISC

>A> @

EQ 100MG BASE

A 091059 002 Aug 28, 2015 Oct DISC

AB

EQ 100MG BASE

A 091059 002 Aug 28, 2015 Aug NEWA

>D> AB

EQ 150MG BASE

A 091059 003 Aug 28, 2015 Oct DISC

>A> @

EQ 150MG BASE

A 091059 003 Aug 28, 2015 Oct DISC

AB

EQ 150MG BASE

A 091059 003 Aug 28, 2015 Aug NEWA

TARCEVA

OSI PHARMS

EQ 25MG BASE

N 021743 001 Nov 18, 2004 Sep CTEC

>D> AB

EQ 100MG BASE

N 021743 002 Nov 18, 2004 Oct CTEC

>A> @

EQ 100MG BASE

N 021743 002 Nov 18, 2004 Oct CTEC

>D> AB +

EQ 150MG BASE

N 021743 003 Nov 18, 2004 Oct CTEC

>A> +

EQ 150MG BASE

N 021743 003 Nov 18, 2004 Oct CTEC

ERYTHROMYCIN ESTOLATE

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

@ G AND W LABS INC

EQ 125MG BASE/5ML

A 062169 001 Oct 17, 1990 Apr CAHN

@

EQ 250MG BASE/5ML

A 062169 002 Oct 17, 1990 Apr CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

@ ANI PHARMS INC

EQ 200MG BASE/5ML

A 062055 001

Jul CAHN

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA ANTRIM PHARMS LLC

EQ 5MG BASE/5ML

A 203967 001 May 26, 2015 May NEWA

TABLET;ORAL

ESCITALOPRAM OXALATE

AB MYLAN PHARMS INC

EQ 5MG BASE

A 077550 001 May 14, 2015 Apr NEWA

AB

EQ 10MG BASE

A 077550 002 May 14, 2015 Apr NEWA

AB

EQ 20MG BASE

A 077550 003 May 14, 2015 Apr NEWA

AB PRINSTON INC

EQ 5MG BASE

A 078032 001 Aug 28, 2015 Aug NEWA

AB

EQ 10MG BASE

A 078032 002 Aug 28, 2015 Aug NEWA

AB

EQ 20MG BASE

A 078032 003 Aug 28, 2015 Aug NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

AP AUROBINDO PHARMA LTD

10MG/ML

A 205520 001 Jul 23, 2015 Jul NEWA

AP LUITPOLD

10MG/ML

A 201126 001 Feb 20, 2015 Feb NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB DR REDDYS LABS LTD

EQ 20MG BASE

A 078279 001 Sep 25, 2015 Sep NEWA

AB

EQ 40MG BASE

A 078279 002 Sep 25, 2015 Sep NEWA

AB HETERO LABS LTD III

EQ 20MG BASE

A 202784 001 Sep 21, 2015 Sep NEWA

AB

EQ 40MG BASE

A 202784 002 Sep 21, 2015 Sep NEWA

AB IVAX SUB TEVA PHARMS

EQ 20MG BASE

A 078003 001 Jan 26, 2015 Jan NEWA

AB

EQ 40MG BASE

A 078003 002 Jan 26, 2015 Jan NEWA

AB MYLAN LABS LTD

EQ 20MG BASE

A 078936 001 Aug 02, 2015 Jul NEWA

AB

EQ 40MG BASE

A 078936 002 Aug 03, 2015 Jul NEWA

AB MYLAN PHARMS INC

EQ 20MG BASE

A 078936 001 Aug 02, 2015 Sep CAHN

AB

EQ 40MG BASE

A 078936 002 Aug 03, 2015 Sep CAHN

>A> AB TORRENT PHARMS LTD

EQ 20MG BASE

A 203636 001 Oct 19, 2015 Oct NEWA

>A> AB

EQ 40MG BASE

A 203636 002 Oct 19, 2015 Oct NEWA

NEXIUM

AB ASTRAZENECA PHARMS

EQ 20MG BASE

N 021153 001 Feb 20, 2001 Jan CFTG

CAPSULE, DELAYED REL PELLETS;ORAL
NEXIUM

AB + EQ 40MG BASE N021153 002 Feb 20, 2001 Jan CFTG

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP ACCORD HLTHCARE EQ 40MG BASE/VIAL A205379 001 Sep 25, 2015 Sep NEWA

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE STRONTIUM

HANMI PHARM CO LTD 24.65MG N202342 001 Aug 06, 2013 Aug CPOT
+ 49.3MG N202342 002 Aug 06, 2013 Aug CPOT

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL
ALORA

BX ACTAVIS LABS UT INC 0.025MG/24HR N020655 004 Apr 05, 2002 Mar CAHN
BX 0.05MG/24HR N020655 001 Dec 20, 1996 Mar CAHN
BX 0.075MG/24HR N020655 002 Dec 20, 1996 Mar CAHN
BX 0.1MG/24HR N020655 003 Dec 20, 1996 Mar CAHN

MINIVELLE
NOVEN 0.025MG/24HR N203752 005 Sep 23, 2014 Jan NEWA

TABLET;ORAL
ESTRADIOL

>A> @ EPIC PHARMA INC 0.5MG A040275 001 Dec 29, 1998 Oct CAHN
>A> @ 1MG A040275 002 Dec 29, 1998 Oct CAHN
>A> @ 2MG A040275 003 Dec 29, 1998 Oct CAHN
>D> @ HERITAGE PHARMS INC 0.5MG A040275 001 Dec 29, 1998 Oct CAHN
>D> @ 1MG A040275 002 Dec 29, 1998 Oct CAHN
>D> @ 2MG A040275 003 Dec 29, 1998 Oct CAHN

TABLET;VAGINAL
ESTRADIOL

@ AMNEAL PHARMS 10MCG A205256 001 May 29, 2015 May DISC

ESZOPICLONE

TABLET;ORAL
ESZOPICLONE

AB MACLEODS PHARMS LTD 1MG A202929 001 Jan 30, 2015 Jan NEWA
AB 2MG A202929 002 Jan 30, 2015 Jan NEWA
AB 3MG A202929 003 Jan 30, 2015 Jan NEWA

ETHACRYNATE SODIUM

INJECTABLE;INJECTION
EDECIN

AP + ATON EQ 50MG BASE/VIAL N016093 001 Jul CFTG

ETHACRYNATE SODIUM
PAR STERILE PRODUCTS EQ 50MG BASE/VIAL A205473 001 Jul 29, 2015 Jul NEWA

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL
ETHAMBUTOL HYDROCHLORIDE

AB VERSAPHARM INC 100MG A075095 001 Nov 30, 1999 Jan CMFD
AB 400MG A075095 002 Nov 30, 1999 Jan CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL
ASHLYNA

AB GLENMARK GENERICS 0.03MG,0.01MG;0.15MG,N/A A203163 001 Feb 23, 2015 Feb NEWA
LEVONORGESTREL AND ETHINYL ESTRADIOL
AB GLENMARK GENERICS 0.02MG;0.09MG A202791 001 Apr 09, 2015 Mar NEWA
AB GLENMARK PHARMS LTD 0.03MG;0.15MG A203164 001 Jun 12, 2015 Jun NEWA
AB + WATSON LABS 0.02MG;0.09MG A079218 001 Jun 06, 2011 Mar CTEC

TABLET;ORAL-28
LEVORA 0.15/30-28

AB + WATSON LABS 0.03MG;0.15MG A073594 001 Dec 13, 1993 Aug CRLD
NORDETTE-28
@ TEVA BRANDED PHARM 0.03MG;0.15MG N018782 001 Jul 21, 1982 Aug DISC
VIENVA
AB1 SANDOZ INC 0.02MG;0.1MG A201088 001 May 21, 2015 May NEWA

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL
XULANE

AB + MYLAN TECHNOLOGIES 0.035MG/24HR;0.15MG/24HR A200910 001 Apr 16, 2014 Feb CRLD

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21
BREVICON 21-DAY

@ ACTAVIS LABS UT INC 0.035MG;0.5MG N017566 001 Mar CAHN
NORINYL 1+35 21-DAY

AB ACTAVIS LABS UT INC 0.035MG;1MG N017565 001 Feb CAHN
TRI-NORINYL 21-DAY

@ ACTAVIS LABS UT INC 0.035MG,0.035MG,0.035MG;0.5MG,1MG, N018977 001 Apr 13, 1984 Feb CAHN
0.5MG

TABLET;ORAL-28
BREVICON 28-DAY

AB ACTAVIS LABS UT INC 0.035MG;0.5MG N017743 001 Mar CAHN
NORETHINDRONE AND ETHINYL ESTRADIOL

AB FAMY CARE LTD 0.035MG;0.4MG A200897 001 May 11, 2015 Apr NEWA

AB + JAI PHARMA LTD 0.035MG;0.4MG A200897 001 May 11, 2015 Jul CRLD

>A> AB 0.035MG;0.5MG A200488 001 Oct 21, 2015 Oct NEWA

>A> AB 0.035MG;1MG A200489 001 Oct 21, 2015 Oct NEWA

+ 0.05MG;1MG A203006 001 Aug 05, 2013 Jul CTEC
NORINYL 1+35 28-DAY

AB ACTAVIS LABS UT INC 0.035MG;1MG N017565 002 Feb CAHN

OVCON-35

@ WARNER CHILCOTT LLC 0.035MG;0.4MG N017716 001 Jul DISC

TRI-NORINYL 28-DAY

AB + ACTAVIS LABS UT INC 0.035MG,0.035MG,0.035MG;0.5MG,1MG, N018977 002 Apr 13, 1984 Feb CAHN
0.5MG

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

>A> BLISOVI 24 FE

>A> AB LUPIN LTD 0.02MG;1MG A091398 001 Oct 28, 2015 Oct NEWA
FEMHRT

AB WARNER CHILCOTT LLC 0.0025MG;0.5MG N021065 001 Jan 14, 2005 Mar CTEC

LARIN 24 FE

AB NOVAST LABS LTD 0.02MG;1MG A202994 001 Feb 18, 2015 Feb NEWA

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB + BARR LABS INC 0.005MG;1MG A076221 001 Nov 06, 2009 Mar CTEC

AB GLENMARK GENERICS 0.0025MG;0.5MG A203038 001 Apr 02, 2015 Mar NEWA

AB 0.005MG;1MG A203038 002 Apr 02, 2015 Mar NEWA

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB + AMNEAL PHARMS 0.02MG;1MG A078267 001 Sep 01, 2009 Jan CRLD

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

>A> AB HAUPT PHARMA 0.035MG,0.035MG,0.035MG;0.18MG,0.2 A203870 001 Nov 12, 2015 Oct NEWA
15MG,0.25MG

>A> AB 0.035MG;0.25MG A203865 001 Oct 27, 2015 Oct NEWA

AB JAI PHARMA LTD 0.025MG,0.025MG,0.025MG;0.18MG,0.2 A202132 001 Sep 09, 2015 Aug NEWA
15MG,0.25MG

AB OC PHARMA 0.035MG;0.035MG;0.035MG;0.18MG;0.2 A200383 001 Apr 07, 2015 Mar NEWA
15MG;0.25MG

AB 0.035MG;0.25MG A200384 001 Apr 07, 2015 Mar NEWA

TRI-LO-ESTARYLLA

AB SANDOZ INC 0.025MG,0.025MG,0.025MG;0.18MG,0.2 A091232 001 Jun 29, 2015 Jun NEWA
15MG,0.25MG

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

LOW-OGESTREL-28

AB WATSON LABS 0.03MG;0.3MG A075288 002 Jul 28, 1999 Feb CMFD

ETHOSUXIMIDECAPSULE;ORAL
ETHOSUXIMIDE

AB	BANNER LIFE SCIENCES	250MG	A040430	001	Oct 28, 2002	Jan	CAHN
AB	HERITAGE PHARMS INC	250MG	A200892	001	Sep 25, 2012	Sep	CAHN

ETODOLACTABLET;ORAL
ETODOLAC

@	LEHIGH VALLEY	400MG	A074927	001	Oct 30, 1997	Sep	CAHN
---	---------------	-------	---------	-----	--------------	-----	------

ETONOGESTRELIMPLANT;IMPLANTATION
IMPLANON

@	ORGANON USA INC	68MG/IMPLANT	N021529	001	Jul 17, 2006	Jun	DISC
---	-----------------	--------------	---------	-----	--------------	-----	------

EZETIMIBETABLET;ORAL
EZETIMIBE

@	GLENMARK PHARMS LTD	10MG	A078560	001	Jun 26, 2015	Jun	DISC
AB		10MG	A078560	001	Jun 26, 2015	Jun	NEWA
	ZETIA						
+	MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002	Jun	CTEC
AB	+	10MG	N021445	001	Oct 25, 2002	Jun	CTFG

FAMOTIDINEINJECTABLE;INJECTION
FAMOTIDINE

+	EUROHLTH INTL SARL	10MG/ML	A075488	001	Apr 16, 2001	Jun	CAHN
@		10MG/ML	A075799	001	Apr 30, 2002	Sep	CAHN
	FAMOTIDINE PRESERVATIVE FREE						
+	EUROHLTH INTL SARL	10MG/ML	A075486	001	Apr 16, 2001	Jun	CAHN
	TABLET;ORAL						
	PEPCID						
AB	VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Feb	CAHN
AB	+	40MG	N019462	002	Oct 15, 1986	Feb	CAHN

FELBAMATETABLET;ORAL
FELBAMATE

>A>	AB	COREPHARMA	400MG	A202284	001	Nov 04, 2015	Oct	NEWA
>A>	AB		600MG	A202284	002	Nov 04, 2015	Oct	NEWA

FELODIPINETABLET, EXTENDED RELEASE;ORAL
FELODIPINE

AB	ORCHID HLTHCARE	2.5MG	A203032	001	May 21, 2015	May	NEWA
AB		5MG	A203032	002	May 21, 2015	May	NEWA
AB		10MG	A203032	003	May 21, 2015	May	NEWA
AB	SUN PHARM INDS LTD	2.5MG	A091200	001	Dec 13, 2013	Apr	CAHN
AB		5MG	A091200	002	Dec 13, 2013	Apr	CAHN
AB		10MG	A091200	003	Dec 13, 2013	Apr	CAHN

FENOFIBRATECAPSULE;ORAL
FENOFIBRATE

AB	SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014	Apr	CAHN
AB		130MG	A201748	002	Oct 31, 2014	Apr	CAHN

TABLET;ORAL
FENOFIBRATE

AB	LUPIN LTD	54MG	A204019	001	Aug 17, 2015	Aug	NEWA
AB		160MG	A204019	002	Aug 17, 2015	Aug	NEWA
AB	SUN PHARM INDS LTD	54MG	A076635	001	Oct 31, 2005	Apr	CAHN
		107MG	A076635	002	Oct 31, 2005	Apr	CAHN
AB		160MG	A076635	003	Oct 31, 2005	Apr	CAHN
AB	VALEANT PHARMS NORTH	48MG	A090715	001	Apr 05, 2012	Aug	CAHN
AB		145MG	A090715	002	Apr 05, 2012	Aug	CAHN

FENOFIBRIC ACIDTABLET;ORAL
FIBRICOR

	TRIBUTE PHARMS INTL	35MG	N022418	001	Aug 14, 2009	Jun	CAHN
+		105MG	N022418	002	Aug 14, 2009	Jun	CAHN

FENTANYLFILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-100

AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar	CAHN
	FENTANYL-12						
AB	MALLINCKRODT INC	12.5MCG/HR	A077154	005	Jun 11, 2015	Jun	NEWA
	FENTANYL-25						
AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar	CAHN
	FENTANYL-50						
AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar	CAHN
	FENTANYL-75						
AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar	CAHN

FENTANYL CITRATEFILM;BUCCAL
ONSOLIS

@	BIODELIVERY SCI INTL	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Mar	CAHN
@		EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Mar	CAHN
@		EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Mar	CAHN
@		EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Mar	CAHN
@		EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Mar	CAHN

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb	CAHN
----	---	--------------------	-------------------	---------	-----	--------------	-----	------

FENTANYL HYDROCHLORIDESYSTEM;IONTOPHORESIS, TRANSDERMAL
IONSYS

@	THE MEDICINES CO	10.8MCG	N021338	001	May 22, 2006	Apr	CAHN
+		EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006	Jun	CMFD

FERRIC CITRATETABLET;ORAL
AURYXIA

+	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Jan	CTNA
---	-----------------	---------------	---------	-----	--------------	-----	------

FERRIC PYROPHOSPHATE CITRATESOLUTION;IV (INFUSION)
TRIFERIC

>A>	+	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015	Jan	NEWA
			272MG IRON/50ML (5.44MG IRON/ML)	N206317	002	Sep 04, 2015	Oct	NEWA

FIDAXOMICINTABLET;ORAL
DIFICID

+	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Aug	CAHN
---	-------------------	-------	---------	-----	--------------	-----	------

FLECAINIDE ACETATETABLET;ORAL
FLECAINIDE ACETATE

AB	ANI PHARMS INC	50MG	A075882	001	Oct 28, 2002	Apr	CAHN
AB		100MG	A075882	002	Oct 28, 2002	Apr	CAHN
AB		150MG	A075882	003	Oct 28, 2002	Apr	CAHN
AB	AUROBINDO PHARMA LTD	50MG	A202821	001	Jul 08, 2015	Jun	NEWA
AB		100MG	A202821	002	Jul 08, 2015	Jun	NEWA
AB		150MG	A202821	003	Jul 08, 2015	Jun	NEWA
AB	SUN PHARM INDS LTD	50MG	A076421	001	Mar 28, 2003	Apr	CAHN
AB		100MG	A076421	002	Mar 28, 2003	Apr	CAHN
AB		150MG	A076421	003	Mar 28, 2003	Apr	CAHN

FLIBANSERIN

TABLET;ORAL
ADDYI

+ SPROUT PHARMS 100MG N022526 001 Aug 18, 2015 Aug NEWA

FLUCONAZOLE

FOR SUSPENSION;ORAL
FLUCONAZOLE

AB SUN PHARM INDS LTD 50MG/5ML A076332 001 Jul 29, 2004 Apr CAHN
AB 200MG/5ML A076332 002 Jul 29, 2004 Apr CAHN

INJECTABLE;INJECTION
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP CLARIS PHARMASERVICE 200MG/100ML (2MG/ML) A077988 001 May 26, 2010 Apr CAHN
AP 400MG/200ML (2MG/ML) A077988 002 May 26, 2010 Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP CLARIS PHARMASERVICE 200MG/100ML (2MG/ML) A077947 001 May 26, 2010 Apr CAHN
AP 400MG/200ML (2MG/ML) A077947 002 May 26, 2010 Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

CLARIS PHARMASERVICE 100MG/50ML (2MG/ML) A077909 003 Apr 20, 2015 Apr NEWA
100MG/50ML (2MG/ML) A077909 003 Apr 20, 2015 Apr CAHN
AP 200MG/100ML (2MG/ML) A077909 001 May 26, 2010 Apr CAHN
AP 400MG/200ML (2MG/ML) A077909 002 May 26, 2010 Apr CAHN

TABLET;ORAL

FLUCONAZOLE

AB HARRIS PHARM 50MG A078423 001 Mar 07, 2011 May CMFD
AB 100MG A078423 002 Mar 07, 2011 May CMFD
AB 150MG A078423 003 Mar 07, 2011 May CMFD
AB 200MG A078423 004 Mar 07, 2011 May CMFD

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

>A> AP 3D IMAGING DRUG 20-300mCi/ML A203778 001 Oct 30, 2015 Oct NEWA
AP IBA MOLECULAR N AM 20-300mCi/ML A203591 001 Aug 31, 2015 Aug NEWA
>A> AP KETTERING MEDCTR 4-40mCi/ML A204759 001 Oct 27, 2015 Oct NEWA
AP METHODIST HOSP RES 20-300mCi/ML A203904 001 Apr 23, 2015 Apr NEWA
AP MIPS CRF 20-300mCi/ML A204472 001 Sep 11, 2015 Aug NEWA
PRECISION NUCLEAR 20-500mCi/ML A204546 001 Apr 07, 2015 Mar NEWA
QUEEN HAMAMATSU PET 10-100mCi/ML A203771 001 Aug 31, 2015 Aug NEWA
SPECTRON MRC LLC 4-500mCi/ML A203911 001 Apr 22, 2015 Apr NEWA
>D> + UCLA BIOMEDICAL 4-40mCi/ML A203811 001 Jun 27, 2013 Oct CTEC
>A> AP + 4-40mCi/ML A203811 001 Jun 27, 2013 Oct CTEC
AP UNIV MICHIGAN 20-300mCi/ML A204531 001 Jul 17, 2015 Jul NEWA

FLUMAZENIL

INJECTABLE;INJECTION
FLUMAZENIL

@ CLARIS PHARMASERVICE 0.5MG/5ML (0.1MG/ML) A076755 002 Oct 12, 2004 Apr CAHN
@ 1MG/10ML (0.1MG/ML) A076755 001 Oct 12, 2004 Apr CAHN
AP EUROHLTH INTL SARL 0.5MG/5ML (0.1MG/ML) A076787 002 Oct 12, 2004 Jun CAHN
AP 1MG/10ML (0.1MG/ML) A076787 001 Oct 12, 2004 Jun CAHN

FLUOCINOLONE ACETONIDE

OIL;TOPICAL
FLUOCINOLONE ACETONIDE

AT VERSAPHARM INC 0.01% A091514 001 Jun 25, 2015 Jun NEWA

SOLUTION;TOPICAL
FLUOCINOLONE ACETONIDE

AT GAVIS PHARMS LLC 0.01% A206422 001 Sep 02, 2015 Aug NEWA

FLUOCINONIDE

GEL;TOPICAL
FLUOCINONIDE

AB G AND W LABS INC 0.05% A072537 001 Feb 07, 1989 Apr CAHN

FLUOROURACIL

CREAM;TOPICAL
CARAC

AB + VALEANT PHARMS NORTH 0.5% N020985 001 Oct 27, 2000 Apr CFTG
+ 0.5% N020985 001 Oct 27, 2000 Feb CAHN

CREAM; TOPICAL
FLUOROURACIL

AB	SPEAR PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Apr	NEWA
	TOLAK						
+	HILL DERMACEUTICALS	4%	N022259	001	Sep 18, 2015	Sep	NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

	@ ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Mar	DISC
	@	EQ 20MG BASE	A076287	002	May 20, 2008	Mar	DISC
+	MYLAN	EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CRLD
	@ SANDOZ	EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CTEC
	@	EQ 10MG BASE	A077469	001	Nov 17, 2008	Mar	DISC
	@	EQ 20MG BASE	A077469	002	Nov 17, 2008	Mar	DISC
AB1	SCIEGEN PHARMS INC	EQ 10MG BASE	A204597	001	Mar 16, 2015	Mar	NEWA
AB1		EQ 20MG BASE	A204597	002	Mar 16, 2015	Mar	NEWA
AB		EQ 40MG BASE	A204597	003	Mar 16, 2015	Mar	NEWA
AB	SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Apr	CAHN

FLURANDRENOLIDE

OINTMENT; TOPICAL

CORDRAN

+	AQUA PHARMS	0.05%	N012806	001		Jun	CRLD
		0.05%	N012806	001		May	CMFD

TAPE; TOPICAL

CORDRAN

+	ACTAVIS LABS UT INC	0.004MG/SQ CM	N016455	001		Mar	CAHN
---	---------------------	---------------	---------	-----	--	-----	------

FLURBIPROFEN

TABLET; ORAL

ANSAID

>D>	PHARMACIA AND UPJOHN	50MG	N018766	002	Oct 31, 1988	Oct	DISC
>A>	@	50MG	N018766	002	Oct 31, 1988	Oct	DISC
>D>	+	100MG	N018766	003	Oct 31, 1988	Oct	DISC
>A>	@	100MG	N018766	003	Oct 31, 1988	Oct	DISC
	FLURBIPROFEN						
>D>	MYLAN	100MG	A074358	002	Jun 20, 1994	Oct	CRLD
>A>	+	100MG	A074358	002	Jun 20, 1994	Oct	CRLD

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREO ELLIPTA

	GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Apr	NEWA
--	---------------	-------------------------------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

CREAM; TOPICAL

FLUTICASONE PROPIONATE

>D>	AB	PERRIGO NEW YORK	0.05%	A076793	001	May 14, 2004	Oct	CRLD
>A>	AB	+	0.05%	A076793	001	May 14, 2004	Oct	CRLD

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE; ORAL

FLUVASTATIN SODIUM

AB	MYLAN PHARMS INC	80MG	A202458	001	Sep 11, 2015	Aug	NEWA	
	LESCOL XL							
AB	+	NOVARTIS	80MG	N021192	001	Oct 06, 2000	Aug	CFTG

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB	ANI PHARMS INC	25MG	A075897	001	Jan 25, 2001	Jul	CAHN
	@	25MG	A075898	001	Mar 12, 2001	Jul	CAHN
AB		50MG	A075897	002	Jan 25, 2001	Jul	CAHN
	@	50MG	A075898	002	Mar 12, 2001	Jul	CAHN
AB		100MG	A075897	003	Jan 25, 2001	Jul	CAHN
	@	100MG	A075898	003	Mar 12, 2001	Jul	CAHN

FOLIC ACIDTABLET; ORAL
FOLIC ACID

AA	AIPING PHARM INC	1MG	A091145	001	Jul 12, 2013	Aug	CAHN
AA	NUVO PHARM INC	1MG	A204418	001	Jul 28, 2015	Jul	NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDETABLET; ORAL
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Apr	CAHN
AB		20MG;12.5MG	A076739	002	Dec 17, 2004	Apr	CAHN

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDE

@	IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985	Mar	CAHN
@		10MG/ML	A070096	001	Sep 09, 1985	Mar	CAHN

GABAPENTINCAPSULE; ORAL
GABAPENTIN

AB	SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Apr	CAHN
AB		300MG	A076606	002	Oct 07, 2005	Apr	CAHN
AB		400MG	A076606	003	Oct 07, 2005	Apr	CAHN

TABLET; ORAL
GABAPENTIN

@	HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011	Jun	DISC
@		800MG	A078782	002	Jul 21, 2011	Jun	DISC

GADOVERSETAMIDEINJECTABLE; INJECTION
OPTIMARK

+	LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999	Feb	CAHN
+		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999	Feb	CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999	Feb	CAHN
+		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999	Feb	CAHN
+		16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999	Feb	CAHN

OPTIMARK IN PLASTIC CONTAINER

+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999	Feb	CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999	Feb	CAHN
+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999	Feb	CAHN
+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999	Feb	CAHN

GEFITINIBTABLET; ORAL
IRESSA

+	ASTRAZENECA PHARMS	250MG	N206995	001	Jul 13, 2015	Jul	NEWA
---	--------------------	-------	---------	-----	--------------	-----	------

GEMFIBROZILTABLET; ORAL
GEMFIBROZIL

AB	AUROBINDO PHARMA LTD	600MG	A202726	001	Sep 16, 2015	Aug	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

GEMIFLOXACIN MESYLATETABLET; ORAL
FACTIVE

AB	+ LG LIFE SCIENCES	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jun	CFTG
AB	GEMIFLOXACIN MESYLATE						
AB	ORCHID HLTHCARE	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jun	NEWA

GLATIRAMER ACETATEINJECTABLE; SUBCUTANEOUS
COPAXONE

AP	+ TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Mar	CFTG
AP	GLATOFA						
AP	SANDOZ INC	20MG/ML	A090218	001	Apr 16, 2015	Mar	NEWA

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

@	HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Apr	DISC
@		2MG	A078952	002	Aug 01, 2013	Apr	DISC
@		4MG	A078952	003	Aug 01, 2013	Apr	DISC

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

@	ANI PHARMS INC	5MG	A074387	001	Mar 04, 1996	Aug	CAHN	
>A>	AB	5MG	A074497	001	Aug 31, 1995	Oct	CAHN	
@		10MG	A074387	002	Mar 04, 1996	Aug	CAHN	
>A>	AB	10MG	A074497	002	Aug 31, 1995	Oct	CAHN	
>D>	AB	IVAX SUB TEVA PHARMS	5MG	A074497	001	Aug 31, 1995	Oct	CAHN
>D>	AB	10MG	A074497	002	Aug 31, 1995	Oct	CAHN	

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

AB	MYLAN PHARMS INC	2.5MG	A202298	001	May 19, 2015	May	NEWA
AB		5MG	A202298	002	May 19, 2015	May	NEWA
AB		10MG	A202298	003	May 19, 2015	May	NEWA

GLUCAGON HYDROCHLORIDE

POWDER; INTRAMUSCULAR, INTRAVENOUS

GLUCAGON

+	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015	May	NEWA
---	--------------------	------------------	---------	-----	--------------	-----	------

GLYBURIDE

TABLET; ORAL

DIABETA

AB2	SANOFI AVENTIS US	1.25MG	N017532	001	May 01, 1984	Sep	CFTG
AB2		2.5MG	N017532	002	May 01, 1984	Sep	CFTG
AB2	+	5MG	N017532	003	May 01, 1984	Sep	CFTG

GLYBURIDE

AB1	AUROBINDO PHARMA	1.25MG	A077537	001	Oct 18, 2007	Sep	CTEC
AB1		2.5MG	A077537	002	Oct 18, 2007	Sep	CTEC
AB1		5MG	A077537	003	Oct 18, 2007	Sep	CTEC
AB1	COREPHARMA	1.25MG	A076257	001	Jun 27, 2002	Sep	CTEC
AB2		1.25MG	A206079	001	Sep 30, 2015	Sep	NEWA
AB1		2.5MG	A076257	002	Jun 27, 2002	Sep	CTEC
AB2		2.5MG	A206079	002	Sep 30, 2015	Sep	NEWA
AB1		5MG	A076257	003	Jun 27, 2002	Sep	CTEC
AB2		5MG	A206079	003	Sep 30, 2015	Sep	NEWA
AB1	HERITAGE PHARMS INC	1.25MG	A090937	001	Feb 28, 2011	Sep	CTEC
AB1		2.5MG	A090937	002	Feb 28, 2011	Sep	CTEC
AB1		5MG	A090937	003	Feb 28, 2011	Sep	CTEC
AB1	TEVA	1.25MG	A074388	001	Aug 29, 1995	Sep	CTEC
AB1		2.5MG	A074388	002	Aug 29, 1995	Sep	CTEC
AB1	+	5MG	A074388	003	Aug 29, 1995	Sep	CTEC

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

>D>	AB	BRISTOL MYERS SQUIBB	1.25MG; 250MG	N021178	001	Jul 31, 2000	Oct	DISC
>A>		@	1.25MG; 250MG	N021178	001	Jul 31, 2000	Oct	DISC

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

+	HORIZON THERAPS INC	1.1GM/ML	N203284	001	Feb 01, 2013	May	CAHN
---	---------------------	----------	---------	-----	--------------	-----	------

GLYCOPYRROLATE

INJECTABLE; INJECTION

ROBINUL

AP	+	EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Jun	CAHN
----	---	--------------------	----------	---------	-----	--	-----	------

>A> POWDER; INHALATION

>A> SEEBRI

>A>	+	NOVARTIS PHARMS CORP	15.6MCG/INH	N207923	001	Oct 29, 2015	Oct	NEWA
-----	---	----------------------	-------------	---------	-----	--------------	-----	------

TABLET; ORAL

GLYCOPYRROLATE

AA		SUN PHARM INDS LTD	1MG	A040844	001	Aug 18, 2009	Apr	CAHN
----	--	--------------------	-----	---------	-----	--------------	-----	------

TABLET;ORAL
GLYCOPYRROLATE

AA 2MG A040844 002 Aug 18, 2009 Apr CAHN

>A> GLYCOPYRROLATE ; INDACATEROL MALEATE

>A> POWDER; INHALATION
>A> UTIBRON

>A> + NOVARTIS PHARMS CORP 15.6MCG/INH;27.5MCG/INH N207930 001 Oct 29, 2015 Oct NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION
GRANISETRON HYDROCHLORIDE

AP BANNER LIFE SCIENCES EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078863 001 Jun 30, 2008 Jan CAHN

AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078880 001 Jun 30, 2008 Jan CAHN

@ CLARIS PHARMASERVICE EQ 1MG BASE/ML (EQ 1MG BASE/ML) A078198 001 Jun 30, 2008 Apr CAHN

@ EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078198 002 Jun 30, 2008 Apr CAHN

AP EUROHLTH INTL SARL EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A077177 001 Dec 31, 2007 Jun CAHN

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP BANNER LIFE SCIENCES EQ 1MG BASE/ML (EQ 1MG BASE/ML) A078863 002 Jun 30, 2008 Jan CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL
FLOWTUSS

MIKART INC 200MG/5ML;2.5MG/5ML N022424 001 May 14, 2015 May NEWA

MISSION PHARMACAL CO 200MG/5ML;2.5MG/5ML N022424 001 May 14, 2015 Sep CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL
HYCOFENIX

+ MIKART INC 200MG/5ML;2.5MG/5ML;30MG/5ML N022279 001 May 14, 2015 May NEWA

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
GUANFACINE HYDROCHLORIDE

>A> AB IMPAX LABS INC EQ 1MG BASE A202238 001 Oct 20, 2015 Oct NEWA

>A> AB EQ 2MG BASE A202238 002 Oct 20, 2015 Oct NEWA

>A> AB EQ 3MG BASE A202238 003 Oct 20, 2015 Oct NEWA

>A> AB EQ 4MG BASE A202238 004 Oct 20, 2015 Oct NEWA

AB MYLAN PHARMS INC EQ 1MG BASE A202578 001 Jun 02, 2015 May NEWA

AB EQ 2MG BASE A202578 002 Jun 02, 2015 May NEWA

AB EQ 3MG BASE A202578 003 Jun 02, 2015 May NEWA

AB EQ 4MG BASE A202578 004 Jun 02, 2015 May NEWA

AB SANDOZ INC EQ 1MG BASE A202568 001 Jun 03, 2015 May NEWA

AB EQ 2MG BASE A202568 002 Jun 03, 2015 May NEWA

AB EQ 3MG BASE A202568 003 Jun 03, 2015 May NEWA

AB EQ 4MG BASE A202568 004 Jun 03, 2015 May NEWA

AB TEVA PHARMS USA EQ 1MG BASE A201382 001 Jun 02, 2015 May NEWA

AB EQ 2MG BASE A201382 002 Jun 02, 2015 May NEWA

AB EQ 3MG BASE A201382 003 Jun 02, 2015 May NEWA

AB EQ 4MG BASE A201382 004 Jun 02, 2015 May NEWA

AB TWI PHARMS INC EQ 1MG BASE A201408 001 Jun 02, 2015 May NEWA

AB EQ 2MG BASE A201408 002 Jun 02, 2015 May NEWA

AB EQ 3MG BASE A201408 003 Jun 02, 2015 May NEWA

AB EQ 4MG BASE A201408 004 Jun 02, 2015 May NEWA

HALOPERIDOL

TABLET;ORAL
HALOPERIDOL

@ CYCLE PHARMS LTD 0.5MG A071128 001 Feb 17, 1987 May CAHN

@ 1MG A071129 001 Feb 17, 1987 Jun CAHN

@ 5MG A071131 001 Feb 17, 1987 Jun CAHN

@ 10MG A071132 001 May 12, 1987 Jun CAHN

@ 20MG A071133 001 May 12, 1987 May CAHN

@ ROXANE 2MG A071130 001 Feb 17, 1987 Jun CAHN

HALOPERIDOL LACTATE

CONCENTRATE;ORAL
HALOPERIDOL INTENSOL

@ CYCLE PHARMS LTD EQ 2MG BASE/ML A072045 001 Apr 12, 1988 May CAHN

INJECTABLE; INJECTION

HALOPERIDOL

@	CLARIS PHARMASERVICE	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr	CAHN
@		EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	May	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

	@	EUROHLTH INTL SARL	1,000 UNITS/ML	N017007	001		Aug	CAHN
AP	+		1,000 UNITS/ML	N017037	001		Jun	CAHN
	@		2,500 UNITS/ML	N017007	007		Aug	CAHN
	@		5,000 UNITS/ML	N017007	002		Aug	CAHN
	@		5,000 UNITS/0.5ML	N017007	010		Aug	CAHN
AP	+		5,000 UNITS/ML	N017037	002		Jun	CAHN
	@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jun	CAHN
	@		7,500 UNITS/ML	N017007	003		Aug	CAHN
	@		10,000 UNITS/ML	N017007	004		Aug	CAHN
AP	+		10,000 UNITS/ML	N017037	003		Jun	CAHN
	@		15,000 UNITS/ML	N017007	005		Aug	CAHN
	@		20,000 UNITS/ML	N017007	006		Aug	CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP	+	AKORN	20MG/ML	A040730	001	Apr 21, 2009	Feb	CRLD
AP		LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb	CRLD
AP		X-GEN PHARMS INC	20MG/ML	A203110	001	Jun 29, 2015	Jun	NEWA

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

	@	HERITAGE PHARMS INC	10MG	A040858	001	Feb 26, 2010	Sep	CAHN
	@		25MG	A040858	002	Feb 26, 2010	Sep	CAHN
	@		50MG	A040858	003	Feb 26, 2010	Sep	CAHN
	@		100MG	A040858	004	Feb 26, 2010	Sep	CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

	@	SUN PHARM INDS INC	12.5MG	A090651	001	Apr 07, 2014	Aug	DISC
--	---	--------------------	--------	---------	-----	--------------	-----	------

MICROZIDE

AB	+	ACTAVIS LABS UT INC	12.5MG	N020504	001	Dec 27, 1996	Feb	CAHN
----	---	---------------------	--------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS LTD	12.5MG;10MG	A076007	001	Jul 01, 2002	Apr	CAHN
AB			12.5MG;20MG	A076007	002	Jul 01, 2002	Apr	CAHN
AB			25MG;20MG	A076007	003	Jul 01, 2002	Apr	CAHN
		ZESTORETIC						
AB		ALVOGEN IPCO SARL	12.5MG;10MG	N019888	003	Nov 18, 1993	Feb	CAHN
AB	+		12.5MG;20MG	N019888	001	Sep 20, 1990	Feb	CAHN
AB	+		25MG;20MG	N019888	002	Jul 20, 1989	Feb	CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPIROL

		CONCORDIA PHARMS INC	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jun	CAHN
			12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jun	CAHN
	+		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jun	CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

>D>									
>D>	AB	+	WYETH PHARMS INC	25MG;40MG	N018031	001		Oct	DISC
>A>		@		25MG;40MG	N018031	001		Oct	DISC
			PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE						
		@	ANI PHARMS INC	25MG;40MG	A070704	001	Oct 01, 1986	Jul	CAHN
	AB			25MG;40MG	A072042	001	Mar 14, 1988	Aug	CAHN
		@		25MG;80MG	A070705	001	Oct 01, 1986	Jul	CAHN
	AB			25MG;80MG	A072043	001	Mar 14, 1988	Aug	CAHN
>D>	AB		MYLAN	25MG;40MG	A070947	002	Mar 04, 1987	Oct	CRLD
>A>	AB	+		25MG;40MG	A070947	002	Mar 04, 1987	Oct	CRLD

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL		QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
AB	SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE		A 078211	001	Mar 04, 2009	Apr CAHN
AB		12.5MG;EQ 20MG BASE		A 078211	002	Mar 04, 2009	Apr CAHN
AB		25MG;EQ 20MG BASE		A 078211	003	Mar 04, 2009	Apr CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL		TELMISARTAN AND HYDROCHLOROTHIAZIDE					
>A>	MACLEODS PHARMS LTD	12.5MG;40MG		A 204169	001	Nov 02, 2015	Oct NEWA
>A>		12.5MG;80MG		A 204169	002	Nov 02, 2015	Oct NEWA
>A>		25MG;80MG		A 204169	003	Nov 02, 2015	Oct NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL		TRIAMTERENE AND HYDROCHLOROTHIAZIDE					
	@ ANI PHARMS INC	25MG;37.5MG		A 074970	001	Jan 06, 1998	Aug CAHN
TABLET;ORAL		TRIAMTERENE AND HYDROCHLOROTHIAZIDE					
AB	ANI PHARMS INC	50MG;75MG		A 073467	001	Jan 31, 1996	Aug CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL		ZOHYDRO ER					
+	FERRIMILL LTD	10MG		N 202880	001	Oct 25, 2013	Apr CAHN
		15MG		N 202880	002	Oct 25, 2013	Apr CAHN
		20MG		N 202880	003	Oct 25, 2013	Apr CAHN
		30MG		N 202880	004	Oct 25, 2013	Apr CAHN
		40MG		N 202880	005	Oct 25, 2013	Apr CAHN
		50MG		N 202880	006	Oct 25, 2013	Apr CAHN
+	PERNIX IRELAND PAIN	10MG		N 202880	001	Oct 25, 2013	Jun CAHN
		15MG		N 202880	002	Oct 25, 2013	Jun CAHN
		20MG		N 202880	003	Oct 25, 2013	Jun CAHN
		30MG		N 202880	004	Oct 25, 2013	Jun CAHN
		40MG		N 202880	005	Oct 25, 2013	Jun CAHN
		50MG		N 202880	006	Oct 25, 2013	Jun CAHN
TABLET, EXTENDED RELEASE;ORAL		HYSINGLA					
+	PURDUE PHARMA LP	20MG		N 206627	001	Nov 20, 2014	Mar CRLD

HYDROCORTISONE

CREAM;TOPICAL		HYDROCORTISONE					
AT	RISING PHARMS INC	2.5%		A 040879	001	Aug 20, 2010	Mar CAHN
POWDER;FOR RX COMPOUNDING		HYDRO-RX					
	@ X GEN PHARMS	100%		A 085982	001		Apr DISC
TABLET;ORAL		HYDROCORTISONE					
AB	HIKMA INTL PHARMS	5MG		A 083365	002	Feb 23, 2015	Feb NEWA
AB		10MG		A 083365	003	Feb 23, 2015	Feb NEWA
AB		20MG		A 083365	001		Feb CMFD

HYDROCORTISONE ACETATE

POWDER;FOR RX COMPOUNDING		HYDROCORTISONE ACETATE					
	@ X GEN PHARMS	100%		A 085981	001		Apr DISC

HYDROCORTISONE VALERATE

CREAM;TOPICAL		HYDROCORTISONE VALERATE					
	@ G AND W LABS INC	0.2%		A 074489	001	Aug 12, 1998	Apr CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OTIC		CORTISPORIN					
AT	+ CITRON PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML		N 060613	001		Jun CMS2

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
DILAUDID-HP

>D> + PURDUE PHARM PRODS 250MG/VIAL N019034 002 Aug 04, 1994 Oct DISC
>A> @ 250MG/VIAL N019034 002 Aug 04, 1994 Oct DISC

TABLET, EXTENDED RELEASE; ORAL
HYDROMORPHONE HYDROCHLORIDE

AB PADDOCK LLC 8MG A204278 001 Apr 06, 2015 Mar NEWA
AB 12MG A204278 002 Apr 06, 2015 Mar NEWA
AB 16MG A204278 003 Apr 06, 2015 Mar NEWA

HYDROXOCOBALAMIN

INJECTABLE; INJECTION
CYANOKIT

@ SERB SAS 2.5GM/VIAL (5GM/KIT) N022041 002 Dec 15, 2006 Apr CAHN
+ 5GM/VIAL (5GM/KIT) N022041 001 Apr 08, 2011 Apr CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
PLAQUENIL

AB + CONCORDIA PHARMS INC 200MG N009768 001 Jun CAHN

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION
HYDROXYPROGESTERONE CAPROATE

@ ACTAVIS LABS UT INC 125MG/ML N017439 001 Mar CAHN
@ 250MG/ML N017439 002 Mar CAHN
+ MCGUFF 250MG/ML A200271 001 Aug 24, 2015 Aug NEWA

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HYDROCHLORIDE

AB ELITE LABS INC 10MG A040600 001 Dec 28, 2004 Jun CAHN
AB 25MG A040602 001 Dec 28, 2004 Jun CAHN
AB 50MG A040604 001 Dec 28, 2004 Jun CAHN
AB HERITAGE PHARMA 10MG A204279 001 Aug 20, 2014 Mar CAHN
AB 25MG A204279 002 Aug 20, 2014 Mar CAHN
AB 50MG A204279 003 Aug 20, 2014 Mar CAHN
AB MIKAH PHARMA 10MG A040600 001 Dec 28, 2004 Mar CMFD
AB 25MG A040602 001 Dec 28, 2004 Mar CMFD
AB 50MG A040604 001 Dec 28, 2004 Mar CMFD
@ MUTUAL PHARM 10MG A089381 001 May 19, 1986 Jul DISC
@ 25MG A089382 001 May 19, 1986 Jul DISC
@ 50MG A089383 001 May 19, 1986 Jul DISC
@ WATSON LABS 10MG A088348 001 Sep 15, 1983 Jul DISC
@ 25MG A088349 001 Sep 15, 1983 Jul DISC
@ 50MG A088350 001 Sep 15, 1983 Jul DISC

HYDROXYZINE PAMOATE

CAPSULE; ORAL
HYDROXYZINE PAMOATE

AB HERITAGE PHARMA EQ 25MG HYDROCHLORIDE A201507 001 Jun 03, 2013 Mar CAHN
AB EQ 50MG HYDROCHLORIDE A201507 002 Jun 03, 2013 Mar CAHN

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS
IBANDRONATE SODIUM

>A> AP APOTEX INC EQ 3MG BASE/3ML A204222 001 Oct 16, 2015 Oct NEWA
AP AUROBINDO PHARMA LTD EQ 3MG BASE/3ML A205332 001 Aug 19, 2015 Aug NEWA

IBUPROFEN

TABLET; ORAL
IBUPROFEN

AB GRANULES INDIA LTD 400MG A091625 001 Sep 15, 2015 Aug NEWA
AB 600MG A091625 002 Sep 15, 2015 Aug NEWA
AB 800MG A091625 003 Sep 15, 2015 Aug NEWA
@ VINTAGE PHARMS 300MG A071230 001 Oct 22, 1986 Jul DISC
@ 400MG A071231 001 Oct 22, 1986 Jul DISC
@ 600MG A071232 001 Oct 22, 1986 Jul DISC
@ 800MG A072004 001 Nov 18, 1987 Jul DISC

ILOPERIDONE

TABLET; ORAL

FANAPT

+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Jan CAHN
		2MG	N022192	002	May 06, 2009	Jan CAHN
		4MG	N022192	003	May 06, 2009	Jan CAHN
		6MG	N022192	004	May 06, 2009	Jan CAHN
		8MG	N022192	005	May 06, 2009	Jan CAHN
		10MG	N022192	006	May 06, 2009	Jan CAHN
		12MG	N022192	007	May 06, 2009	Jan CAHN

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB	G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Apr CAHN
----	------------------	----	---------	-----	--------------	----------

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

AB	ANI PHARMS INC	1.25MG	A074299	002	Apr 29, 1996	Jul CAHN
	@	1.25MG	A074498	002	Feb 12, 1998	Jul CAHN
AB		2.5MG	A074299	001	Jul 27, 1995	Jul CAHN
	@	2.5MG	A074498	001	Oct 31, 1996	Jul CAHN

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB	JUBILANT GENERICS	75MG	A202706	001	Oct 05, 2015	Sep NEWA
----	-------------------	------	---------	-----	--------------	----------

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

+	LEO PHARMA AS	0.015%	N202833	001	Jan 23, 2012	May CRLD
---	---------------	--------	---------	-----	--------------	----------

INSULIN DEGLUDEC

SOLUTION; SUBCUTANEOUS

TRESIBA

	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N203314	001	Sep 25, 2015	Sep NEWA
+		600 UNITS/3ML (200 UNITS/ML)	N203314	002	Sep 25, 2015	Sep NEWA

INSULIN GLARGINE RECOMBINANT

SOLUTION; SUBCUTANEOUS

TOUJEO SOLOSTAR

+	SANOFI US SERVICES	300 UNITS/ML (300 UNITS/ML)	N206538	001	Feb 25, 2015	Feb NEWA
---	--------------------	-----------------------------	---------	-----	--------------	----------

INSULIN LISPRO RECOMBINANT

SOLUTION; SUBCUTANEOUS

HUMALOG KWIKPEN

+	ELI LILLY AND CO	200 UNITS/ML	N205747	001	May 26, 2015	May NEWA
---	------------------	--------------	---------	-----	--------------	----------

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION

AFREZZA

	SANOFI AVENTIS	12 UNITS/INH	N022472	003	Apr 17, 2015	Apr NEWA
--	----------------	--------------	---------	-----	--------------	----------

IOHEXOL

FOR SOLUTION; ORAL

ORALTAG

	INTERPHARMA PRAHA AS	9.7GM/BOT	N205383	001	Mar 26, 2015	Mar NEWA
--	----------------------	-----------	---------	-----	--------------	----------

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-250

	@ FRESENIUS KABI USA	51%	A074679	001	Apr 02, 1997	Jan DISC
	IOPAMIDOL-300					
	@ FRESENIUS KABI USA	61%	A074679	002	Apr 02, 1997	Jan DISC
	IOPAMIDOL-370					
	@ FRESENIUS KABI USA	76%	A074679	003	Apr 02, 1997	Jan DISC
	ISOVUE-200					
+	BRACCO	41%	N018735	006	Jul 07, 1987	Feb CTEC

	INJECTABLE; INJECTION						
	ISOVUE-250						
	+ BRACCO	51%	N018735	007	Jul 06, 1992	Feb	CTEC
	+ ISOVUE-300	51%	N020327	002	Oct 12, 1994	Feb	CTEC
	+ BRACCO	61%	N020327	003	Oct 12, 1994	Feb	CTEC
	ISOVUE-370						
	+ BRACCO	76%	N020327	004	Oct 12, 1994	Feb	CTEC
	SCANLUX-300						
AP	MYLAN INSTITUTIONAL	61%	A090394	001	Jun 18, 2010	Aug	CAHN
	SCANLUX-370						
AP	MYLAN INSTITUTIONAL	76%	A090394	002	Jun 18, 2010	Aug	CAHN

IOTHALAMATE MEGLUMINE

	INJECTABLE; INJECTION						
	CONRAY						
	+ LIEBEL-FLARSHEIM	60%	N013295	001		Feb	CAHN
	CONRAY 30						
	+ LIEBEL-FLARSHEIM	30%	N016983	001		Feb	CAHN
	CONRAY 43						
	+ LIEBEL-FLARSHEIM	43%	N013295	002		Feb	CAHN
	SOLUTION; INTRAVESICAL						
	CYSTO-CONRAY II						
	LIEBEL-FLARSHEIM	17.2%	N017057	002		Feb	CAHN

IOVERSOL

	INJECTABLE; INJECTION						
	OPTIRAY 160						
	@ LIEBEL-FLARSHEIM	34%	N019710	003	Dec 30, 1988	Feb	CAHN
	OPTIRAY 240						
	+ LIEBEL-FLARSHEIM	51%	N019710	002	Dec 30, 1988	Feb	CAHN
	@	51%	N020923	001	May 28, 1998	Feb	CAHN
	OPTIRAY 300						
	+ LIEBEL-FLARSHEIM	64%	N019710	004	Jan 22, 1992	Feb	CAHN
	+	64%	N020923	004	May 13, 1999	Feb	CAHN
	OPTIRAY 320						
	+ LIEBEL-FLARSHEIM	68%	N019710	001	Dec 30, 1988	Feb	CAHN
>D>	@	68%	N020923	002	May 29, 1998	Oct	CMFD
>A>	+	68%	N020923	002	May 29, 1998	Oct	CMFD
	@	68%	N020923	002	May 29, 1998	Feb	CAHN
	OPTIRAY 350						
	+ LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992	Feb	CAHN
	+	74%	N020923	003	May 28, 1998	Feb	CAHN

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

	INJECTABLE; INJECTION						
	HEXABRIX						
	@ GUERBET	39.3%;19.6%	N018905	002	Jul 26, 1985	May	DISC

IRBESARTAN

	TABLET; ORAL						
	IRBESARTAN						
AB	JUBILANT GENERICS	75MG	A203534	001	Feb 23, 2015	Feb	NEWA
AB		150MG	A203534	002	Feb 23, 2015	Feb	NEWA
AB		300MG	A203534	003	Feb 23, 2015	Feb	NEWA

IRINOTECAN HYDROCHLORIDE

	INJECTABLE, LIPOSOMAL; IV (INFUSION)						
>A>	ONIVYDE						
>A>	+ MERRIMACK PHARMS	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793	001	Oct 22, 2015	Oct	NEWA

IRON DEXTRAN

	INJECTABLE; INJECTION						
	INFED						
BP	+ ACTAVIS LABS UT INC	EQ 50MG IRON/ML	N017441	001		Mar	CAHN

ISAVUCONAZONIUM SULFATE

CAPSULE; ORAL

CRESEMBA

+ ASTELLAS 186MG N207500 001 Mar 06, 2015 Mar NEWA

POWDER; IV (INFUSION)

CRESEMBA

+ ASTELLAS 372MG N207501 001 Mar 06, 2015 Mar NEWA

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

AB VALEANT PHARMS NORTH 5MG N012093 007 Jul 29, 1988 Feb CAHN

+ 40MG N012093 001 Jul 29, 1988 Feb CAHN

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

RANBAXY 25MG N021951 005 Aug 15, 2014 Feb NEWA

35MG N021951 006 Aug 15, 2014 Feb NEWA

MYORISAN

AB DOUGLAS PHARMS 30MG A076485 004 Aug 25, 2015 Aug NEWA

SOTRET

AB SUN PHARM INDS LTD 10MG A076041 001 Dec 24, 2002 Apr CAHN

AB 20MG A076041 002 Dec 24, 2002 Apr CAHN

AB 30MG A076503 001 Jun 20, 2003 Apr CAHN

AB 40MG A076041 003 Dec 24, 2002 Apr CAHN

ZENATANE

AB DR REDDYS LABS LTD 30MG A202099 004 Feb 23, 2015 Feb NEWA

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

AB ELITE LABS INC 2.5MG A077169 001 Apr 24, 2006 Mar CAHN

AB 5MG A077169 002 Apr 24, 2006 Mar CAHN

ITRACONAZOLE

SOLUTION; ORAL

ITRACONAZOLE

>A> AMNEAL PHARMS 10MG/ML A205573 001 Oct 30, 2015 Oct NEWA

>A> AA SPORANOX

>D> + JANSSEN PHARMS 10MG/ML N020657 001 Feb 21, 1997 Oct CFTG

>A> AA + 10MG/ML N020657 001 Feb 21, 1997 Oct CFTG

IVABRADINE HYDROCHLORIDE

TABLET; ORAL

CORLANOR

AMGEN INC EQ 5MG BASE N206143 001 Apr 15, 2015 Apr NEWA

+ EQ 7.5MG BASE N206143 002 Apr 15, 2015 Apr NEWA

IVACAFTOR

GRANULE; ORAL

KALYDECO

VERTEX PHARMS INC 50MG/PACKET N207925 001 Mar 17, 2015 Mar NEWA

+ 75MG/PACKET N207925 002 Mar 17, 2015 Mar NEWA

IVACAFTOR; LUMACAFTOR

TABLET; ORAL

ORKAMBI

+ VERTEX PHARMS INC 125MG; 200MG N206038 001 Jul 02, 2015 Jul NEWA

IXABEPILONE

INJECTABLE; IV (INFUSION)

IXEMPRA KIT

+ R-PHARM US LLC 15MG/VIAL N022065 001 Oct 16, 2007 Jun CAHN

+ 45MG/VIAL N022065 002 Oct 16, 2007 Jun CAHN

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN

@	EUROHLTH INTL SARL	EQ 75MG BASE/2ML	A 062324	001		Jun	CAHN
@		EQ 500MG BASE/2ML	A 062324	002		Jun	CAHN
@		EQ 1GM BASE/3ML	A 062324	003		Jun	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

AP	BD RX	15MG/ML	A 203242	001	Oct 07, 2015	Sep	NEWA
AP		30MG/ML	A 203242	002	Oct 07, 2015	Sep	NEWA
	@ CLARIS PHARMASERVICE	15MG/ML	A 075631	002	Jun 29, 2001	Apr	CAHN
	@	30MG/ML	A 075631	001	Jun 29, 2001	Apr	CAHN
	@ EUROHLTH INTL SARL	15MG/ML	A 075772	001	Jul 21, 2004	Jun	CAHN
	@	30MG/ML	A 075772	002	Jul 21, 2004	Jun	CAHN

SPRAY, METERED; NASAL
SPRIX

+	EGALET US INC	15.75MG/SPRAY	N 022382	001	May 14, 2010	Jan	CAHN
---	---------------	---------------	----------	-----	--------------	-----	------

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION
OMIDRIA

+	OMEROS	EQ 4.24MG BASE/ML; EQ 12.4MG BASE/ML	N 205388	001	May 30, 2014	Feb	CPOT
---	--------	--------------------------------------	----------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION
LABETALOL HYDROCHLORIDE

@	CLARIS PHARMASERVICE	5MG/ML	A 076051	001	Jul 05, 2002	Apr	CAHN
---	----------------------	--------	----------	-----	--------------	-----	------

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	MUTUAL PHARM	100MG	A 075215	001	Jul 29, 1999	Jan	CMFD
AB		200MG	A 075215	002	Jul 29, 1999	Jan	CMFD
AB		300MG	A 075215	003	Jul 29, 1999	Jan	CMFD

LACTULOSE

SOLUTION; ORAL, RECTAL
LACTULOSE

AA	BIO-PHARM INC	10GM/15ML	A 203762	001	Mar 27, 2015	Mar	NEWA
----	---------------	-----------	----------	-----	--------------	-----	------

LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET; ORAL
DUTREBIS

@	MERCK SHARP DOHME	150MG; EQ 300MG BASE	N 206510	001	Feb 06, 2015	Aug	DISC
+		150MG; EQ 300MG BASE	N 206510	001	Feb 06, 2015	Feb	NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	HETERO LABS LTD III	150MG; 300MG	A 079124	001	Sep 17, 2015	Aug	NEWA
AB	STRIDES ARCOLAB LTD	150MG; 300MG	A 079128	001	May 13, 2015	Apr	NEWA
AB	STRIDES PHARMA	150MG; 300MG	A 079128	001	May 13, 2015	Aug	CAHN

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@	HIKMA PHARMS	25MG	A 078134	001	Apr 19, 2011	May	DISC
@		100MG	A 078134	002	Apr 19, 2011	May	DISC
@		150MG	A 078134	003	Apr 19, 2011	May	DISC
@		200MG	A 078134	004	Apr 19, 2011	May	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

LAMOTRIGINE

>A>	AB	PAR PHARM	25MG	A 204158	001	Oct 27, 2015	Oct	NEWA
>A>	AB		50MG	A 204158	002	Oct 27, 2015	Oct	NEWA
>A>	AB		100MG	A 204158	003	Oct 27, 2015	Oct	NEWA
>A>	AB		200MG	A 204158	004	Oct 27, 2015	Oct	NEWA

LAPATINIB DITOSYLATE

TABLET; ORAL

TYKERB

+	NOVARTIS PHARMS CORP	EQ 250MG BASE	N022059	001	Mar 13, 2007	Mar	CAHN
---	----------------------	---------------	---------	-----	--------------	-----	------

LENVATINIB MESYLATE

CAPSULE; ORAL

LENVIMA

	EISAI INC	EQ 4MG BASE	N206947	001	Feb 13, 2015	Feb	NEWA
+		EQ 10MG BASE	N206947	002	Feb 13, 2015	Feb	NEWA

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090876	001	Aug 13, 2015	Jul	NEWA
----	--------------------	----------------------	---------	-----	--------------	-----	------

SOLUTION; ORAL

LEVETIRACETAM

AA	PHARM ASSOC	100MG/ML	A201157	001	Jun 04, 2015	May	NEWA
----	-------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

SPRITAM

	APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Jul	NEWA
		500MG	N207958	002	Jul 31, 2015	Jul	NEWA
		750MG	N207958	003	Jul 31, 2015	Jul	NEWA
		1GM	N207958	004	Jul 31, 2015	Jul	NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	APOTEX INC	1GM	A202958	001	Feb 25, 2015	Feb	NEWA
AB	DEXCEL PHARMA	500MG	A202167	001	Sep 04, 2015	Aug	NEWA
AB		750MG	A202167	002	Sep 04, 2015	Aug	NEWA
AB	PHARMADAX INC	500MG	A201464	001	May 25, 2012	Aug	CAHN
AB		750MG	A201464	002	May 25, 2012	Aug	CAHN
AB	PRINSTON INC	500MG	A203468	001	May 21, 2015	May	NEWA
AB		750MG	A203468	002	May 21, 2015	May	NEWA

LEVOCARNITINE

INJECTABLE; INJECTION

LEVOCARNITINE

	@ TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	Apr	DISC
--	-------------------	----------	---------	-----	--------------	-----	------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	APOTEX INC	5MG	A203027	001	Feb 13, 2015	Feb	NEWA
AB	SUN PHARM INDS LTD	5MG	A201653	001	Jun 26, 2015	Jun	NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AP	CLARIS PHARMASERVICE	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr	CAHN
AP	HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)	A078577	001	Aug 12, 2015	Jul	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A078577	002	Aug 12, 2015	Jul	NEWA
	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	CLARIS PHARMASERVICE	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Apr	CAHN
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Apr	CAHN
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Apr	CAHN
AP	HOSPIRA INC	EQ 250MG/50ML (EQ 5MG/ML)	A078579	001	Sep 03, 2015	Aug	NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A078579	002	Sep 03, 2015	Aug	NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A078579	003	Sep 03, 2015	Aug	NEWA

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

AT	+ NEXUS PHARMS	0.5%	A077700	001	Dec 20, 2010	Jul	CRLD
	QUIXIN						
	@ SANTEN	0.5%	N021199	001	Aug 18, 2000	Jul	DISC

TABLET; ORAL

LEVOFLOXACIN

AB	JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015	Jun	NEWA
AB		500MG	A203613	002	Jun 19, 2015	Jun	NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

>A>	AP	MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015	Oct	NEWA
>A>	AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015	Oct	NEWA
		SANDOZ	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Feb	NEWA
>D>		SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Oct	CTEC
>A>	AP		EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Oct	CTEC
			EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Feb	NEWA
>D>	+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Oct	CTEC
>A>	AP	+	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Oct	CTEC
		+	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Mar	CRLD

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

LILETTA

MEDICINES360

52MG

N206229 001 Feb 26, 2015 Feb NEWA

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

+ SENTYNL THERAPS INC 2MG

A074278 001 Mar 31, 2000 Apr CAHN

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

AT		AMNEAL PHARMS	5%	A206297	001	Aug 07, 2015	Jul	NEWA
		@ BELMORA LLC	5%	A080210	001		Sep	CAHN

PATCH; TOPICAL

LIDOCAINE

AB		ACTAVIS LABS UT INC	5%	A200675	001	Aug 23, 2012	Mar	CAHN
AB		MYLAN TECHNOLOGIES	5%	A202346	001	Aug 07, 2015	Jul	NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

		@ EUROHLTH INTL SARL	1%	A080407	001		Mar	CAHN
		@	2%	A080407	002		Mar	CAHN
AP		LUITPOLD	1%	A091564	001	Aug 14, 2015	Aug	NEWA
		LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE						
		@ EUROHLTH INTL SARL	1%	A084625	001		Feb	CAHN
		@	2%	A084625	002		Feb	CAHN

JELLY; TOPICAL

ANESTACON

@ BANNER LIFE SCIENCES 2%

A080429 001 Jan CAHN

LIDOCAINE HYDROCHLORIDE

@ G AND W LABS INC 2%

A081318 001 Apr 29, 1993 Apr CAHN

LIDOCAINE; PRILCAINE

CREAM; TOPICAL

EMLA

AB	+	ACTAVIS LABS UT INC	2.5%; 2.5%	N019941	001	Dec 30, 1992	Feb	CAHN
----	---	---------------------	------------	---------	-----	--------------	-----	------

LINACLOTIDE

CAPSULE; ORAL

LINZESS

+ FOREST LABS LLC 145MCG

N202811 001 Aug 30, 2012 Mar CAHN

+ 290MCG

N202811 002 Aug 30, 2012 Mar CAHN

LINCOMYCIN HYDROCHLORIDEINJECTABLE; INJECTION
LINCOCIN

AP	+	PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N050317	001		May	CFTG
AP		X-GEN PHARMS INC	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015	May	NEWA

LINEZOLIDFOR SUSPENSION; ORAL
LINEZOLID

AB		ROXANE	100MG/5ML	A200068	001	Jun 03, 2015	May	NEWA
AB	+	PHARMACIA AND UPJOHN	100MG/5ML	N021132	001	Apr 18, 2000	May	CFTG
			SOLUTION; IV (INFUSION)					
			LINEZOLID					
AP		HOSPIRA INC	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015	Jun	NEWA
AP		SANDOZ INC	200MG/100ML (2MG/ML)	A200904	001	Jul 16, 2015	Jul	NEWA
AP			600MG/300ML (2MG/ML)	A200904	002	Jul 16, 2015	Jul	NEWA
AP		TEVA PHARMS	600MG/300ML (2MG/ML)	A200222	001	Jun 27, 2012	May	CDFR
			LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	+	HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015	Jun	NEWA
			ZYVOX					
AP		PHARMACIA AND UPJOHN	200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000	Jul	CTEC
			200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000	May	CDFR
			400MG/200ML (2MG/ML)	N021131	002	Apr 18, 2000	May	NEWA
AP	+		600MG/300ML (2MG/ML)	N021131	003	Apr 18, 2000	May	NEWA
			TABLET; ORAL					
			LINEZOLID					
AB		TEVA PHARMS USA	600MG	A078061	001	May 18, 2015	May	NEWA
			ZYVOX					
AB	+	PHARMACIA AND UPJOHN	600MG	N021130	002	Apr 18, 2000	May	CFTG

LISINAPRILTABLET; ORAL
LISINAPRIL

AB		SUN PHARM INDS LTD	2.5MG	A075944	001	Jul 01, 2002	Apr	CAHN
AB			5MG	A075944	002	Jul 01, 2002	Apr	CAHN
AB			10MG	A075944	003	Jul 01, 2002	Apr	CAHN
AB			20MG	A075944	004	Jul 01, 2002	Apr	CAHN
AB			30MG	A075944	006	Feb 11, 2003	Apr	CAHN
AB			40MG	A075944	005	Jul 01, 2002	Apr	CAHN
			ZESTRIL					
AB		ALVOGEN IPCO SARL	2.5MG	N019777	005	Apr 29, 1993	Feb	CAHN
AB			5MG	N019777	001	May 19, 1988	Feb	CAHN
AB			10MG	N019777	002	May 19, 1988	Feb	CAHN
AB			20MG	N019777	003	May 19, 1988	Feb	CAHN
AB			30MG	N019777	006	Jan 20, 1999	Feb	CAHN
AB	+		40MG	N019777	004	May 19, 1988	Feb	CAHN

LITHIUM CARBONATETABLET, EXTENDED RELEASE; ORAL
LITHIUM CARBONATE

AB		ALEMBIC PHARMS LTD	300MG	A204445	001	Jun 10, 2015	May	NEWA
		@ HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003	Feb	DISC
AB		UNIQUE PHARM LABS	300MG	A204779	001	Jul 27, 2015	Jul	NEWA

LOMITAPIDE MESYLATECAPSULE; ORAL
JUXTAPID

AEGERION

EQ 30MG BASE
EQ 40MG BASE
EQ 60MG BASEN203858 004 Apr 23, 2015 Apr NEWA
N203858 005 Apr 23, 2015 Apr NEWA
N203858 006 Apr 23, 2015 Apr NEWALOMUSTINECAPSULE; ORAL
GLEOSTINE

CORDEN PHARMA

5MG

N017588 004 Dec 19, 2014 Jan NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
 IMODIUM
 @ J AND J CONSUMER INC 2MG N017690 001 Jul CAHN
 AB + 2MG N017694 001 Jul CAHN

LOPINAVIR; RITONAVIR

CAPSULE; ORAL
 KALETRA
 @ ABBVIE 133.3MG; 33.3MG N021226 001 Sep 15, 2000 Jun DISC

LORAZEPAM

INJECTABLE; INJECTION
 ATIVAN
 AP + EUROHLTH INTL SARL 2MG/ML N018140 001 Jun CAHN
 AP + 4MG/ML N018140 002 Jun CAHN
 TABLET; ORAL
 LORAZEPAM
 >A> AB ANI PHARMS INC 0.5MG A077396 001 Dec 13, 2006 Oct CAHN
 >A> AB 1MG A077396 002 Dec 13, 2006 Oct CAHN
 >A> AB 2MG A077396 003 Dec 13, 2006 Oct CAHN
 >D> AB IVAX SUB TEVA PHARMS 0.5MG A077396 001 Dec 13, 2006 Oct CAHN
 >D> AB 1MG A077396 002 Dec 13, 2006 Oct CAHN
 >D> AB 2MG A077396 003 Dec 13, 2006 Oct CAHN
 AB SUN PHARM INDS LTD 0.5MG A076045 001 Aug 29, 2001 Apr CAHN
 AB 1MG A076045 002 Aug 29, 2001 Apr CAHN
 AB 2MG A076045 003 Aug 29, 2001 Apr CAHN

LOSARTAN POTASSIUM

TABLET; ORAL
 LOSARTAN POTASSIUM
 AB HETERO LABS LTD V 25MG A203835 001 Aug 12, 2015 Jul NEWA
 AB 50MG A203835 002 Aug 12, 2015 Jul NEWA
 AB 100MG A203835 003 Aug 12, 2015 Jul NEWA
 >A> AB UNICHEM LABS LTD 25MG A203030 001 Oct 14, 2015 Oct NEWA
 >A> AB 50MG A203030 002 Oct 14, 2015 Oct NEWA
 >A> AB 100MG A203030 003 Oct 14, 2015 Oct NEWA
 AB WATSON LABS 25MG A091129 001 Oct 06, 2010 Feb CMFD
 AB 50MG A091129 002 Oct 06, 2010 Feb CMFD
 AB 100MG A091129 003 Oct 06, 2010 Feb CMFD

LOVASTATIN

TABLET, EXTENDED RELEASE; ORAL
 ALTOPREV
 @ COVIS PHARMA SARL 10MG N021316 001 Jun 26, 2002 May CAHN
 20MG N021316 002 Jun 26, 2002 May CAHN
 40MG N021316 003 Jun 26, 2002 May CAHN
 + 60MG N021316 004 Jun 26, 2002 May CAHN

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL
 LOXITANE C
 @ ACTAVIS LABS UT INC EQ 25MG BASE/ML N017658 001 Mar CAHN
 INJECTABLE; INJECTION
 LOXITANE IM
 @ ACTAVIS LABS UT INC EQ 50MG BASE/ML N018039 001 Mar CAHN

LOXAPINE SUCCINATE

CAPSULE; ORAL
 LOXAPINE SUCCINATE
 AB ELITE LABS INC EQ 5MG BASE A076868 001 Aug 04, 2005 May CAHN
 AB EQ 10MG BASE A076868 002 Aug 04, 2005 May CAHN
 AB EQ 25MG BASE A076868 003 Aug 04, 2005 May CAHN
 AB EQ 50MG BASE A076868 004 Aug 04, 2005 May CAHN
 LOXITANE
 @ ACTAVIS LABS UT INC EQ 5MG BASE N017525 001 Mar CAHN
 @ EQ 10MG BASE N017525 002 Mar CAHN
 @ EQ 25MG BASE N017525 003 Mar CAHN
 @ EQ 50MG BASE N017525 004 Mar CAHN

TABLET;ORAL

LOXITANE

@	ACTAVIS LABS UT INC	EQ 10MG BASE	N017525	006			Mar	CAHN
@		EQ 25MG BASE	N017525	007			Mar	CAHN
@		EQ 50MG BASE	N017525	008			Mar	CAHN

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

@	DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012		May	DISC
---	----------------	-------	---------	-----	--------------	--	-----	------

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984		Mar	DISC
---	-----------------	------------------------------------	---------	-----	--------------	--	-----	------

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP	EXELA PHARMA SCS LLC	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014		Apr	CDFR
AP	+ FRESENIUS KABI USA	5GM/10ML (500MG/ML)	N019316	001	Sep 08, 1986		Apr	CPOT
AP	+ HOSPIRA	5GM/10ML (500MG/ML)	A075151	001	Apr 25, 2000		Apr	CDFR
	HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015		Apr	NEWA

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986		Apr	NEWA
---	--------------------	--------------------	---------	-----	--------------	--	-----	------

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

SUCLEAR

@	BRAINTREE LABS	1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A; N/A, N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM	N203595	001	Jan 18, 2013		Aug	DISC
---	----------------	---	---------	-----	--------------	--	-----	------

MANNITOL

INJECTABLE; INJECTION

MANNITOL 25%

@	IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987		Mar	CAHN
@		12.5GM/50ML	A089240	001	May 06, 1987		Mar	CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

@	ANI PHARMS INC	12.5MG	A084975	001			Aug	CAHN
@		25MG	A084657	001			Aug	CAHN
@	VINTAGE PHARMS	12.5MG	A040179	001	Jan 30, 1997		Jun	DISC
@		25MG	A040179	002	Jan 30, 1997		Jun	DISC

MELOXICAM

>A> CAPSULE; ORAL

>A> VIVLODEX

>A>	IROKO PHARMS LLC	5MG	N207233	001	Oct 22, 2015		Oct	NEWA
>A>	+	10MG	N207233	002	Oct 22, 2015		Oct	NEWA

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMENDA XR

	FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010		Mar	CAHN
		14MG	N022525	002	Jun 21, 2010		Mar	CAHN
		21MG	N022525	003	Jun 21, 2010		Mar	CAHN
+		28MG	N022525	004	Jun 21, 2010		Mar	CAHN

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

AA	MACLEODS PHARMS LTD	2MG/ML	A202790	001	Oct 13, 2015		Sep	NEWA
AA	SILARX PHARMS INC	2MG/ML	A204033	001	Oct 13, 2015		Sep	NEWA
AA	+	2MG/ML	N021627	001	Apr 18, 2005		Sep	CFTG
+		2MG/ML	N021627	001	Apr 18, 2005		Mar	CAHN

TABLET;ORAL									
MEMANTINE									
>D>	AB	SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Oct	CTNA	
	AB		5MG	A090058	001	May 05, 2010	Mar	CMFD	
>D>	AB		10MG	A090058	002	May 05, 2010	Oct	CTNA	
	AB		10MG	A090058	002	May 05, 2010	Mar	CMFD	
MEMANTINE HYDROCHLORIDE									
	AB	ALEMBIC PHARMS LTD	5MG	A200891	001	Oct 13, 2015	Sep	NEWA	
	AB		10MG	A200891	002	Oct 13, 2015	Sep	NEWA	
	AB	AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	Mar	NEWA	
	AB		10MG	A090041	002	Apr 10, 2015	Mar	NEWA	
	AB	AUROBINDO PHARMA LTD	5MG	A203175	001	Oct 13, 2015	Sep	NEWA	
	AB		10MG	A203175	002	Oct 13, 2015	Sep	NEWA	
	AB	DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010	Jun	CMFD	
	AB		10MG	A090048	002	Apr 14, 2010	Jun	CMFD	
	AB	JUBILANT GENERICS	5MG	A091585	001	Oct 13, 2015	Sep	NEWA	
	AB		10MG	A091585	002	Oct 13, 2015	Sep	NEWA	
	AB	LUPIN LTD	5MG	A090051	001	Apr 10, 2015	Mar	NEWA	
	AB		10MG	A090051	002	Apr 10, 2015	Mar	NEWA	
	AB	MACLEODS PHARMS LTD	5MG	A202840	001	Oct 13, 2015	Sep	NEWA	
	AB		10MG	A202840	002	Oct 13, 2015	Sep	NEWA	
	AB	MYLAN PHARMS INC	5MG	A079225	001	Jan 30, 2015	Jun	CMFD	
	@		5MG	A079225	001	Jan 30, 2015	Mar	DISC	
	AB		5MG	A079225	001	Jan 30, 2015	Jan	NEWA	
	AB		10MG	A079225	002	Jan 30, 2015	Jun	CMFD	
	@		10MG	A079225	002	Jan 30, 2015	Mar	DISC	
	AB		10MG	A079225	002	Jan 30, 2015	Jan	NEWA	
>A>	AB	SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Oct	CTNA	
>A>	AB		10MG	A090058	002	May 05, 2010	Oct	CTNA	
	AB	TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	May	CMFD	
	AB		10MG	A090052	002	Oct 25, 2011	May	CMFD	
	AB	TORRENT PHARMS LTD	5MG	A200155	001	Oct 13, 2015	Sep	NEWA	
	AB		10MG	A200155	002	Oct 13, 2015	Sep	NEWA	
	AB	UNICHEM LABS LTD	5MG	A200022	001	Oct 13, 2015	Sep	NEWA	
	AB		10MG	A200022	002	Oct 13, 2015	Sep	NEWA	
	AB	UPSHER SMITH	5MG	A090043	001	Jul 31, 2015	Jul	NEWA	
	AB		10MG	A090043	002	Jul 31, 2015	Jul	NEWA	
	AB	WOCKHARDT LTD	5MG	A090073	001	Sep 04, 2015	Aug	NEWA	
	AB		10MG	A090073	002	Sep 04, 2015	Aug	NEWA	
NAMENDA									
	AB	FOREST LABS LLC	5MG	N021487	001	Oct 16, 2003	Mar	CAHN	
	AB	+	10MG	N021487	002	Oct 16, 2003	Mar	CAHN	
<u>MENOTROPINS (FSH;LH)</u>									
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS									
REPRONEX									
	@	FERRING	75 IU/VIAL;75 IU/VIAL	N021047	001	Aug 27, 1999	May	DISC	
<u>MEPERIDINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
MEPERIDINE HYDROCHLORIDE									
AP		EUROHLTH INTL SARL	25MG/ML	A080445	001		Feb	CAHN	
AP			50MG/ML	A080445	002		Feb	CAHN	
AP			75MG/ML	A080445	003		Feb	CAHN	
AP			100MG/ML	A080445	004		Feb	CAHN	
	@	IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989	May	CAHN	
	@		50MG/ML	A089782	001	Mar 31, 1989	Mar	CAHN	
	@		50MG/ML	A089783	001	Mar 31, 1989	Mar	CAHN	
	@		50MG/ML	A089784	001	Mar 31, 1989	Mar	CAHN	
	@		75MG/ML	A089785	001	Mar 31, 1989	Mar	CAHN	
	@		100MG/ML	A089786	001	Mar 31, 1989	Mar	CAHN	
	@		100MG/ML	A089787	001	Mar 31, 1989	Mar	CAHN	
	@		100MG/ML	A089788	001	Mar 31, 1989	Mar	CAHN	
<u>MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
MEPERGAN									
	@	EUROHLTH INTL SARL	25MG/ML;25MG/ML	N011730	001		Jun	CAHN	

MEROPENEM

POWDER;IV (INFUSION)
 MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
 B BRAUN MEDICAL INC 500MG/VIAL
 1GM/VIAL

N202106 001 Apr 30, 2015 Apr NEWA
 N202106 002 Apr 30, 2015 Apr NEWA

MESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL
 APRISO

+ VALEANT PHARMS INTL 375MG
 ENEMA;RECTAL
 MESALAMINE

N022301 001 Oct 31, 2008 Jul CAHN

AB G AND W LABS INC 4GM/60ML
 SUPPOSITORY;RECTAL
 CANASA

A076841 001 Sep 30, 2004 Aug CAHN

@ FOREST LABS LLC 500MG
 + 1GM

N021252 001 Jan 05, 2001 Aug CAHN
 N021252 002 Nov 05, 2004 Aug CAHN

TABLET, DELAYED RELEASE;ORAL

>D> ASACOL

>D> + WARNER CHILCOTT LLC 400MG

N019651 001 Jan 31, 1992 Oct DISC

>A> @ 400MG

N019651 001 Jan 31, 1992 Oct DISC

MESTRANOL; NORETHINDRONE

TABLET;ORAL-20
 NORINYL

@ ACTAVIS LABS UT INC 0.1MG;2MG

N013625 004 Mar CAHN

TABLET;ORAL-21

NORINYL 1+50 21-DAY

@ ACTAVIS LABS UT INC 0.05MG;1MG

N013625 002 Mar CAHN

TABLET;ORAL-28

NORINYL 1+50 28-DAY

+ ACTAVIS LABS UT INC 0.05MG;1MG

N016659 001 Mar CAHN

METAPROTERENOL SULFATE

SOLUTION;INHALATION
 METAPROTERENOL SULFATE

@ MYLAN SPECLT 0.4%

A071786 001 Aug 05, 1988 Apr DISC

@ 0.6%

A070804 001 Aug 17, 1987 Apr DISC

@ WOCKHARDT 0.4%

A075586 001 May 30, 2002 Apr DISC

@ 0.6%

A075586 002 May 30, 2002 Apr DISC

SYRUP;ORAL

METAPROTERENOL SULFATE

@ G AND W LABS INC 10MG/5ML

A072761 001 Feb 27, 1992 Apr CAHN

@ 10MG/5ML

A073034 001 Aug 30, 1991 Apr CAHN

METAXALONE

TABLET;ORAL
 METAXALONE

COREPHARMA 400MG

A040486 001 Feb 27, 2015 Feb NEWA

640MG

N022503 001 Jun 01, 2015 Jun NEWA

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL
 RIOMET

+ SUN PHARM INDS LTD 500MG/5ML

N021591 001 Sep 11, 2003 Apr CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

>A> AB MACLEODS PHARMS LTD 500MG;EQ 15MG BASE

A204802 001 Nov 05, 2015 Oct NEWA

>A> AB 850MG;EQ 15MG BASE

A204802 002 Nov 05, 2015 Oct NEWA

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL

PRANDIMET

AB NOVO NORDISK INC 500MG;1MG

N022386 001 Jun 23, 2008 Jun CFTG

AB + 500MG;2MG

N022386 002 Jun 23, 2008 Jun CFTG

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

AB LUPIN LTD 500MG;1MG

A200624 001 Jul 15, 2015 Jun NEWA

AB 500MG;2MG

A200624 002 Jul 15, 2015 Jun NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

@ SB PHARMCO	500MG;EQ 2MG BASE	N021410	002	Oct 10, 2002	May DISC
@	500MG;EQ 4MG BASE	N021410	003	Oct 10, 2002	May DISC
@	1GM;EQ 2MG BASE	N021410	004	Aug 25, 2003	May DISC
@	1GM;EQ 4MG BASE	N021410	005	Aug 25, 2003	May DISC

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

TEVA	500MG;EQ 2MG BASE	A077337	001	May 07, 2014	May CTEC
	500MG;EQ 4MG BASE	A077337	002	May 07, 2014	May CTEC
+	1GM;EQ 4MG BASE	A077337	004	May 07, 2014	May CRLD
	1GM;EQ 2MG BASE	A077337	003	May 07, 2014	May CTEC

METHADONE HYDROCHLORIDE

TABLET; ORAL

METHADONE HYDROCHLORIDE

AA AUROLIFE PHARMA LLC	5MG	A203502	001	Aug 31, 2015	Aug NEWA
AA	10MG	A203502	002	Aug 31, 2015	Aug NEWA
AA COREPHARMA	5MG	A090065	001	Aug 18, 2015	Aug NEWA
AA	10MG	A090065	002	Aug 18, 2015	Aug NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB HERITAGE PHARMA	5MG	A040734	001	Dec 14, 2007	Mar CAHN
AB	10MG	A040734	002	Dec 14, 2007	Mar CAHN

METHOCARBAMOL

SOLUTION; IM-IV

ROBAXIN

AP + EUROHLTH INTL SARL	1GM/10ML (100MG/ML)	N011790	001		Jun CAHN
-------------------------	---------------------	---------	-----	--	----------

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP FRESENIUS KABI USA	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999	May CMFD
-----------------------	-----------------	---------	-----	--------------	----------

METHOXSALEN

CAPSULE; ORAL

METHOXSALEN

AB ACTAVIS INC	10MG	A202603	001	Jun 09, 2015	May NEWA
----------------	------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

APTENSIO XR

RHODES PHARMS	10MG	N205831	001	Apr 17, 2015	Apr NEWA
	15MG	N205831	002	Apr 17, 2015	Apr NEWA
	20MG	N205831	003	Apr 17, 2015	Apr NEWA
	30MG	N205831	004	Apr 17, 2015	Apr NEWA
	40MG	N205831	005	Apr 17, 2015	Apr NEWA
	50MG	N205831	006	Apr 17, 2015	Apr NEWA
+	60MG	N205831	007	Apr 17, 2015	Apr NEWA

METHYLPHENIDATE HYDROCHLORIDE

AB2 MALLINCKRODT INC	10MG	A203583	001	Sep 29, 2015	Sep NEWA
AB2	20MG	A203583	002	Sep 29, 2015	Sep NEWA
AB2	30MG	A203583	003	Sep 29, 2015	Sep NEWA
AB2	40MG	A203583	004	Sep 29, 2015	Sep NEWA
AB2	50MG	A203583	005	Sep 29, 2015	Sep NEWA
AB2	60MG	A203583	006	Sep 29, 2015	Sep NEWA

RITALIN LA

AB1 NOVARTIS	40MG	N021284	003	Jun 05, 2002	Feb CRLD
+	60MG	N021284	005	Oct 27, 2014	Feb CRLD

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA NOVEL LABS INC	5MG/5ML	A204602	001	Aug 14, 2015	Aug NEWA
AA	10MG/5ML	A204602	002	Aug 14, 2015	Aug NEWA

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB ASCENT PHARMS INC	5MG	A207416	001	Sep 22, 2015	Sep NEWA
AB	10MG	A207416	002	Sep 22, 2015	Sep NEWA
AB	20MG	A207416	003	Sep 22, 2015	Sep NEWA

TABLET, CHEWABLE;ORAL

METHYLIN

AB	MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Feb CFTG
AB		5MG	N021475	002	Apr 15, 2003	Feb CFTG
AB	+	10MG	N021475	003	Apr 15, 2003	Feb CFTG
	METHYLPHENIDATE HYDROCHLORIDE					
AB	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Feb NEWA
AB		5MG	A204115	002	Feb 25, 2015	Feb NEWA
AB		10MG	A204115	003	Feb 25, 2015	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL

METHYLIN ER

AB	MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	May CTEC
	METHYLPHENIDATE HYDROCHLORIDE					
AB	ABHAI	10MG	A207488	001	Jun 09, 2015	May NEWA
AB		20MG	A207488	002	Jun 09, 2015	May NEWA

METHYLTESTOSTERONE

CAPSULE;ORAL

METHYLTESTOSTERONE

AB	IMPAX LABS INC	10MG	A204851	001	Sep 21, 2015	Sep NEWA
	TESTRED					
AB	+	VALEANT PHARM INTL	10MG	A083976	001	Sep CTEC

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP	CLARIS PHARMASERVICE	1MG/ML	A078950	001	Apr 29, 2013	Apr CAHN
----	----------------------	--------	---------	-----	--------------	----------

TABLET;ORAL

METOPROLOL TARTRATE

	MYLAN	37.5MG	A076704	004	Mar 18, 2015	Mar NEWA
		75MG	A076704	005	Mar 18, 2015	Mar NEWA

METRONIDAZOLE

CREAM;TOPICAL

NORITATE

+	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997	Feb CAHN
---	----------------------	----	---------	-----	--------------	----------

GEL;VAGINAL

METRONIDAZOLE

+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb CAHN
	NUVESSA					
+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb CTNA

INJECTABLE;INJECTION

METRONIDAZOLE

	@ EUROHLTH INTL SARL	500MG/100ML	N018907	001	Mar 30, 1984	Aug CAHN
	METRONIDAZOLE IN PLASTIC CONTAINER					
AP	CLARIS PHARMASERVICE	500MG/100ML	A078084	001	Mar 31, 2008	Apr CAHN

TABLET;ORAL

METRONIDAZOLE

AB	APPCO PHARMA LLC	250MG	A205245	001	Sep 23, 2015	Sep NEWA
AB		500MG	A205245	002	Sep 23, 2015	Sep NEWA
AB	AUROBINDO PHARMA LTD	250MG	A203974	001	May 29, 2015	May NEWA
AB		500MG	A203974	002	May 29, 2015	May NEWA

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE

>A>	@ IDT AUSTRALIA LTD	150MG	A074450	001	May 16, 1996	Oct CAHN
>A>	@	200MG	A074450	002	May 16, 1996	Oct CAHN
>A>	@	250MG	A074450	003	May 16, 1996	Oct CAHN
>D>	@ SANDOZ	150MG	A074450	001	May 16, 1996	Oct CAHN
>D>	@	200MG	A074450	002	May 16, 1996	Oct CAHN
>D>	@	250MG	A074450	003	May 16, 1996	Oct CAHN

MICONAZOLE

TABLET;BUCCAL

ORAVIG

+	DARA BIOSCIENCES	50MG	N022404	001	Apr 16, 2010	Apr CAHN
---	------------------	------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

	@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML	A 075637	001	Oct 31, 2000	Apr	CAHN
	@	EQ 5MG BASE/ML	A 075637	002	Oct 31, 2000	Apr	CAHN
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A 075243	001	Jun 20, 2000	Jun	CAHN
AP		EQ 5MG BASE/ML	A 075243	002	Jun 20, 2000	Jun	CAHN
	@ IGI LABS INC	EQ 5MG BASE/ML	A 075263	001	Jun 26, 2000	Apr	CAHN
	@ WOCKHARDT	EQ 1MG BASE/ML	A 078141	001	May 30, 2008	Mar	DISC
	@	EQ 1MG BASE/ML	A 078511	001	Nov 10, 2008	Mar	DISC
	@	EQ 5MG BASE/ML	A 078141	002	May 30, 2008	Mar	DISC
	@	EQ 5MG BASE/ML	A 078511	002	Nov 10, 2008	Mar	DISC

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

AA	SUN PHARM INDS LTD	EQ 2MG BASE/ML	A 076058	001	Mar 15, 2002	Apr	CAHN
----	--------------------	----------------	----------	-----	--------------	-----	------

MIGLITOL

TABLET; ORAL

GLYSET

AB	PHARMACIA AND UPJOHN	25MG	N 020682	001	Dec 18, 1996	Mar	CTEC
AA		25MG	N 020682	001	Dec 18, 1996	Feb	CFTG
AB		50MG	N 020682	002	Dec 18, 1996	Mar	CTEC
AA		50MG	N 020682	002	Dec 18, 1996	Feb	CFTG
AB	+	100MG	N 020682	003	Dec 18, 1996	Mar	CTEC
AA	+	100MG	N 020682	003	Dec 18, 1996	Feb	CFTG

MIGLITOL

AB	ORIENT PHARMA CO LTD	25MG	A 203965	001	Feb 24, 2015	Mar	CTEC
AA		25MG	A 203965	001	Feb 24, 2015	Feb	NEWA
AB		50MG	A 203965	002	Feb 24, 2015	Mar	CTEC
AA		50MG	A 203965	002	Feb 24, 2015	Feb	NEWA
AB		100MG	A 203965	003	Feb 24, 2015	Mar	CTEC
AA		100MG	A 203965	003	Feb 24, 2015	Feb	NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP	BEDFORD	EQ 1MG BASE/ML	A 075660	001	May 28, 2002	Jan	CRLD
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A 075530	001	May 28, 2002	Jun	CAHN
	@	EQ 1MG BASE/ML	A 075852	001	May 28, 2002	Sep	CAHN
AP	+ HIKMA FARMACEUTICA	EQ 1MG BASE/ML	A 077966	001	Dec 03, 2010	Jan	CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A 065062	001	Nov 30, 2000	Apr	CAHN
AB		EQ 75MG BASE	A 065062	002	Nov 30, 2000	Apr	CAHN
AB		EQ 100MG BASE	A 065062	003	Nov 30, 2000	Apr	CAHN
AB	TORRENT PHARMA INC	EQ 50MG BASE	A 065062	001	Nov 30, 2000	Jun	CAHN
AB		EQ 75MG BASE	A 065062	002	Nov 30, 2000	Jun	CAHN
AB		EQ 100MG BASE	A 065062	003	Nov 30, 2000	Jun	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

@	SUN PHARM INDS LTD	EQ 45MG BASE	N 201922	001	Jul 11, 2012	Apr	CAHN
@		EQ 67.5MG BASE	N 201922	002	Jul 11, 2012	Apr	CAHN
@		EQ 90MG BASE	N 201922	003	Jul 11, 2012	Apr	CAHN
@		EQ 112.5MG BASE	N 201922	004	Jul 11, 2012	Apr	CAHN
@		EQ 135MG BASE	N 201922	005	Jul 11, 2012	Apr	CAHN

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A 065156	001	Jan 06, 2004	Apr	CAHN
AB		EQ 75MG BASE	A 065156	002	Jan 06, 2004	Apr	CAHN
AB		EQ 100MG BASE	A 065156	003	Jan 06, 2004	Apr	CAHN
AB	TORRENT PHARMA INC	EQ 50MG BASE	A 065156	001	Jan 06, 2004	Jun	CAHN
AB		EQ 75MG BASE	A 065156	002	Jan 06, 2004	Jun	CAHN
AB		EQ 100MG BASE	A 065156	003	Jan 06, 2004	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	+ SANDOZ	EQ 135MG BASE	A 090422	003	Aug 13, 2009	Sep	CRLD
AB	SUN PHARM INDS LTD	EQ 45MG BASE	A 091118	001	Sep 25, 2014	Apr	CAHN
AB		EQ 80MG BASE	A 091118	004	Sep 25, 2014	Apr	CAHN
AB		EQ 90MG BASE	A 091118	005	Sep 25, 2014	Apr	CAHN

TABLET, EXTENDED RELEASE;ORAL
MINOCYCLINE HYDROCHLORIDE

AB		EQ 105MG BASE	A091118	006	Sep 25, 2014	Apr CAHN
AB		EQ 135MG BASE	A091118	008	Sep 25, 2014	Apr CAHN
	SOLODYN					
	MEDICIS	EQ 55MG BASE	N050808	008	Aug 27, 2010	Sep CRLD
AB		EQ 80MG BASE	N050808	007	Aug 27, 2010	Sep CRLD
AB	+	EQ 115MG BASE	N050808	005	Jul 23, 2009	Sep CRLD

MIVACURIUM CHLORIDE

SOLUTION; INTRAVENOUS
MIVACRON

	ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992	Jan NEWA
+		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992	Jan NEWA

MOLINDONE HYDROCHLORIDE

TABLET; ORAL
MOLINDONE HYDROCHLORIDE

	COREPHARMA	5MG	A090453	001	Mar 20, 2015	Mar NEWA
		10MG	A090453	002	Mar 20, 2015	Mar NEWA
+		25MG	A090453	003	Mar 20, 2015	Mar NEWA

MONTELUKAST SODIUM

GRANULE; ORAL
MONTELUKAST SODIUM

AB	AJANTA PHARMA LTD	EQ 4MG BASE/PACKET	A203438	001	Jul 31, 2015	Jul NEWA
	TABLET; ORAL					
	MONTELUKAST SODIUM					
AB	AJANTA PHARMA LTD	EQ 10MG BASE	A203432	001	Jul 31, 2015	Jul NEWA
AB	AMNEAL PHARMS	EQ 10MG BASE	A204604	001	Sep 04, 2015	Aug NEWA
AB	KREMERS URBAN PHARMS	EQ 10MG BASE	A201522	001	Aug 03, 2012	Mar CAHN
AB	UNICHEM LABS LTD	EQ 10MG BASE	A204290	001	Oct 08, 2015	Sep NEWA

TABLET, CHEWABLE; ORAL
MONTELUKAST SODIUM

AB	AJANTA PHARMA LTD	EQ 4MG BASE	A203328	001	Jul 31, 2015	Jul NEWA	
AB		EQ 5MG BASE	A203328	002	Jul 31, 2015	Jul NEWA	
>A>	AB	ANBISON LAB CO LTD	EQ 4MG BASE	A205695	001	Nov 05, 2015	Oct NEWA
>A>	AB		EQ 5MG BASE	A205695	002	Nov 05, 2015	Oct NEWA
AB	HETERO LABS LTD V	EQ 4MG BASE	A204093	001	May 22, 2015	May NEWA	
AB		EQ 5MG BASE	A204093	002	May 22, 2015	May NEWA	
AB	JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Feb NEWA	
AB		EQ 5MG BASE	A203795	002	Feb 27, 2015	Feb NEWA	
AB	KREMERS URBAN PHARMS	EQ 4MG BASE	A200405	001	Aug 03, 2012	Mar CAHN	
AB		EQ 5MG BASE	A200405	002	Aug 03, 2012	Mar CAHN	
AB	MACLEODS PHARMS LTD	EQ 4MG BASE	A203582	001	Mar 12, 2015	Feb NEWA	
AB		EQ 5MG BASE	A203582	002	Mar 12, 2015	Feb NEWA	

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
AVINZA

	@ KING PHARMS LLC	30MG	N021260	001	Mar 20, 2002	Sep DISC	
	@	45MG	N021260	005	Dec 18, 2008	Sep DISC	
	@	60MG	N021260	002	Mar 20, 2002	Sep DISC	
	@	75MG	N021260	006	Dec 18, 2008	Sep DISC	
	@	90MG	N021260	003	Mar 20, 2002	Sep DISC	
	@	120MG	N021260	004	Mar 20, 2002	Sep DISC	
	KADIAN						
AB1	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Mar CAHN
AB1			20MG	N020616	001	Jul 03, 1996	Mar CAHN
AB1			30MG	N020616	004	Mar 09, 2001	Mar CAHN
AB1			40MG	N020616	009	Jul 09, 2012	May CTEC
			40MG	N020616	009	Jul 09, 2012	Mar CAHN
AB1			50MG	N020616	002	Jul 03, 1996	Mar CAHN
AB1			60MG	N020616	005	Mar 09, 2001	Mar CAHN
AB1			70MG	N020616	010	Jul 09, 2012	May CTEC
			70MG	N020616	010	Jul 09, 2012	Mar CAHN
AB1			80MG	N020616	006	Oct 27, 2006	Mar CAHN
AB1	+		100MG	N020616	003	Jul 03, 1996	Mar CAHN
			130MG	N020616	011	Jul 09, 2012	Mar CAHN
			150MG	N020616	012	Jul 09, 2012	Mar CAHN
AB1	+		200MG	N020616	007	Feb 27, 2007	Mar CAHN

CAPSULE, EXTENDED RELEASE;ORAL							
MORPHINE SULFATE							
	ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013	Sep	CTEC
		45MG	A079040	002	Jan 16, 2013	Sep	CTEC
		60MG	A079040	003	Jan 16, 2013	Sep	CTEC
		75MG	A079040	004	Jan 16, 2013	Sep	CTEC
		90MG	A079040	005	Jan 16, 2013	Sep	CTEC
	+	120MG	A079040	006	Jan 16, 2013	Sep	CTEC
AB1	TEVA PHARMS USA	40MG	A202718	007	Jun 03, 2015	May	NEWA
AB1		70MG	A202718	008	Jun 03, 2015	May	NEWA
INJECTABLE;INJECTION							
DURAMORPH PF							
AP	+	EUROHLTH INTL SARL	0.5MG/ML	N018565	001	Sep 18, 1984	Jun CAHN
AP	+		1MG/ML	N018565	002	Sep 18, 1984	Jun CAHN
INFUMORPH							
	+	EUROHLTH INTL SARL	10MG/ML	N018565	003	Jul 19, 1991	Jun CAHN
	+		25MG/ML	N018565	004	Jul 19, 1991	Jun CAHN
MORPHINE SULFATE							
AP		EUROHLTH INTL SARL	4MG/ML	A205758	001	May 21, 2015	May NEWA
AP			8MG/ML	A205758	002	May 21, 2015	May NEWA
AP			10MG/ML	A205758	003	May 21, 2015	May NEWA
AP	+	HOSPIRA INC	4MG/ML	N202515	002	Nov 14, 2011	May CFTG
AP	+		8MG/ML	N202515	003	Nov 14, 2011	May CFTG
AP	+		10MG/ML	N202515	004	Nov 14, 2011	May CFTG
SOLUTION;ORAL							
MORPHINE SULFATE							
AA		TRIS PHARMA INC	10MG/5ML	A203518	001	May 12, 2015	May NEWA
AA			100MG/5ML	A203518	002	May 12, 2015	May NEWA
>A>	AA	VINTAGE PHARMS LLC	20MG/5ML	A202310	001	Oct 30, 2015	Oct NEWA
TABLET, EXTENDED RELEASE;ORAL							
MORPHABOND							
>A>		IDT	15MG	N206544	001	Oct 02, 2015	Oct NEWA
>A>			30MG	N206544	002	Oct 02, 2015	Oct NEWA
>A>			60MG	N206544	003	Oct 02, 2015	Oct NEWA
>A>	+		100MG	N206544	004	Oct 02, 2015	Oct NEWA
MORPHINE SULFATE							
AB		ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Mar NEWA
AB			30MG	A203849	002	Apr 06, 2015	Mar NEWA
AB			60MG	A203849	003	Apr 06, 2015	Mar NEWA
AB			100MG	A203849	004	Apr 06, 2015	Mar NEWA
AB			200MG	A203849	005	Apr 06, 2015	Mar NEWA
AB		SUN PHARM INDS LTD	15MG	A078761	001	May 11, 2012	Apr CAHN
AB			30MG	A078761	002	May 11, 2012	Apr CAHN
AB			60MG	A078761	003	May 11, 2012	Apr CAHN
AB			100MG	A078761	004	May 11, 2012	Apr CAHN
AB			200MG	A078761	005	May 11, 2012	Apr CAHN
<u>MOXIFLOXACIN HYDROCHLORIDE</u>							
SOLUTION;IV (INFUSION)							
MOXIFLOXACIN HYDROCHLORIDE							
	+	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015	Apr NEWA
SOLUTION/DROPS;OPHTHALMIC							
MOXEZA							
AT2	+	ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May CFTG
MOXIFLOXACIN HYDROCHLORIDE							
AT1		LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	May CTEC
AT2			EQ 0.5% BASE	A204079	001	May 28, 2015	May NEWA
AT1		WATSON LABS INC	EQ 0.5% BASE	A202525	001	Mar 06, 2015	May CTEC
AT			EQ 0.5% BASE	A202525	001	Mar 06, 2015	Feb NEWA
VIGAMOX							
AT1	+	ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	May CTEC
TABLET;ORAL							
MOXIFLOXACIN HYDROCHLORIDE							
AB		MYLAN PHARMS INC	EQ 400MG BASE	A204635	001	Aug 31, 2015	Aug NEWA
<u>MYCOPHENOLATE MOFETIL</u>							
CAPSULE;ORAL							
MYCOPHENOLATE MOFETIL							
>D>	AB	DR REDDYS LABS LTD	250MG	A091315	001	Oct 27, 2011	Oct DISC
>A>	@		250MG	A091315	001	Oct 27, 2011	Oct DISC

NADOLOL

TABLET; ORAL

CORGARD

>D>	AB	KING PHARMS	20MG	N018063	005	Oct 28, 1986	Oct	CAHN
>D>	AB		40MG	N018063	001		Oct	CAHN
>D>	AB	+	80MG	N018063	002		Oct	CAHN
>D>		@	120MG	N018063	003		Oct	CAHN
>D>		@	160MG	N018063	004		Oct	CAHN
>A>	AB	US WORLD MEDS LLC	20MG	N018063	005	Oct 28, 1986	Oct	CAHN
>A>	AB		40MG	N018063	001		Oct	CAHN
>A>	AB	+	80MG	N018063	002		Oct	CAHN
>A>		@	120MG	N018063	003		Oct	CAHN
>A>		@	160MG	N018063	004		Oct	CAHN
		NADOLOL						
AB		ORION CORP ORION	40MG	A201893	001	Sep 16, 2015	Aug	NEWA
AB			80MG	A201893	002	Sep 16, 2015	Aug	NEWA

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HYDROCHLORIDE

		@	IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989	Mar	CAHN
		@		10MG/ML	A072071	001	Apr 10, 1989	Mar	CAHN
		@		10MG/ML	A072072	001	Apr 10, 1989	Mar	CAHN
		@		20MG/ML	A072073	001	Apr 10, 1989	Mar	CAHN
		@		20MG/ML	A072074	001	Apr 10, 1989	Mar	CAHN
		@		20MG/ML	A072075	001	Apr 10, 1989	Mar	CAHN

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

REVEX

		@	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Jun	CAHN
		@		EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Jun	CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

		@	EUROHLTH INTL SARL	0.4MG/ML	A070299	001	Sep 24, 1986	Mar	CAHN
--	--	---	--------------------	----------	---------	-----	--------------	-----	------

NALOXONE HYDROCHLORIDE

		@	IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989	Mar	CAHN
		@		0.02MG/ML	A072083	001	Apr 11, 1989	Mar	CAHN
		@		0.02MG/ML	A072084	001	Apr 11, 1989	Mar	CAHN
		@		0.02MG/ML	A072085	001	Apr 11, 1989	Mar	CAHN
		@		0.4MG/ML	A072086	001	Apr 11, 1989	Mar	CAHN
		@		0.4MG/ML	A072087	001	Apr 11, 1989	Mar	CAHN
		@		0.4MG/ML	A072088	001	Apr 11, 1989	Mar	CAHN
		@		0.4MG/ML	A072089	001	Apr 11, 1989	Mar	CAHN
		@		0.4MG/ML	A072090	001	Apr 11, 1989	Mar	CAHN
		@		1MG/ML	A072091	001	Apr 11, 1989	Mar	CAHN
		@		1MG/ML	A072092	001	Apr 11, 1989	Mar	CAHN
		@		1MG/ML	A072093	001	Apr 11, 1989	Mar	CAHN
		NARCAN							
		@	ADAPT	0.02MG/ML	N016636	002		Aug	CAHN
		@		0.4MG/ML	N016636	001		Aug	CAHN
		@		1MG/ML	N016636	003	Jun 14, 1982	Aug	CAHN

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 0.5MG BASE;EQ 50MG BASE	A075523	001	Mar 17, 2000	Apr	CAHN
----	--	--------------------	----------------------------	---------	-----	--------------	-----	------

NAPROXEN

SUSPENSION; ORAL

NAPROSYN

AB	+	PEDIAPHARM INC	25MG/ML	N018965	001	Mar 23, 1987	Apr	CAHN
----	---	----------------	---------	---------	-----	--------------	-----	------

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

>D>	AB	ALMATICA PHARMA INC	EQ 375MG BASE	N020353	001	Jan 05, 1996	Oct	CAHN
>D>	AB		EQ 500MG BASE	N020353	002	Jan 05, 1996	Oct	CAHN
>D>		+	EQ 750MG BASE	N020353	003	Jan 05, 1996	Oct	CAHN

TABLET, EXTENDED RELEASE;ORAL

NAPRELAN

>A>	AB	ALVOGEN MALTA	EQ 375MG BASE	N020353	001	Jan 05, 1996	Oct CAHN
>A>	AB		EQ 500MG BASE	N020353	002	Jan 05, 1996	Oct CAHN
>A>	+		EQ 750MG BASE	N020353	003	Jan 05, 1996	Oct CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

TREMIMET

		PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Jun NEWA
--	--	--------------------	-------------------	---------	-----	--------------	----------

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

		@ ALKEM LABS LTD	EQ 2.5MG BASE	A203741	001	Jun 24, 2015	Jun DISC
			EQ 2.5MG BASE	A203741	001	Jun 24, 2015	Jun NEWA
		@	EQ 5MG BASE	A203741	002	Jun 24, 2015	Jun DISC
			EQ 5MG BASE	A203741	002	Jun 24, 2015	Jun NEWA
		@	EQ 10MG BASE	A203741	003	Jun 24, 2015	Jun DISC
			EQ 10MG BASE	A203741	003	Jun 24, 2015	Jun NEWA
		@	EQ 20MG BASE	A203741	004	Jun 24, 2015	Jun DISC
			EQ 20MG BASE	A203741	004	Jun 24, 2015	Jun NEWA
		@ AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Apr DISC
AB			EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Mar NEWA
		@	EQ 5MG BASE	A203659	002	Apr 16, 2015	Apr DISC
AB			EQ 5MG BASE	A203659	002	Apr 16, 2015	Mar NEWA
		@	EQ 10MG BASE	A203659	003	Apr 16, 2015	Apr DISC
AB			EQ 10MG BASE	A203659	003	Apr 16, 2015	Mar NEWA
		@	EQ 20MG BASE	A203659	004	Apr 16, 2015	Apr DISC
AB			EQ 20MG BASE	A203659	004	Apr 16, 2015	Mar NEWA
		@ INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul DISC
			EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul NEWA
		@	EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul DISC
			EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul NEWA
		@	EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul DISC
			EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul NEWA
		@	EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul DISC
			EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul NEWA

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

		@ IDT AUSTRALIA LTD	50MG	A076072	001	Sep 16, 2003	Apr CAHN
		@	100MG	A076072	002	Sep 16, 2003	Apr CAHN
		@	150MG	A076072	003	Sep 16, 2003	Apr CAHN
		@	200MG	A076072	004	Sep 16, 2003	Apr CAHN
		@	250MG	A076072	005	Sep 16, 2003	Apr CAHN
AB		SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Apr CAHN
AB			100MG	A076409	002	Sep 16, 2003	Apr CAHN
AB			150MG	A076409	003	Sep 16, 2003	Apr CAHN
AB			200MG	A076409	004	Sep 16, 2003	Apr CAHN
AB			250MG	A076409	005	Sep 16, 2003	Apr CAHN

NELARABINE

INJECTABLE;IV (INFUSION)

ARRANON

+		NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Mar CAHN
---	--	----------------------	---------------------	---------	-----	--------------	----------

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

		FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Jan NEWA
			10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Jan NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

>A>	AB	ALVOGEN MALTA	100MG	A204621	002	Nov 09, 2015	Oct NEWA
>A>	AB		100MG	A204621	002	Nov 09, 2015	Oct CAHN
>A>	AB		400MG	A204621	001	Jul 10, 2015	Oct CAHN
>D>	AB	ALVOGEN PINE BROOK	400MG	A204621	001	Jul 10, 2015	Oct CAHN
	AB		400MG	A204621	001	Jul 10, 2015	Jun NEWA
>A>	AB	CIPLA LTD	400MG	A206448	001	Oct 15, 2015	Oct NEWA

TABLET, EXTENDED RELEASE;ORAL
NEVIRAPINE

>A>	AB	MYLAN PHARMS INC	100MG	A206271	001	Nov 09, 2015	Oct	NEWA
		VIRAMUNE XR						
>D>		BOEHRINGER INGELHEIM	100MG	N201152	002	Nov 08, 2012	Oct	CFTG
>A>	AB		100MG	N201152	002	Nov 08, 2012	Oct	CFTG

NIACIN

TABLET, EXTENDED RELEASE;ORAL
NIACIN

AB		AMNEAL PHARMS	500MG	A203578	001	Jul 24, 2015	Jul	NEWA
AB			1GM	A203578	002	Jul 24, 2015	Jul	NEWA

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

AB		HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013	Mar	CAHN
AB			20MG	A202644	002	Apr 25, 2013	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

AB2		VALEANT PHARMS NORTH	30MG	A075289	002	Feb 06, 2001	Aug	CAHN
AB2			60MG	A075289	001	Sep 27, 2000	Aug	CAHN

NILUTAMIDE

TABLET;ORAL

NILANDRON

		@ CONCORDIA PHARMS INC	50MG	N020169	001	Sep 19, 1996	Apr	CAHN
		+	150MG	N020169	002	Apr 30, 1999	Apr	CAHN

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

AB	+	BANNER LIFE SCIENCES	30MG	A076740	001	Jan 17, 2008	Jan	CAHN
AB		SOFGEN PHARMS	30MG	A201832	001	Jul 24, 2015	Jul	NEWA

NINTEDANIB ESYLATE

CAPSULE;ORAL

OFEV

		BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014	Mar	CAIN
		+	EQ 150MG BASE	N205832	002	Oct 15, 2014	Mar	CAIN

NITRIC OXIDE

GAS; INHALATION

INOMAX

		@ INO	100PPM	N020845	002	Dec 23, 1999	Jun	DISC
--	--	-------	--------	---------	-----	--------------	-----	------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACRODANTIN

>D>	AB	ALVOGEN INC	25MG	N016620	003		Oct	CAHN
	AB		25MG	N016620	003		Jun	CTEC
>D>	AB		50MG	N016620	001		Oct	CAHN
>D>	AB	+	100MG	N016620	002		Oct	CAHN
>A>	AB	ALVOGEN MALTA	25MG	N016620	003		Oct	CAHN
>A>	AB		50MG	N016620	001		Oct	CAHN
>A>	AB	+	100MG	N016620	002		Oct	CAHN

NITROFURANTOIN

AB		ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015	Jun	NEWA
AB			50MG	A091095	002	Jun 18, 2015	Jun	NEWA
AB			100MG	A091095	003	Jun 18, 2015	Jun	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALLS)

AB		WATSON LABS INC	75MG;25MG	A202250	001	Jul 08, 2015	Jun	NEWA
----	--	-----------------	-----------	---------	-----	--------------	-----	------

NORETHINDRONE

TABLET;ORAL-28
NOR-QD

AB1 + ACTAVIS LABS UT INC 0.35MG N017060 001 Mar CAHN

NORGESTREL

TABLET;ORAL
OVRETTE

@ LABORATOIRE HRA 0.075MG N017031 001 Jun CAHN

NYSTATIN

CREAM;TOPICAL
NYSTATIN

AT G AND W LABS INC 100,000 UNITS/GM A061966 001 Jun CMFD

SUSPENSION;ORAL
NYSTATIN

AA G AND W LABS INC 100,000 UNITS/ML A062349 001 Jul 14, 1982 Apr CAHN
@ 100,000 UNITS/ML A062776 001 Dec 17, 1987 Apr CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL
MYKACET

AT G AND W LABS INC 100,000 UNITS/GM;0.1% A062367 001 May 28, 1985 Mar CMFD

OINTMENT;TOPICAL
MYKACET

AT G AND W LABS INC 100,000 UNITS/GM;0.1% A062733 001 Mar 09, 1987 Mar CMFD

OFLOXACIN

TABLET;ORAL
OFLOXACIN

AB LARKEN LABS 400MG A076093 003 Sep 02, 2003 Jul CMFD

OLANZAPINE

TABLET;ORAL
OLANZAPINE

>A> AB ALKEM LABS LTD 2.5MG A202295 001 Oct 20, 2015 Oct NEWA
>A> AB 5MG A202295 002 Oct 20, 2015 Oct NEWA
>A> AB 7.5MG A202295 003 Oct 20, 2015 Oct NEWA
>A> AB 10MG A202295 004 Oct 20, 2015 Oct NEWA
>A> AB 15MG A202295 005 Oct 20, 2015 Oct NEWA
>A> AB 20MG A202295 006 Oct 20, 2015 Oct NEWA
AB IVAX PHARMS INC 20MG A077301 001 Apr 29, 2015 Apr NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

AB MACLEODS PHARMS LTD 5MG A203044 001 Feb 20, 2015 Feb NEWA
AB 10MG A203044 002 Feb 20, 2015 Feb NEWA
AB 15MG A203044 003 Feb 20, 2015 Feb NEWA
AB 20MG A203044 004 Feb 20, 2015 Feb NEWA
AB ORCHID HLTHCARE 5MG A202937 001 Mar 02, 2015 Feb NEWA
AB 10MG A202937 002 Mar 02, 2015 Feb NEWA
AB 15MG A202937 003 Mar 02, 2015 Feb NEWA
AB 20MG A202937 004 Mar 02, 2015 Feb NEWA

OLAPARIB

CAPSULE;ORAL
LYNPARZA

ASTRAZENECA PHARMS 50MG N206162 001 Dec 19, 2014 Jan CTNA

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED;INHALATION
STIOLTO RESPIMAT

+ BOEHRINGER INGELHEIM EQ 0.0025MG BASE/INH;EQ 0.0025MG N206756 001 May 21, 2015 May NEWA
BASE/INH

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT BARR LABS INC EQ 0.2% BASE A090848 001 Jul 13, 2015 Jun NEWA

PATADAY

AT + ALCON PHARMS LTD EQ 0.2% BASE N021545 001 Dec 22, 2004 Jun CFTG

SOLUTION/DROPS;OPHTHALMIC

PAZEO

+ ALCON RES LTD EQ 0.7% BASE N206276 001 Jan 30, 2015 Jan NEWA

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET;ORAL

TECHNIVIE

+ ABBVIE INC 12.5MG;75MG;50MG N207931 001 Jul 24, 2015 Aug CMS1
 + 12.5MG;75MG;50MG N207931 001 Jul 25, 2015 Jul NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

AB AUROBINDO PHARMA USA 10MG A203270 001 Aug 19, 2015 Aug NEWA
 AB 20MG A203270 002 Aug 19, 2015 Aug NEWA
 AB 40MG A203270 003 Aug 19, 2015 Aug NEWA
 AB LUPIN LTD 40MG A202384 001 Aug 25, 2015 Aug NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

AB SUN PHARM INDS LTD 4MG A078602 001 Feb 24, 2011 Apr CAHN
 AB 8MG A078602 002 Feb 24, 2011 Apr CAHN
 ZOFRAN ODT
 AB NOVARTIS PHARMS CORP 4MG N020781 001 Jan 27, 1999 Mar CAHN
 AB + 8MG N020781 002 Jan 27, 1999 Mar CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP ACCORD HLTHCARE EQ 2MG BASE/ML A206846 001 Jul 13, 2015 Jun NEWA
 AP CLARIS PHARMASERVICE EQ 2MG BASE/ML A078288 001 Feb 22, 2013 Apr CAHN
 AP EUROHLTH INTL SARL EQ 2MG BASE/ML A077365 001 Dec 26, 2006 Jun CAHN
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE
 AP CLARIS PHARMASERVICE EQ 2MG BASE/ML A078287 001 Feb 22, 2013 Apr CAHN
 AP EUROHLTH INTL SARL EQ 2MG BASE/ML A077541 001 Dec 26, 2006 Jun CAHN
 @ TARO PHARMS IRELAND EQ 2MG BASE/ML A078014 001 Mar 21, 2008 Jan DISC
 ZOFRAN
 AP + NOVARTIS PHARMS CORP EQ 2MG BASE/ML N020007 001 Jan 04, 1991 Mar CAHN
 ZOFRAN PRESERVATIVE FREE
 AP + NOVARTIS PHARMS CORP EQ 2MG BASE/ML N020007 003 Dec 10, 1993 Mar CAHN
 SOLUTION;ORAL
 ZOFRAN
 AA + NOVARTIS PHARMS CORP EQ 4MG BASE/5ML N020605 001 Jan 24, 1997 Mar CAHN
 TABLET;ORAL
 ZOFRAN
 AB NOVARTIS PHARMS CORP EQ 4MG BASE N020103 001 Dec 31, 1992 Mar CAHN
 AB EQ 8MG BASE N020103 002 Dec 31, 1992 Mar CAHN
 AB + EQ 24MG BASE N020103 003 Aug 27, 1999 Mar CAHN

ORPHENADRINE CITRATE

INJECTABLE;INJECTION

NORFLEX

@ IGI LABS INC 30MG/ML N013055 001 Apr CAHN
 @ MEDICIS 30MG/ML N013055 001 Mar DISC
 ORPHENADRINE CITRATE
 AP + AKORN 30MG/ML A040484 001 May 24, 2006 Mar CRLD

OXACILLIN SODIUM

CAPSULE;ORAL

OXACILLIN SODIUM

@ ANI PHARMS INC EQ 250MG BASE A062222 001 Aug CAHN
 @ EQ 500MG BASE A062222 002 Aug CAHN

OXANDROLONE

TABLET;ORAL

OXANDRIN

AB GEMINI LABS LLC 2.5MG N013718 001 Aug CAHN
 AB + 10MG N013718 002 Nov 05, 2001 Aug CAHN

OXCARBAZEPINESUSPENSION;ORAL
OXCARBAZEPINE

AB	SUN PHARM INDS LTD	300MG/5ML	A078734	001	Jun 26, 2009	Apr	CAHN
----	--------------------	-----------	---------	-----	--------------	-----	------

OXYBUTYNINFILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL

AB	+ ACTAVIS LABS UT INC	3.9MG/24HR	N021351	002	Feb 26, 2003	Mar	CAHN
----	-----------------------	------------	---------	-----	--------------	-----	------

GEL, METERED;TRANSDERMAL
GELNIQUE 3%

+	ACTAVIS LABS UT INC	3%	N202513	001	Dec 07, 2011	Mar	CAHN
---	---------------------	----	---------	-----	--------------	-----	------

OXYBUTYNIN CHLORIDEGEL;TRANSDERMAL
GELNIQUE

+	ACTAVIS LABS UT INC	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Mar	CAHN
---	---------------------	--------------------	---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB	AVANTHI INC	5MG	A202773	001	Aug 17, 2015	Aug	NEWA
----	-------------	-----	---------	-----	--------------	-----	------

AB	NOVEL LABS INC	5MG	A204752	001	Aug 24, 2015	Aug	NEWA
----	----------------	-----	---------	-----	--------------	-----	------

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA	ANI PHARMS INC	5MG/5ML	A204979	001	Jun 01, 2015	May	NEWA
----	----------------	---------	---------	-----	--------------	-----	------

AA	NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015	Apr	NEWA
----	----------------	-----------	---------	-----	--------------	-----	------

AA	WOCKHARDT BIO AG	5MG/5ML	A206456	001	Jun 16, 2015	Jun	NEWA
----	------------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

OXAYDO

ACURA PHARMS INC

5MG	N202080	001	Jun 17, 2011	Mar	CTNA
-----	---------	-----	--------------	-----	------

7.5MG

N202080	002	Jun 17, 2011	Mar	CTNA
---------	-----	--------------	-----	------

EGALET LTD

5MG	N202080	001	Jun 17, 2011	May	CAHN
-----	---------	-----	--------------	-----	------

7.5MG	N202080	002	Jun 17, 2011	May	CAHN
-------	---------	-----	--------------	-----	------

EGALET US INC

5MG	N202080	001	Jun 17, 2011	Jul	CAHN
-----	---------	-----	--------------	-----	------

7.5MG	N202080	002	Jun 17, 2011	Jul	CAHN
-------	---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	5MG	A076636	003	Apr 07, 2015	Mar	NEWA
----	-------------------	-----	---------	-----	--------------	-----	------

AB	EPIC PHARMA LLC	5MG	A202662	001	Sep 22, 2015	Sep	NEWA
----	-----------------	-----	---------	-----	--------------	-----	------

AB		10MG	A202662	002	Sep 22, 2015	Sep	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		15MG	A202662	003	Sep 22, 2015	Sep	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		30MG	A202662	004	Sep 22, 2015	Sep	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	VINTAGE PHARMS	10MG	A077712	004	Apr 13, 2015	Mar	NEWA
----	----------------	------	---------	-----	--------------	-----	------

AB		20MG	A077712	005	Apr 13, 2015	Mar	NEWA
----	--	------	---------	-----	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015	Apr	NEWA
----	--------------------	-----	---------	-----	--------------	-----	------

AB		7.5MG	A203506	002	Apr 24, 2015	Apr	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		10MG	A203506	003	Apr 24, 2015	Apr	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		15MG	A203506	004	Apr 24, 2015	Apr	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		20MG	A203506	005	Apr 24, 2015	Apr	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		30MG	A203506	006	Apr 24, 2015	Apr	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		40MG	A203506	007	Apr 24, 2015	Apr	NEWA
----	--	------	---------	-----	--------------	-----	------

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

AP	+ EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Feb	CAHN
----	----------------------	---------------------------------	---------	-----	--	-----	------

AP	+	100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Feb	CAHN
----	---	------------------------------------	---------	-----	--------------	-----	------

PALBOCICLIB

CAPSULE;ORAL

IBRANCE

PFIZER INC

75MG	N207103	001	Feb 03, 2015	Feb	NEWA
------	---------	-----	--------------	-----	------

100MG	N207103	002	Feb 03, 2015	Feb	NEWA
-------	---------	-----	--------------	-----	------

+		125MG	N207103	003	Feb 03, 2015	Feb	NEWA
---	--	-------	---------	-----	--------------	-----	------

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL
INVEGA

AB	JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008	Jul	CFTG
AB		3MG	N021999	001	Dec 19, 2006	Jul	CFTG
AB	+	6MG	N021999	002	Dec 19, 2006	Jul	CFTG
AB		9MG	N021999	003	Dec 19, 2006	Jul	CFTG
PALIPERIDONE							
AB	ACTAVIS LABS FL INC	1.5MG	A202645	001	Aug 03, 2015	Jul	NEWA
AB		3MG	A202645	002	Aug 03, 2015	Jul	NEWA
AB		6MG	A202645	003	Aug 03, 2015	Jul	NEWA
AB		9MG	A202645	004	Aug 03, 2015	Jul	NEWA
AB	MYLAN PHARMS INC	1.5MG	A203802	001	Sep 24, 2015	Sep	NEWA
AB		3MG	A203802	002	Sep 24, 2015	Sep	NEWA
AB		6MG	A203802	003	Sep 24, 2015	Sep	NEWA
AB		9MG	A203802	004	Sep 24, 2015	Sep	NEWA

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA TRINZA

	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015	May	NEWA
		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015	May	NEWA
		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015	May	NEWA
	+	819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015	May	NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS
ALOXI

AP	+	HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008	Sep	CFTG
AP	+		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003	Sep	CFTG
PALONOSETRON HYDROCHLORIDE								
AP		SANDOZ INC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202521	001	Oct 13, 2015	Sep	NEWA
AP		TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Oct 13, 2015	Sep	NEWA
AP			EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A090713	001	Oct 13, 2015	Sep	NEWA

PANCURONIUM BROMIDE

INJECTABLE;INJECTION
PANCURONIUM BROMIDE

@	IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988	Mar	CAHN
@		2MG/ML	A072211	001	Mar 31, 1988	Mar	CAHN
@		2MG/ML	A072212	001	Mar 31, 1988	Mar	CAHN
@		2MG/ML	A072213	001	Mar 31, 1988	Mar	CAHN

PANOBINOSTAT

CAPSULE;ORAL
FARYDAK

	NOVARTIS PHARMS CORP	10MG	N205353	001	Feb 23, 2015	Feb	NEWA
		15MG	N205353	002	Feb 23, 2015	Feb	NEWA
	+	20MG	N205353	003	Feb 23, 2015	Feb	NEWA

PANOBINOSTAT LACTATE

CAPSULE;ORAL
FARYDAK

	NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar	CAIN
		EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar	CPOT
		EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar	CAIN
		EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar	CPOT
	+	EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar	CAIN
	+	EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar	CPOT

PANTOPRAZOLE SODIUM

INJECTABLE;IV (INFUSION)
PANTOPRAZOLE SODIUM

AP	SANDOZ INC	EQ 40MG BASE/VIAL	A090296	001	Jul 14, 2015	Jun	NEWA
TABLET, DELAYED RELEASE;ORAL PANTOPRAZOLE SODIUM							
AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A078281	001	Jan 20, 2011	Mar	CAHN

TABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Mar	CAHN
AB	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr	CAHN
AB		EQ 40MG BASE	A200794	002	May 02, 2012	Apr	CAHN

PARICALCITOL

CAPSULE;ORAL
PARICALCITOL

AB	BANNER LIFE SCIENCES	1MCG	A202539	001	Mar 27, 2014	Jan	CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan	CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan	CAHN

>A> PATROMER SORBITEX CALCIUM

>A> POWDER;ORAL
>A> VELTASSA

>A>	RELYPSA INC	EQ 8.4GM BASE/PACKET	N205739	001	Oct 21, 2015	Oct	NEWA
>A>		EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015	Oct	NEWA
>A>	+	EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015	Oct	NEWA

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL
VOTRIENT

+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009	Mar	CAHN
@		EQ 400MG BASE	N022465	002	Oct 19, 2009	Aug	DISC
		EQ 400MG BASE	N022465	002	Oct 19, 2009	Mar	CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

AB	VALEANT PHARMS	400MG	A075028	001	Jul 20, 1998	Feb	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL
BONTRIL

@	VALEANT	105MG	A088021	001	Sep 21, 1982	Jan	DISC
+	SANDOZ	105MG	N018074	001		Jan	CTEC

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL
DIBENZYLINE

AB	+	CONCORDIA PHARMS INC	10MG	N008708	001		Jun	CAHN
----	---	----------------------	------	---------	-----	--	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL
PHENTERMINE HYDROCHLORIDE

AA	MIKAH PHARMA LLC	37.5MG	A040228	001	Jun 19, 1997	Jun	CMFD
----	------------------	--------	---------	-----	--------------	-----	------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE

+	AKORN INC	2.5%	N207926	001	Jan 15, 2015	Sep	CRLD
		2.5%	N207926	001	Jan 15, 2015	Jan	NEWA
+		10%	N207926	002	Jan 15, 2015	Sep	CRLD
		10%	N207926	002	Jan 15, 2015	Jan	NEWA
+	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013	Sep	CRLD

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETH VC PLAIN

AA	+	G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Jul	CAHN
----	---	------------------	--------------------	---------	-----	--------------	-----	------

PHENYTOIN SODIUM

CAPSULE;ORAL
EXTENDED PHENYTOIN SODIUM

@	WOCKHARDT	30MG EXTENDED	A040759	001	Dec 18, 2007	Jun	DISC
@	WOCKHARDT USA	100MG EXTENDED	A040732	001	Jan 30, 2008	Jun	DISC
AB	AUROBINDO PHARMA LTD	100MG EXTENDED	A204309	001	Jun 10, 2015	May	NEWA

	INJECTABLE; INJECTION							
	PHENYTOIN SODIUM							
AP	+	EUROHLTH INTL SARL	50MG/ML	A084307	001			Feb CAHN
	<u>PHYTONADIONE</u>							
	INJECTABLE; INJECTION							
	AQUAMEPHYTON							
	@	IGI LABS INC	1MG/0.5ML	N012223	002			Apr CAHN
	@		10MG/ML	N012223	001			Apr CAHN
	<u>PILOCARPINE HYDROCHLORIDE</u>							
	GEL; OPHTHALMIC							
	PILOPINE HS							
	@	ALCON	4%	N018796	001	Oct 01, 1984		Aug DISC
	TABLET; ORAL							
	PILOCARPINE HYDROCHLORIDE							
AB		ELAN PHARMA INTL LTD	5MG	A076746	001	Nov 16, 2004		Mar CAHN
	<u>PIMOZIDE</u>							
	TABLET; ORAL							
	ORAP							
AB		TEVA	1MG	N017473	003	Aug 27, 1997		Sep CFTG
AB	+		2MG	N017473	001	Jul 31, 1984		Sep CFTG
	PIMOZIDE							
AB		PAR PHARM	1MG	A204521	001	Sep 28, 2015		Sep NEWA
AB			2MG	A204521	002	Sep 28, 2015		Sep NEWA
	<u>PINDOLOL</u>							
	TABLET; ORAL							
	PINDOLOL							
	@	G AND W LABS INC	5MG	A073661	001	Oct 31, 1993		Apr CAHN
	@		5MG	A073687	001	Feb 26, 1993		Apr CAHN
	@		5MG	A074123	001	Apr 17, 1997		Apr CAHN
	@		10MG	A073661	002	Oct 31, 1993		Apr CAHN
	@		10MG	A073687	002	Feb 26, 1993		Apr CAHN
	@		10MG	A074123	002	Apr 17, 1997		Apr CAHN
	<u>PIRBUTEROL ACETATE</u>							
	AEROSOL, METERED; INHALATION							
	MAXAIR							
	@	MEDICIS	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992		Jan DISC
	<u>PIRFENIDONE</u>							
	CAPSULE; ORAL							
	ESBRIET							
	+	GENENTECH INC	267MG	N022535	001	Oct 15, 2014		Feb CAHN
	<u>PIROXICAM</u>							
	CAPSULE; ORAL							
	PIROXICAM							
AB		MYLAN PHARMS INC	10MG	A074116	001	Jun 15, 1993		May CAHN
AB			20MG	A074118	001	Jun 15, 1993		May CAHN
	<u>PODOFILOX</u>							
	GEL; TOPICAL							
	CONDYLOX							
	+	ACTAVIS LABS UT INC	0.5%	N020529	001	Mar 13, 1997		Feb CAHN
	SOLUTION; TOPICAL							
	CONDYLOX							
AT	+	ACTAVIS LABS UT INC	0.5%	N019795	001	Dec 13, 1990		Jan CAHN
	PODOFILOX							
AT		BAUSCH AND LOMB INC	0.5%	A090184	001	Jul 21, 2010		May CAHN
	<u>POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE</u>							
	SOLUTION/DROPS; OPHTHALMIC							
	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE							
AT		ALCON RES LTD	10,000 UNITS/ML; EQ 1MG BASE/ML	A064211	001	Apr 13, 1998		Jan CAHN

PONATINIB HYDROCHLORIDE

TABLET;ORAL

ICLUSIG

ARIAD

EQ 30MG BASE

N203469 003 Apr 23, 2015 Apr NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

KLOR-CON

AB UPSHER SMITH

8MEQ

A203106 001 Jul 10, 2015 Jun NEWA

AB 10MEQ

A203106 002 Jul 10, 2015 Jun NEWA

FOR SOLUTION;ORAL

POTASSIUM CHLORIDE

PHARMA RES SOFTWARE 20MEQ

N208019 001 Aug 19, 2015 Aug NEWA

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB1 ADARE PHARMS INC 20MEQ

A076368 001 Aug 18, 2004 Jul CAHN

AB2 MYLAN PHARMS INC 8MEQ

A204662 001 Aug 21, 2014 Feb CPOT

AB2 10MEQ

A204662 002 Aug 21, 2014 Feb CPOT

>A> AB2 PADDOCK LLC 8MEQ

A205993 001 Nov 05, 2015 Oct NEWA

>A> AB2 10MEQ

A205993 002 Nov 05, 2015 Oct NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB GLENMARK GENERICS 0.75MG

A090781 006 Sep 11, 2015 Aug NEWA

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB DR REDDYS LABS LTD 0.375MG

A203354 001 Aug 07, 2015 Jul NEWA

AB 0.75MG

A203354 002 Aug 07, 2015 Jul NEWA

AB 1.5MG

A203354 003 Aug 07, 2015 Jul NEWA

AB 3MG

A203354 004 Aug 07, 2015 Jul NEWA

AB 4.5MG

A203354 005 Aug 07, 2015 Jul NEWA

PREDNICARBATE

OINTMENT;TOPICAL

DERMATOP

AB + VALEANT PHARMS NORTH 0.1%

N019568 001 Sep 23, 1991 Apr CAHN

PREDNISONE

TABLET;ORAL

PREDNISONE

@ HIKMA PHARMS

1MG

A040890 001 Nov 01, 2010 Aug DISC

PREGABALIN

CAPSULE;ORAL

LYRICA

PF PRISM CV 25MG

N021446 001 Dec 30, 2004 Apr CTEC

50MG

N021446 002 Dec 30, 2004 Apr CTEC

75MG

N021446 003 Dec 30, 2004 Apr CTEC

100MG

N021446 004 Dec 30, 2004 Apr CTEC

150MG

N021446 005 Dec 30, 2004 Apr CTEC

200MG

N021446 006 Dec 30, 2004 Apr CTEC

225MG

N021446 007 Dec 30, 2004 Apr CTEC

+ 300MG

N021446 008 Dec 30, 2004 Apr CTEC

PROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL

PROCAINAMIDE HYDROCHLORIDE

@ IDT AUSTRALIA LTD 250MG

A089219 001 Jul 01, 1986 Jun CAHN

@ 500MG

A089221 001 Jul 01, 1986 Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

PROCAINAMIDE HYDROCHLORIDE

@ IDT AUSTRALIA LTD 250MG

A089369 001 Aug 14, 1987 Jun CAHN

@ 500MG

A089370 001 Jan 09, 1987 Jun CAHN

@ 750MG

A089371 001 Aug 14, 1987 Jun CAHN

<u>PROCHLORPERAZINE EDISYLATE</u>									
INJECTABLE; INJECTION									
PROCHLORPERAZINE EDISYLATE									
AP	+	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Feb	CAHN	
<u>PROGESTERONE</u>									
CAPSULE; ORAL									
PROGESTERONE									
AB		BANNER LIFE SCIENCES	100MG	A200900	001	Aug 16, 2013	Jan	CAHN	
AB			200MG	A200900	002	Aug 16, 2013	Jan	CAHN	
GEL; VAGINAL									
CRINONE									
		ACTAVIS LABS UT INC	4%	N020701	001	Jul 31, 1997	Feb	CAHN	
	+		8%	N020701	002	Jul 31, 1997	Feb	CAHN	
INJECTABLE; INJECTION									
PROGESTERONE									
AO	+	ACTAVIS LABS UT INC	50MG/ML	N017362	002		Mar	CAHN	
<u>PROMETHAZINE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
PROMETHAZINE HYDROCHLORIDE									
AP	+	EUROHLTH INTL SARL	25MG/ML	A083312	001		Jun	CAHN	
AP	+		50MG/ML	A083312	002		Jun	CAHN	
SUPPOSITORY; RECTAL									
PHENERGAN									
	@	DELCOR ASSET CORP	12.5MG	N010926	002		Apr	CAHN	
	@		25MG	N010926	001		Apr	CAHN	
TABLET; ORAL									
PROMETHAZINE HYDROCHLORIDE									
AB		HERITAGE PHARMA	12.5MG	A040673	001	Mar 05, 2008	Mar	CAHN	
AB			25MG	A040673	002	Mar 05, 2008	Mar	CAHN	
AB			50MG	A040673	003	Mar 05, 2008	Mar	CAHN	
<u>PROPAFENONE HYDROCHLORIDE</u>									
CAPSULE, EXTENDED RELEASE; ORAL									
PROPAFENONE HYDROCHLORIDE									
AB		WATSON LABS INC	225MG	A202688	001	Aug 24, 2015	Aug	NEWA	
AB			325MG	A202688	002	Aug 24, 2015	Aug	NEWA	
AB			425MG	A202688	003	Aug 24, 2015	Aug	NEWA	
<u>PYRIDOSTIGMINE BROMIDE</u>									
TABLET; ORAL									
PYRIDOSTIGMINE BROMIDE									
	@	ANI PHARMS INC	30MG	A040512	002	Jul 20, 2005	Aug	CAHN	
	@		60MG	A040512	001	Oct 08, 2003	Aug	CAHN	
AB		ZYDUS PHARMS USA INC	60MG	A205650	001	Jun 22, 2015	Jun	NEWA	
TABLET, EXTENDED RELEASE; ORAL									
MESTINON									
AB	+	VALEANT PHARMS LLC	180MG	N011665	001		Jun	CFTG	
PYRIDOSTIGMINE BROMIDE									
AB		ALVOGEN INC	180MG	A204737	001	Jun 26, 2015	Jun	NEWA	
AB		IMPAX LABS INC	180MG	A203184	001	Sep 15, 2015	Aug	NEWA	
<u>PYRIMETHAMINE</u>									
TABLET; ORAL									
DARAPRIM									
	+	TURING PHARMS AG	25MG	N008578	001		Aug	CAHN	
<u>QUAZEPAM</u>									
TABLET; ORAL									
DORAL									
	@	SCIECURE PHARMA INC	15MG	N018708	001	Dec 27, 1985	Jun	DISC	
<u>QUETIAPINE FUMARATE</u>									
TABLET; ORAL									
SEROQUEL									
AB	+	ASTRAZENECA PHARMS	EQ 25MG BASE	N020639	001	Sep 26, 1997	May	CAHN	
AB			EQ 50MG BASE	N020639	007	Oct 04, 2005	May	CAHN	
AB			EQ 100MG BASE	N020639	002	Sep 26, 1997	May	CAHN	
	@		EQ 150MG BASE	N020639	004	Dec 20, 1998	May	CAHN	

TABLET;ORAL									
SEROQUEL									
AB		EQ 200MG BASE		N020639	003	Sep 26, 1997		May	CAHN
AB	+	EQ 300MG BASE		N020639	005	Jul 26, 2000		May	CAHN
AB		EQ 400MG BASE		N020639	006	Oct 04, 2005		May	CAHN
<u>QUINAPRIL HYDROCHLORIDE</u>									
TABLET;ORAL									
QUINAPRIL HYDROCHLORIDE									
AB	SUN PHARM INDS LTD	EQ 5MG BASE		A076607	001	Dec 15, 2004		Apr	CAHN
AB		EQ 10MG BASE		A076607	002	Dec 15, 2004		Apr	CAHN
AB		EQ 20MG BASE		A076607	003	Dec 15, 2004		Apr	CAHN
AB		EQ 40MG BASE		A076607	004	Dec 15, 2004		Apr	CAHN
<u>QUINIDINE GLUCONATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
QUINIDINE GLUCONATE									
	@ CYCLE PHARMS LTD	324MG		A088431	001	Jan 06, 1984		Jun	CAHN
<u>QUINIDINE SULFATE</u>									
TABLET;ORAL									
QUINIDINE SULFATE									
	@ CYCLE PHARMS LTD	200MG		A083640	001			Jun	CAHN
	@	300MG		A085632	001			Jun	CAHN
TABLET, EXTENDED RELEASE;ORAL									
QUINIDINE SULFATE									
+	G AND W LABS INC	300MG		A040045	001	Jun 30, 1994		Apr	CAHN
<u>QUININE SULFATE</u>									
CAPSULE;ORAL									
QUININE SULFATE									
AB	AMNEAL PHARMS	324MG		A203729	001	Jul 15, 2015		Jun	NEWA
AB	LUPIN LTD	324MG		A203112	001	Apr 24, 2015		Apr	NEWA
AB	RICONPHARMA LLC	324MG		A204372	001	Jul 22, 2015		Jul	NEWA
<u>RABEPRAZOLE SODIUM</u>									
TABLET, DELAYED RELEASE;ORAL									
RABEPRAZOLE SODIUM									
AB	AMNEAL PHARMS	20MG		A204179	001	Jul 31, 2015		Jul	NEWA
<u>RALOXIFENE HYDROCHLORIDE</u>									
TABLET;ORAL									
RALOXIFENE HYDROCHLORIDE									
AB	AUROBINDO PHARMA LTD	60MG		A204310	001	Aug 28, 2015		Aug	NEWA
AB	WATSON LABS INC	60MG		A200825	001	Jan 21, 2015		Jan	NEWA
<u>RAMELTEON</u>									
TABLET;ORAL									
RAMELTEON									
AB	ACTAVIS LABS FL INC	8MG		A091610	001	Aug 19, 2015		Aug	NEWA
<u>RANITIDINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
ZANTAC									
AP	+ CONCORDIA PHARMS INC	EQ 25MG BASE/ML		N019090	001	Oct 19, 1984		Jun	CAHN
TABLET;ORAL									
RANITIDINE HYDROCHLORIDE									
	@ SUN PHARM INDS LTD	EQ 150MG BASE		A075439	001	Apr 19, 2000		Apr	CAHN
	@	EQ 300MG BASE		A075439	002	Apr 19, 2000		Apr	CAHN
<u>REPAGLINIDE</u>									
TABLET;ORAL									
REPAGLINIDE									
AB	STANDARD CHEM PHARM	0.5MG		A091517	001	Apr 24, 2015		Apr	NEWA
AB		1MG		A091517	002	Apr 24, 2015		Apr	NEWA
AB		2MG		A091517	003	Apr 24, 2015		Apr	NEWA

RIBAVIRIN

CAPSULE;ORAL

REBETOL

@	MERCK SHARP DOHME	200MG	N020903	001	Jun 03, 1998	Jun	DISC
---	-------------------	-------	---------	-----	--------------	-----	------

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE;ORAL

ATELVIA

AB	+	WARNER CHILCOTT LLC	35MG	N022560	001	Oct 08, 2010	May	CFTG
AB		TEVA PHARMS USA	35MG	A203217	001	May 18, 2015	May	NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

AB		SUN PHARM INDS LTD	0.5MG	A077542	001	Aug 06, 2010	Apr	CAHN
AB			1MG	A077542	002	Aug 06, 2010	Apr	CAHN
AB			2MG	A077542	003	Aug 06, 2010	Apr	CAHN
AB			3MG	A078474	001	Aug 06, 2010	Apr	CAHN
AB			4MG	A078474	002	Aug 06, 2010	Apr	CAHN

RIVAROXABAN

TABLET;ORAL

XARELTO

		JANSSEN PHARMS	10MG	N022406	001	Jul 01, 2011	Apr	CRLD
--	--	----------------	------	---------	-----	--------------	-----	------

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EXELON

AB		NOVARTIS	4.6MG/24HR	N022083	001	Jul 06, 2007	Aug	CFTG
AB	+		9.5MG/24HR	N022083	002	Jul 06, 2007	Aug	CFTG
AB			13.3MG/24HR	N022083	005	Aug 31, 2012	Aug	CFTG
AB		ALVOGEN INC	4.6MG/24HR	A204403	001	Sep 03, 2015	Aug	NEWA
AB			9.5MG/24HR	A204403	002	Sep 03, 2015	Aug	NEWA
AB			13.3MG/24HR	A204403	003	Aug 31, 2015	Aug	NEWA
AB		ALVOGEN PINE BROOK	4.6MG/24HR	A204403	001	Sep 03, 2015	Aug	CAHN
AB			9.5MG/24HR	A204403	002	Sep 03, 2015	Aug	CAHN
AB			13.3MG/24HR	A204403	003	Aug 31, 2015	Aug	CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB		ORCHID HLTHCARE	EQ 1.5MG BASE	A090879	001	Jun 10, 2015	May	NEWA
AB			EQ 3MG BASE	A090879	002	Jun 10, 2015	May	NEWA
AB			EQ 4.5MG BASE	A090879	003	Jun 10, 2015	May	NEWA
AB			EQ 6MG BASE	A090879	004	Jun 10, 2015	May	NEWA

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

>A>	AB	JUBILANT GENERICS	EQ 5MG BASE	A203334	001	Oct 16, 2015	Oct	NEWA
>A>	AB		EQ 10MG BASE	A203334	002	Oct 16, 2015	Oct	NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP		SAGENT PHARMS	50MG/5ML (10MG/ML)	A091458	001	Jul 28, 2010	Aug	CAHN
AP			100MG/10ML (10MG/ML)	A091458	002	Jul 28, 2010	Aug	CAHN

ROFLUMILAST

TABLET;ORAL

DALIRESP

+	ASTRAZENECA PHARMS	500MCG	N022522	001	Feb 28, 2011	Mar	CAHN
---	--------------------	--------	---------	-----	--------------	-----	------

ROLAPITANT HYDROCHLORIDE

TABLET;ORAL

VARUBI

+	TESARO INC	EQ 90MG BASE	N206500	001	Sep 01, 2015	Sep	NEWA
---	------------	--------------	---------	-----	--------------	-----	------

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB	G AND W LABS INC	EQ 0.25MG BASE	A 077460	001	May 05, 2008	Apr	CAHN
AB		EQ 0.5MG BASE	A 077460	002	May 05, 2008	Apr	CAHN
AB		EQ 1MG BASE	A 077460	003	May 05, 2008	Apr	CAHN
AB		EQ 2MG BASE	A 077460	004	May 05, 2008	Apr	CAHN
AB		EQ 3MG BASE	A 077460	005	May 05, 2008	Apr	CAHN
AB		EQ 4MG BASE	A 077460	006	May 05, 2008	Apr	CAHN
AB		EQ 5MG BASE	A 077460	007	May 19, 2008	Apr	CAHN

SACUBITRIL; VALSARTAN

TABLET;ORAL

ENTRESTO

NOVARTIS PHARMS CORP

24MG;26MG

49MG;51MG

+ 97MG;103MG

N207620	001	Jul 07, 2015	Jul	NEWA
N207620	002	Jul 07, 2015	Jul	NEWA
N207620	003	Jul 07, 2015	Jul	NEWA

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

KUVAN

>A>	BIOMARIN PHARM	500MG/PACKET	N205065	002	Oct 27, 2015	Oct	NEWA
-----	----------------	--------------	---------	-----	--------------	-----	------

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

SCOPOLAMINE

AB	PERRIGO PHARMS CO	1MG/72HR	A 078830	001	Jan 30, 2015	Mar	CAHN
AB	PERRIGO R AND D	1MG/72HR	A 078830	001	Jan 30, 2015	Jan	NEWA
AB	+ NOVARTIS	1MG/72HR	N017874	001		Jan	CFTG

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@ G AND W LABS INC 5MG

@ 5MG

@ 5MG

A 074537	001	Aug 02, 1996	Apr	CAHN
A 074744	001	Jan 27, 1997	Apr	CAHN
A 074756	001	Nov 25, 1998	Apr	CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@ HIKMA PHARMS EQ 25MG BASE

@ EQ 50MG BASE

@ EQ 100MG BASE

AB	SUN PHARM INDS LTD	EQ 25MG BASE	A 077977	001	Feb 06, 2007	Apr	CAHN
AB		EQ 50MG BASE	A 077977	002	Feb 06, 2007	Apr	CAHN
AB		EQ 100MG BASE	A 077977	003	Feb 06, 2007	Apr	CAHN
		EQ 150MG BASE	A 077977	004	Feb 06, 2007	Apr	CAHN
		EQ 200MG BASE	A 077977	005	Feb 06, 2007	Apr	CAHN

SEVOFLURANE

LIQUID;INHALATION

SEVOFLURANE

>A>	AN SHANGHAI HENGRUI	100%	A203793	001	Nov 03, 2015	Oct	NEWA
-----	---------------------	------	---------	-----	--------------	-----	------

SILDENAFIL CITRATE

SOLUTION;INTRAVENOUS

REVATIO

AP	+ PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Mar	CFTG
----	----------	--	---------	-----	--------------	-----	------

SILDENAFIL CITRATE

AP	AUROBINDO PHARMA LTD	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	A203988	001	Apr 01, 2015	Mar	NEWA
----	----------------------	--	---------	-----	--------------	-----	------

SILODOSIN

CAPSULE;ORAL

RAPAFLO

+ ACTAVIS LABS UT INC 4MG

8MG

N022206	001	Oct 08, 2008	Mar	CAHN
N022206	002	Oct 08, 2008	Mar	CAHN

SIMVASTATINTABLET; ORAL
SIMVASTATIN

>A>	AB	BIOCON LIMITED	5MG	A 078034	001	Dec 20, 2006	Oct	CAHN
>A>	AB		10MG	A 078034	002	Dec 20, 2006	Oct	CAHN
>A>	AB		20MG	A 078034	003	Dec 20, 2006	Oct	CAHN
>A>	AB		40MG	A 078034	004	Dec 20, 2006	Oct	CAHN
>A>	AB		80MG	A 078034	005	Dec 20, 2006	Oct	CAHN
>D>	AB	BLU CARIBE	5MG	A 078034	001	Dec 20, 2006	Oct	CAHN
>D>	AB		10MG	A 078034	002	Dec 20, 2006	Oct	CAHN
>D>	AB		20MG	A 078034	003	Dec 20, 2006	Oct	CAHN
>D>	AB		40MG	A 078034	004	Dec 20, 2006	Oct	CAHN
>D>	AB		80MG	A 078034	005	Dec 20, 2006	Oct	CAHN
	AB	SUN PHARM INDS LTD	5MG	A 076285	001	Dec 20, 2006	Apr	CAHN
	AB		10MG	A 076285	002	Dec 20, 2006	Apr	CAHN
	AB		20MG	A 076285	003	Dec 20, 2006	Apr	CAHN
	AB		40MG	A 076285	004	Dec 20, 2006	Apr	CAHN
	AB		80MG	A 076285	005	Jun 23, 2006	Apr	CAHN

SODIUM CHLORIDEINJECTABLE; INJECTION
SODIUM CHLORIDE 0.9%

AP		EUROHLTH INTL SARL	9MG/ML	A 201850	001	Jan 20, 2012	Feb	CAHN
		SODIUM CHLORIDE 0.9%						
		EUROHLTH INTL SARL	9MG/ML	A 201833	001	Sep 24, 2013	Feb	CAHN
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
+		LIEBEL-FLARSHEIM	45MG/50ML (9MG/ML)	N 021569	001	Jul 27, 2006	Feb	CAHN
			112.5MG/125ML (9MG/ML)	N 021569	002	Jul 27, 2006	Feb	CAHN
+			405MG/50ML (9MG/ML)	N 021569	001	Jul 27, 2006	Feb	CPOT
			1012.5MG/125ML (9MG/ML)	N 021569	002	Jul 27, 2006	Feb	CPOT

SODIUM FERRIC GLUCONATE COMPLEXINJECTABLE; INJECTION
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		EUROHLTH INTL SARL	62.5MG/5ML	A 078215	001	Mar 31, 2011	Jun	CAHN
----	--	--------------------	------------	----------	-----	--------------	-----	------

SODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

>A>	AP	3D IMAGING DRUG	10-200mCi/ML	A 203777	001	Oct 19, 2015	Oct	NEWA
	AP	CARDINAL HEALTH 414	10-200mCi/ML	A 203780	001	Jul 30, 2015	Jul	NEWA
	AP	HOT SHOTS NM LLC	10-200mCi/ML	A 204530	001	Jul 29, 2015	Jul	NEWA
	AP	IBA MOLECULAR N AM	10-200mCi/ML	A 203592	001	Aug 18, 2015	Aug	NEWA
	AP	MIPS CRF	10-200mCi/ML	A 204517	001	Jul 21, 2015	Jul	NEWA
	AP	PRECISION NUCLEAR	10-200mCi/ML	A 204542	001	Feb 27, 2015	Feb	NEWA
	AP	SPECTRON MRC LLC	10-200mCi/ML	A 203912	001	Apr 22, 2015	Apr	NEWA
>A>	AP	TRIAD ISOTOPES INC	10-200mCi/ML	A 203968	001	Oct 23, 2015	Oct	NEWA
	AP	UNIV UTAH CYCLOTRON	10-200mCi/ML	A 204497	001	Apr 20, 2015	Apr	NEWA

SODIUM IODIDE I-123CAPSULE; ORAL
SODIUM IODIDE I 123

AA	+	CARDINAL HEALTH 418	100uCi	N 018671	001	May 27, 1982	Apr	CAHN
AA	+		200uCi	N 018671	002	May 27, 1982	Apr	CAHN
		@	400uCi	N 018671	003	May 27, 1982	Apr	CAHN

SODIUM LACTATEINJECTABLE; INJECTION
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	1.87GM/100ML	N 016692	001		Sep	DISC
		SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER						
		B BRAUN	1.87GM/100ML	N 020004	001	Apr 21, 1992	Sep	CTEC

SODIUM POLYSTYRENE SULFONATEPOWDER; ORAL, RECTAL
KALEXATE

		KVK TECH	15GM/BOT	A 040905	002	Apr 03, 2015	Mar	NEWA
		KAYEXALATE						
AA	+	CONCORDIA PHARMS INC	453.6GM/BOT	N 011287	001		Apr	CAHN

<u>SODIUM TETRADECYL SULFATE</u>									
INJECTABLE; INJECTION									
SOTRADECOL									
	+	MYLAN INSTITUTIONAL	20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004	Jul	CRLD	
<u>SOMATROPIN RECOMBINANT</u>									
INJECTABLE; INJECTION									
NORDITROPIN FLEXPRO									
		NOVO NORDISK INC	30MG/3ML	N021148	011	Jan 23, 2015	Jan	NEWA	
NORDITROPIN NORDIFLEX									
	@	NOVO NORDISK INC	30MG/3ML	N021148	007	Mar 10, 2009	Jul	DISC	
			30MG/3ML	N021148	007	Mar 10, 2009	Mar	CMFD	
	@		30MG/3ML	N021148	007	Mar 10, 2009	Jan	DISC	
NUTROPIN									
	@	GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993	Jun	DISC	
	@		10MG/VIAL	N020168	002	Nov 17, 1993	Jun	DISC	
BX	+		10MG/VIAL	N020168	002	Nov 17, 1993	Mar	CTEC	
NUTROPIN AQ									
	@	GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Jun	DISC	
NUTROPIN AQ NUSPIN									
	+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Jun	CTNA	
	+		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008	Jun	NEWA	
	+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Jun	CTNA	
NUTROPIN AQ PEN									
	+	GENENTECH	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Jun	NEWA	
ZOMACTON									
BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Mar	CTNA	
BX			10MG/VIAL	N019774	003	Mar 07, 2012	Apr	CRLD	
BX	+		10MG/VIAL	N019774	003	Mar 07, 2012	Mar	NEWA	
<u>SONIDEGIB PHOSPHATE</u>									
CAPSULE; ORAL									
ODOMZO									
	+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N205266	001	Jul 24, 2015	Jul	NEWA	
<u>SOTALOL HYDROCHLORIDE</u>									
SOLUTION; INTRAVENOUS									
SOTALOL HYDROCHLORIDE									
	+	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009	Apr	CAHN	
TABLET; ORAL									
BETAPACE									
AB1		COVIS PHARMA SARL	80MG	N019865	001	Oct 30, 1992	Mar	CAHN	
AB1			120MG	N019865	005	Apr 20, 1994	Mar	CAHN	
AB1	+		160MG	N019865	002	Oct 30, 1992	Mar	CAHN	
AB1			240MG	N019865	003	Oct 30, 1992	Mar	CAHN	
	@		320MG	N019865	004	Oct 30, 1992	Mar	CAHN	
<u>STERILE WATER FOR INJECTION</u>									
LIQUID; N/A									
STERILE WATER FOR INJECTION									
AP		EUROHLTH INTL SARL	100%	A206369	001	Sep 02, 2015	Aug	NEWA	
<u>SUCCINYLCHOLINE CHLORIDE</u>									
INJECTABLE; INJECTION									
QUELICIN PRESERVATIVE FREE									
	@	HOSPIRA	100MG/ML	N008845	004		Jun	DISC	
<u>SUCRALFATE</u>									
TABLET; ORAL									
SUCRALFATE									
AB		MYLAN PHARMS INC	1GM	A074415	001	Jun 08, 1998	May	CAHN	
<u>SUFENTANIL CITRATE</u>									
INJECTABLE; INJECTION									
SUFENTANIL CITRATE									
AP		EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Jun	CAHN	

SULFACETAMIDE SODIUM

	LOTION;TOPICAL							
	KLARON							
AB	+	VALEANT PHARMS NORTH	10%		N019931	001	Dec 23, 1996	Mar CAHN
		OINTMENT;OPHTHALMIC						
>D>		CETAMIDE						
>D>	AT	+	ALCON	10%	A080021	001		Oct DISC
>A>			@	10%	A080021	001		Oct DISC
		SULFACETAMIDE SODIUM						
>D>	AT		PERRIGO CO TENNESSEE	10%	A080029	001		Oct CRLD
>A>		+		10%	A080029	001		Oct CRLD
		SOLUTION/DROPS;OPHTHALMIC						
		SULFACETAMIDE SODIUM						
AT			AKORN	10%	A040215	001	May 25, 1999	Mar CMFD

SULFAMETHOXAZOLE; TRIMETHOPRIM

	SUSPENSION;ORAL							
	SULFAMETHOXAZOLE AND TRIMETHOPRIM							
		@ ANI PHARMS INC	200MG/5ML;40MG/5ML		A070028	001	Jun 02, 1987	Jul CAHN

SULFANILAMIDE

	CREAM;VAGINAL							
	SULFANILAMIDE							
		@ G AND W LABS INC	15%		A088718	001	Sep 19, 1985	Apr CAHN

SULFISOXAZOLE

	TABLET;ORAL							
	SULFISOXAZOLE							
>A>		@ ANI PHARMS INC	500MG		A080142	001		Oct CAHN
>D>		@ IVAX SUB TEVA PHARMS	500MG		A080142	001		Oct CAHN

SULINDAC

	TABLET;ORAL							
	SULINDAC							
		@ ANI PHARMS INC	150MG		A072972	001	Feb 28, 1992	Aug CAHN
		@	200MG		A072973	001	Feb 28, 1992	Aug CAHN

SUMATRIPTAN SUCCINATE

	TABLET;ORAL							
	SUMATRIPTAN SUCCINATE							
		@ SANDOZ	EQ 25MG BASE		A076976	001	Aug 10, 2009	Sep DISC
		@	EQ 50MG BASE		A076976	002	Aug 10, 2009	Sep DISC
		@	EQ 100MG BASE		A076976	003	Aug 10, 2009	Sep DISC
AB		SUN PHARM INDS LTD	EQ 25MG BASE		A076554	001	Aug 10, 2009	Apr CAHN
AB			EQ 50MG BASE		A076554	002	Aug 10, 2009	Apr CAHN
AB			EQ 100MG BASE		A076572	001	Feb 09, 2009	Apr CAHN

TACROLIMUS

	TABLET, EXTENDED RELEASE;ORAL							
	ENVARUS XR							
		VELOXIS PHARMS INC	EQ 0.75MG BASE		N206406	001	Jul 10, 2015	Jul NEWA
			EQ 1MG BASE		N206406	002	Jul 10, 2015	Jul NEWA
	+		EQ 4MG BASE		N206406	003	Jul 10, 2015	Jul NEWA

TAPENTADOL HYDROCHLORIDE

	SOLUTION;ORAL							
	NUCYNTA							
	+	DEPOMED INC	EQ 20MG BASE/ML		N203794	001	Oct 15, 2012	May CAHN
		TABLET;ORAL						
		NUCYNTA						
		DEPOMED INC	EQ 50MG BASE		N022304	001	Nov 20, 2008	May CAHN
			EQ 75MG BASE		N022304	002	Nov 20, 2008	May CAHN
	+		EQ 100MG BASE		N022304	003	Nov 20, 2008	May CAHN
		TABLET, EXTENDED RELEASE;ORAL						
		NUCYNTA ER						
		DEPOMED INC	EQ 50MG BASE		N200533	001	Aug 25, 2011	May CAHN
			EQ 100MG BASE		N200533	002	Aug 25, 2011	May CAHN
			EQ 150MG BASE		N200533	003	Aug 25, 2011	May CAHN
			EQ 200MG BASE		N200533	004	Aug 25, 2011	May CAHN
	+		EQ 250MG BASE		N200533	005	Aug 25, 2011	May CAHN

TEDIZOLID PHOSPHATEPOWDER; IV (INFUSION)
SIVEXTRO

+ CUBIST PHARMS LLC 200MG/VIAL N205436 001 Jun 20, 2014 Sep CAHN

TABLET; ORAL
SIVEXTRO

+ CUBIST PHARMS LLC 200MG N205435 001 Jun 20, 2014 Sep CAHN

TELAPREVIRTABLET; ORAL
INCIVEK

@ VERTEX PHARMS 375MG N201917 001 May 23, 2011 Jan DISC

TELMISARTANTABLET; ORAL
TELMISARTAN

AB	AMNEAL PHARMS	20MG	A204415	001	Sep 08, 2015	Aug	NEWA
AB		40MG	A204415	002	Sep 08, 2015	Aug	NEWA
AB		80MG	A204415	003	Sep 08, 2015	Aug	NEWA
AB	AUROBINDO PHARMA LTD	20MG	A206511	001	Sep 03, 2015	Aug	NEWA
AB		40MG	A206511	002	Sep 03, 2015	Aug	NEWA
AB		80MG	A206511	003	Sep 03, 2015	Aug	NEWA
>A>	AB	INVENTIA HLTHCARE	A205150	001	Oct 30, 2015	Oct	NEWA
>A>	AB		A205150	002	Oct 30, 2015	Oct	NEWA
>A>	AB		A205150	003	Oct 30, 2015	Oct	NEWA

TEMAZEPAMCAPSULE; ORAL
TEMAZEPAM

AB	VINTAGE PHARMS	7.5MG	A201781	001	Jun 04, 2015	May	NEWA
AB		15MG	A201781	002	Jun 04, 2015	May	NEWA
AB		22.5MG	A201781	003	Jun 04, 2015	May	NEWA
AB		30MG	A201781	004	Jun 04, 2015	May	NEWA

TEMOZOLOMIDECAPSULE; ORAL
TEMOZOLOMIDE

AB	AMNEAL PHARMS	5MG	A203691	001	May 08, 2015	Apr	NEWA
AB		20MG	A203691	002	May 08, 2015	Apr	NEWA
AB		100MG	A203691	003	May 08, 2015	Apr	NEWA
AB		140MG	A203691	004	May 08, 2015	Apr	NEWA
AB		180MG	A203691	005	May 08, 2015	Apr	NEWA
AB		250MG	A203691	006	May 08, 2015	Apr	NEWA

TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
TENOFOVIR DISOPROXIL FUMARATE

AB TEVA PHARMS USA 300MG A091612 001 Mar 18, 2015 Mar NEWA

AB + GILEAD SCIENCES INC 300MG N021356 001 Oct 26, 2001 Mar CFTG

TERBINAFINEGEL; TOPICAL
LAMISIL

@ GLAXOSMITHKLINE CONS 1% N020846 001 Apr 29, 1998 Aug CAHN

TERBINAFINE HYDROCHLORIDESOLUTION; TOPICAL
LAMISIL

@ GLAXOSMITHKLINE CONS 1% N020749 001 Oct 17, 1997 Aug CAHN

TABLET; ORAL
TERBINAFINE HYDROCHLORIDE

@ WOCKHARDT EQ 250MG BASE A078229 001 Jul 02, 2007 Feb DISC

TERCONAZOLESUPPOSITORY; VAGINAL
TERCONAZOLE

AB TARO 80MG A077553 001 Mar 09, 2007 Sep CMFD

TESTOSTERONEGEL;TRANSDERMAL
ANDROGEL

AB1	ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan	CTEC	
AB1	+	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan	CTEC	
	TESTIM							
AB2	+	AUXILIUM PHARMS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Jan	CTEC
	TESTOSTERONE							
	@	ACTAVIS LABS UT INC	1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006	Mar	CAHN
	@		1% (5GM/PACKET)	A076737	002	Jan 27, 2006	Mar	CAHN
AB1			25MG/2.5GM PACKET	A076737	001	Jan 27, 2006	Jul	CMFD
AB1			50MG/5GM PACKET	A076737	002	Jan 27, 2006	Jul	CMFD
BX	ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	May	CAHN	
BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	May	CAHN	
AB1	PAR PHARM	25MG/2.5GM PACKET	A076744	001	May 23, 2007	Aug	CMFD	
AB1		50MG/5GM PACKET	A076744	002	May 23, 2007	Aug	CMFD	
AB1	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan	CTEC	
AB1		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan	CTEC	
	VOGELXO							
AB2	UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jan	CTEC	
	GEL, METERED;TRANSDERMAL							
	ANDROGEL							
AB	+	ABBVIE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Jul	CFTG
	FORTESTA							
AB	+	ENDO PHARMS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jul	CFTG
	TESTOSTERONE							
AB		ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jul	NEWA
AB			12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Aug	NEWA
AB		PERRIGO ISRAEL	1.62% (20.25MG/1.25GM ACTUATION)	A204268	001	Aug 04, 2015	Jul	NEWA

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

AB	SUN PHARMA GLOBAL	12.5MG	A206129	001	Aug 17, 2015	Aug	NEWA
AB		25MG	A206129	002	Aug 17, 2015	Aug	NEWA
	XENAZINE						
AB	VALEANT PHARMS NORTH	12.5MG	N021894	001	Aug 15, 2008	Aug	CFTG
		12.5MG	N021894	001	Aug 15, 2008	Feb	CAHN
AB	+	25MG	N021894	002	Aug 15, 2008	Aug	CFTG
	+	25MG	N021894	002	Aug 15, 2008	Feb	CAHN

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

ACHROMYCIN V

AB	+	HERITAGE PHARMS INC	500MG	N050278	001		Apr	CRLD
		TETRACYCLINE HYDROCHLORIDE						
	@	CHARTWELL CIENCA	250MG	A062752	001	Aug 12, 1988	Sep	CAHN
	@		500MG	A062752	002	Aug 12, 1988	Sep	CAHN
	@	IVAX SUB TEVA PHARMS	250MG	A060704	001		Apr	DISC
	@		500MG	A060704	002		Apr	DISC

THEOPHYLLINE

TABLET;ORAL

THEOLAIR

	@	MEDICIS	125MG	A086399	001		Mar	DISC
	@		250MG	A086399	002		Mar	DISC
	TABLET, EXTENDED RELEASE;ORAL							
	THEOPHYLLINE							
AB	MYLAN PHARMS INC	400MG	A040595	001	Apr 21, 2006	May	CAHN	
AB	+	600MG	A040560	002	Apr 21, 2006	May	CAHN	

THIOTEPA

INJECTABLE;INJECTION

THIOTEPA

+	EUROHLTH INTL SARL	15MG/VIAL	A075547	001	Apr 02, 2001	May	CRLD
---	--------------------	-----------	---------	-----	--------------	-----	------

TICAGRELORTABLET; ORAL
BRILINTA

ASTRAZENECA LP 60MG N022433 002 Sep 03, 2015 Sep NEWA

TIGECYCLINEINJECTABLE; IV (INFUSION)
TIGECYCLINE

AP SANDOZ INC 50MG/VIAL A091620 001 May 27, 2015 May NEWA

TYGACIL

AP + PF PRISM CV 50MG/VIAL N021821 001 Jun 15, 2005 May CFTG

TIMOLOL MALEATESOLUTION/DROPS; OPHTHALMIC
ISTALOL

AT2 + BAUSCH AND LOMB EQ 0.5% BASE N021516 001 Jun 04, 2004 Apr CFTG

TIMOLOL MALEATE

AT1 AKORN EQ 0.5% BASE A074466 001 Mar 25, 1997 Apr CTEC

AT1 EQ 0.5% BASE A074516 001 Mar 25, 1997 Apr CTEC

AT1 ALCON RES LTD EQ 0.5% BASE A074262 001 Apr 28, 1995 Apr CTEC

AT2 APOTEX INC EQ 0.5% BASE A204936 001 Apr 17, 2015 Apr NEWA

AT1 BAUSCH AND LOMB EQ 0.5% BASE A074776 001 Mar 25, 1997 Apr CTEC

AT1 FDC LTD EQ 0.5% BASE A077259 002 Apr 30, 2008 Apr CTEC

AT1 HI TECH PHARMA EQ 0.5% BASE A075163 001 Sep 10, 2002 Apr CTEC

AT1 PACIFIC PHARMA EQ 0.5% BASE A074747 001 Mar 25, 1997 Apr CTEC

AT1 WOCKHARDT EQ 0.5% BASE A078771 002 Sep 28, 2009 Apr CTEC

TIMOPTIC

AT1 + ATON EQ 0.5% BASE N018086 002 Apr CTEC

TINIDAZOLETABLET; ORAL
TINIDAZOLE

AB EDENBRIDGE PHARMS 250MG A203808 001 Aug 04, 2015 Jul NEWA

AB 500MG A203808 002 Aug 04, 2015 Jul NEWA

TIOTROPIUM BROMIDESPRAY, METERED; INHALATION
SPIRIVA RESPIMAT

BOEHRINGER INGELHEIM EQ 0.00125MG BASE/INH N021936 002 Sep 15, 2015 Sep NEWA

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINETABLET; ORAL
LONSURF

TAIHO ONCOLOGY EQ 6.14MG BASE; 15MG N207981 001 Sep 22, 2015 Sep NEWA

+ EQ 8.19MG BASE; 20MG N207981 002 Sep 22, 2015 Sep NEWA

TOBRAMYCINSOLUTION; INHALATION
KITABIS PAK

AN PULMOFLOW INC 300MG/5ML N205433 001 Dec 02, 2014 Feb CTEC

TOBRAMYCIN

AN AMNEAL PHARMS 300MG/5ML A205501 001 Jul 13, 2015 Jun NEWA

SOLUTION/DROPS; OPHTHALMIC
TOBREX

AT + ALCON LABS INC 0.3% N050541 001 Mar CAHN

TOBRAMYCIN SULFATEINJECTABLE; INJECTION
TOBRAMYCIN SULFATE

@ IGI LABS INC EQ 10MG BASE/ML A063119 001 Oct 31, 1994 Mar CAHN

@ EQ 40MG BASE/ML A063120 001 Oct 31, 1994 Mar CAHN

@ EQ 40MG BASE/ML A063121 001 Oct 31, 1994 Mar CAHN

@ EQ 40MG BASE/ML A063122 001 Oct 31, 1994 Mar CAHN

TOBRAMYCIN SULFATE (PHARMACY BULK)

+ FRESENIUS KABI USA EQ 40MG BASE/ML A065120 001 Nov 29, 2002 Jul CTEC

AP + EQ 40MG BASE/ML A065120 001 Nov 29, 2002 Jul CRLD

@ HOSPIRA EQ 40MG BASE/ML A063116 001 May 18, 1992 Jul DISC

AP EQ 40MG BASE/ML A063116 001 May 18, 1992 Jul CTNA

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

@	G AND W LABS INC	100MG	N018894	001	Nov 02, 1984	Apr	CAHN
@		250MG	N018894	002	Nov 02, 1984	Apr	CAHN
@		500MG	N018894	003	Nov 02, 1984	Apr	CAHN

TOLCAPONE

TABLET; ORAL

TASMAR

AB	+	VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	Mar	CFTG
AB		PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar	NEWA

TOLMETIN SODIUM

TABLET; ORAL

TOLMETIN SODIUM

@	G AND W LABS INC	EQ 600MG BASE	A074399	001	Mar 28, 1996	May	CAHN
@		EQ 600MG BASE	A074729	001	Feb 27, 1997	Apr	CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TOLTERODINE TARTRATE

AB		TORRENT PHARMS LTD	2MG	A203016	001	Aug 11, 2015	Jul	NEWA
AB			4MG	A203016	002	Aug 11, 2015	Jul	NEWA

TABLET; ORAL

TOLTERODINE TARTRATE

AB		IVAX SUB TEVA PHARMS	1MG	A077006	001	Feb 23, 2015	Feb	NEWA
AB			2MG	A077006	002	Feb 23, 2015	Feb	NEWA
AB		MACLEODS PHARMS LTD	1MG	A203409	001	Aug 31, 2015	Aug	NEWA
AB			2MG	A203409	002	Aug 31, 2015	Aug	NEWA

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

AB		SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Apr	CAHN
AB			100MG	A076327	002	Mar 27, 2009	Apr	CAHN
AB			200MG	A076327	003	Mar 27, 2009	Apr	CAHN
@		WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010	Apr	DISC
@			50MG	A090353	002	Sep 01, 2010	Apr	DISC
@			100MG	A090353	003	Sep 01, 2010	Apr	DISC
@			200MG	A090353	004	Sep 01, 2010	Apr	DISC
@		HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013	May	DISC
@			50MG	A091185	002	Nov 25, 2013	May	DISC
@			100MG	A091185	003	Nov 25, 2013	May	DISC
@			200MG	A091185	004	Nov 25, 2013	May	DISC

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL

HYCAMTIN

		NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Mar	CAHN
+			EQ 1MG BASE	N020981	002	Oct 11, 2007	Mar	CAHN

INJECTABLE; INJECTION

HYCAMTIN

AP	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	Mar	CAHN
AP		CHEM WERTH INC	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	May	CAHN

TORSEMIDE

INJECTABLE; INJECTION

TORSEMIDE

@	EUROHLTH INTL SARL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Jan	DISC
@		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Jan	DISC
@	LUITPOLD	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Jan	DISC
@		50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Jan	DISC

>A>	<u>TRABECTEDIN</u>								
>A>	POWDER; IV (INFUSION)								
>A>	YONDELIS								
>A>	+	JANSSEN PRODS	1MG/VIAL	N207953	001	Oct 23, 2015	Oct	NEWA	
	<u>TRAMADOL HYDROCHLORIDE</u>								
	TABLET; ORAL								
	TRAMADOL HYDROCHLORIDE								
AB		MACLEODS PHARMS LTD	50MG	A205702	001	Sep 25, 2015	Sep	NEWA	
	TABLET, EXTENDED RELEASE; ORAL								
	TRAMADOL HYDROCHLORIDE								
>A>	AB1	AUROBINDO PHARMA LTD	100MG	A204421	001	Oct 20, 2015	Oct	NEWA	
>A>	AB1		200MG	A204421	002	Oct 20, 2015	Oct	NEWA	
>A>	AB1		300MG	A204421	003	Oct 20, 2015	Oct	NEWA	
	<u>TRAMETINIB DIMETHYL SULFOXIDE</u>								
	TABLET; ORAL								
	MEKINIST								
		NOVARTIS PHARMS CORP	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	Mar	CAHN	
			EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	Mar	CAHN	
	+		EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	Mar	CAHN	
	<u>TRANEXAMIC ACID</u>								
	INJECTABLE; INJECTION								
	TRANEXAMIC ACID								
AP		FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Apr	CMFD	
	TABLET; ORAL								
	TRANEXAMIC ACID								
AB		MYLAN	650MG	A205133	001	Sep 21, 2015	Sep	NEWA	
	<u>TRANYLCPROMINE SULFATE</u>								
	TABLET; ORAL								
	PARNATE								
AB	+	CONCORDIA PHARMS INC	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jun	CAHN	
	<u>TRAVOPROST</u>								
	SOLUTION/DROPS; OPHTHALMIC								
	IZBA								
		@ ALCON LABS INC	0.003%	N204822	001	May 15, 2014	Jul	DISC	
	TRAVATAN Z								
AT	+	ALCON PHARMS LTD	0.004%	N021994	001	Sep 21, 2006	Jun	CTEC	
	TRAVOPROST								
AT		APOTEX INC	0.004%	A203431	001	Jul 10, 2015	Jun	NEWA	
	<u>TRAZODONE HYDROCHLORIDE</u>								
	TABLET; ORAL								
	DESYREL								
		@ PRAGMA PHARMS LLC	50MG	N018207	001		May	CAHN	
		@	100MG	N018207	002		May	CAHN	
		@	150MG	N018207	003	Mar 25, 1985	May	CAHN	
		@	300MG	N018207	004	Nov 07, 1988	May	CAHN	
	<u>TRETINOIN</u>								
	CREAM; TOPICAL								
	RENOVA								
	+	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000	Apr	CAHN	
AB2	+		0.05%	N019963	001	Dec 29, 1995	Apr	CAHN	
	RETIN-A								
AB	+	VALEANT PHARMS NORTH	0.1%	N017340	001		Apr	CAHN	
	GEL; TOPICAL								
	ATRALIN								
AB	+	DOW PHARM	0.05%	N022070	001	Jul 26, 2007	Jul	CTEC	
	TRETINOIN								
AB		SPEAR PHARMS INC	0.05%	A207955	001	Aug 13, 2015	Jul	NEWA	

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL		TRIAMCINOLONE ACETONIDE							
AT	G AND W LABS	0.025%	A089797	001	May 31, 1991	Apr	CMFD		
AT		0.1%	A089798	001	May 31, 1991	Apr	CMFD		
TRIDERM									
AT	CROWN LABS	0.025%	A088042	002	Mar 25, 2015	Mar	NEWA		
AT		0.5%	A088042	003	Mar 25, 2015	Mar	NEWA		
LOTION; TOPICAL		TRIAMCINOLONE ACETONIDE							
AT	G AND W LABS INC	0.1%	A089129	001	Aug 14, 1986	Mar	CMFD		
OINTMENT; TOPICAL		KENALOG							
AT	DELCOR ASSET CORP	0.025%	N011600	003		Mar	CMFD		
AT		0.1%	N011600	001		Mar	CMFD		
TRIAMCINOLONE ACETONIDE									
AT	G AND W LABS	0.025%	A089795	001	Dec 23, 1988	Aug	CMFD		
AT		0.1%	A089796	001	Dec 23, 1988	Aug	CMFD		
SPRAY; TOPICAL		KENALOG							
AT	+ RANBAXY	0.147MG/GM	N012104	001		Mar	CFTG		
AT	+ SUN PHARM INDS LTD	0.147MG/GM	N012104	001		Aug	CAHN		
TRIAMCINOLONE ACETONIDE									
AT	PERRIGO UK FINCO	0.147MG/GM	A205782	001	Apr 13, 2015	Mar	NEWA		

TRIAMTERENE

CAPSULE; ORAL		DYRENIUM							
	CONCORDIA PHARMS INC	50MG	N013174	001		Apr	CAHN		
	+	100MG	N013174	002		Apr	CAHN		

TRIMIPRAMINE MALEATE

CAPSULE; ORAL		SURMONTIL							
AB	+ ODYSSEY PHARMS	EQ 50MG BASE	N016792	002		Jun	CRLD		
AB		EQ 100MG BASE	N016792	003	Sep 15, 1982	Jun	CRLD		

TRIPLE SULFA (SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE)

CREAM; VAGINAL		VAGILIA							
	@ G AND W LABS INC	3.7%;2.86%;3.42%	A088821	001	Nov 09, 1987	Jul	CAHN		

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR		TRELSTAR							
	+ ACTAVIS LABS UT INC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Jan	CAHN		
	+	EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Jan	CAHN		
	+	EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Jan	CAHN		

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL		SANCTURA XR							
	@ ALLERGAN	60MG	N022103	001	Aug 03, 2007	May	DISC		
TROSPIUM CHLORIDE									
AB	ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012	Jun	CRLD		
AB	+	60MG	A091289	001	Oct 12, 2012	May	CRLD		
AB	SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr	NEWA		
TABLET; ORAL		SANCTURA							
	@ ALLERGAN	20MG	N021595	001	May 28, 2004	May	DISC		
TROSPIUM CHLORIDE									
AB	GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010	Jun	CRLD		
AB	+	20MG	A091575	001	Aug 13, 2010	May	CRLD		

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC		RESCULA							
	+ R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000	May	CAHN		
	+ SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000	Jan	CAHN		

URIDINE TRIACETATEGRANULE;ORAL
XURIDEN

	+	WELLSTAT THERAP	2GM/PACKET	N208169	001	Sep 04, 2015	Sep NEWA
--	---	-----------------	------------	---------	-----	--------------	----------

URSODIOLCAPSULE;ORAL
ACTIGALL

AB	+	@ ACTAVIS LABS UT INC	150MG	N019594	001	Dec 31, 1987	Mar CAHN
			300MG	N019594	002	Dec 31, 1987	Mar CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB		HETERO LABS LTD V	EQ 500MG BASE	A203047	001	Apr 08, 2015	Mar NEWA
AB			EQ 1GM BASE	A203047	002	Apr 08, 2015	Mar NEWA
AB		SUN PHARM INDS LTD	EQ 500MG BASE	A076588	001	Jan 31, 2007	Apr CAHN
AB			EQ 1GM BASE	A076588	002	Jan 31, 2007	Apr CAHN

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

AB		BANNER LIFE SCIENCES	250MG	A073484	001	Jun 29, 1993	Jan CAHN
----	--	----------------------	-------	---------	-----	--------------	----------

CAPSULE, DELAYED RELEASE;ORAL
STAVZOR

	@	BANNER LIFE SCIENCES	125MG	N022152	001	Jul 29, 2008	Jan CAHN
	@		250MG	N022152	002	Jul 29, 2008	Jan CAHN
	@		500MG	N022152	003	Jul 29, 2008	Jan CAHN

VALSARTAN

TABLET;ORAL

VALSARTAN

AB		PRINSTON INC	40MG	A204821	001	Jun 09, 2015	May NEWA
AB			80MG	A204821	002	Jun 09, 2015	May NEWA
AB			160MG	A204821	003	Jun 09, 2015	May NEWA
AB			320MG	A204821	004	Jun 09, 2015	May NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

AB		LUPIN LTD	EQ 125MG BASE	A090439	001	Jan 28, 2015	Jan NEWA
AB			EQ 250MG BASE	A090439	002	Jan 28, 2015	Jan NEWA

INJECTABLE;INJECTION

VANCOLED

	@	EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986	Jun CAHN
	@		EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988	Jun CAHN
	@		EQ 2GM BASE/VIAL	A062682	003	May 11, 1988	Jun CAHN
	@		EQ 5GM BASE/VIAL	A062682	004	May 11, 1988	Jun CAHN
	@		EQ 10GM BASE/VIAL	A062682	005	May 11, 1988	Jun CAHN

VANCOMYCIN HYDROCHLORIDE

AP		XELLIA PHARMS APS	EQ 500MG BASE/VIAL	A091377	001	Sep 09, 2015	Aug NEWA
AP			EQ 1GM BASE/VIAL	A091377	002	Sep 09, 2015	Aug NEWA

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

STAXYN

AB	+	BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Apr CFTG
----	---	----------------	------	---------	-----	--------------	----------

VARDENAFIL HYDROCHLORIDE

AB		WATSON LABS INC	10MG	A203689	001	Apr 22, 2015	Apr NEWA
----	--	-----------------	------	---------	-----	--------------	----------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Feb CAHN
AB			EQ 75MG BASE	A090071	002	Apr 15, 2011	Feb CAHN
AB			EQ 150MG BASE	A090071	003	Apr 15, 2011	Feb CAHN

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		YAOPHARMA CO LTD	EQ 25MG BASE	A202036	001	May 28, 2015	May NEWA
AB			EQ 37.5MG BASE	A202036	002	May 28, 2015	May NEWA
AB			EQ 50MG BASE	A202036	003	May 28, 2015	May NEWA

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		EQ 75MG BASE	A202036	004	May 28, 2015	May	NEWA
AB		EQ 100MG BASE	A202036	005	May 28, 2015	May	NEWA

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN

AB	RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990	Apr	CAHN
AB		180MG	N019614	003	Jan 09, 1992	Apr	CAHN
AB		240MG	N019614	002	May 29, 1990	Apr	CAHN
	+	360MG	N019614	004	May 10, 1996	Apr	CAHN

VERELAN PM

AB	RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Apr	CAHN
AB		200MG	N020943	002	Nov 25, 1998	Apr	CAHN
AB	+	300MG	N020943	003	Nov 25, 1998	Apr	CAHN

INJECTABLE;INJECTION

CALAN

@ EXELA PHARMA SCS LLC 2.5MG/ML
ISOPTIN

N018925 001 Mar 30, 1984 Aug CAHN

@ MT ADAMS 2.5MG/ML

N018485 001 Apr CAHN

TABLET;ORAL

ISOPTIN

@ MT ADAMS 40MG
@ 80MG
@ 120MG

N018593 003 Nov 23, 1987 Apr CAHN
N018593 001 Mar 08, 1982 Apr CAHN
N018593 002 Mar 08, 1982 Apr CAHN

VERAPAMIL HYDROCHLORIDE

>A>	AB	HERITAGE PHARMS INC	40MG	A071881	002	Oct 14, 2015	Oct	NEWA
-----	----	---------------------	------	---------	-----	--------------	-----	------

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

	+	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000	Mar	CAHN
--	---	--------------------	-----------	---------	-----	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

	+	FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011	Mar	CAHN
			20MG	N022567	002	Jan 21, 2011	Mar	CAHN
			40MG	N022567	003	Jan 21, 2011	Mar	CAHN

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

AP	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Sep	CAHN
----	--------------------	-----------------	---------	-----	--------------	-----	------

VORICONAZOLE

TABLET;ORAL

VORICONAZOLE

AB	GLENMARK PHARMS LTD	50MG	A203503	001	Sep 02, 2015	Aug	NEWA
AB		200MG	A203503	002	Sep 02, 2015	Aug	NEWA

ZAFIRLUKAST

TABLET;ORAL

ACCOLATE

AB	PAR PHARM INC	10MG	N020547	003	Sep 17, 1999	Feb	CAHN
AB	+	20MG	N020547	001	Sep 26, 1996	Feb	CAHN

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

ZOLEDRONIC ACID

AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Apr	NEWA
AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar	NEWA
AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Jul	CAHN
AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar	CPOT

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

AB	ALEMBIC PHARMS LTD	2.5MG	A204232	001	Sep 30, 2015	Sep NEWA
AB		5MG	A204232	002	Sep 30, 2015	Sep NEWA
AB	MACLEODS PHARMS LTD	2.5MG	A203772	001	Sep 30, 2015	Sep NEWA
AB		5MG	A203772	002	Sep 30, 2015	Sep NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

AB	JUBILANT GENERICS	2.5MG	A202956	001	Sep 17, 2015	Sep NEWA
AB		5MG	A202956	002	Sep 17, 2015	Sep NEWA
>A> AB	MACLEODS PHARMS LTD	2.5MG	A204336	001	Oct 22, 2015	Oct NEWA
>A> AB		5MG	A204336	002	Oct 22, 2015	Oct NEWA

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

ZOLPIMIST

+ AMHERST PHARMS LLC 5MG/SPRAY

N022196 001 Dec 19, 2008 Sep CAHN

TABLET;ORAL

ZOLPIDEM TARTRATE

	@ HIKMA	5MG	A078129	001	Apr 30, 2008	Mar DISC
	@	10MG	A078129	002	Apr 30, 2008	Mar DISC
AB	SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr CAHN
AB		10MG	A078055	002	Apr 23, 2007	Apr CAHN

TABLET;SUBLINGUAL

INTERMEZZO

AB	PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011	May CFTG
AB	+	3.5MG	N022328	002	Nov 23, 2011	May CFTG

ZOLPIDEM TARTRATE

AB	NOVEL LABS INC	1.75MG	A204299	001	Jun 03, 2015	May NEWA
AB		3.5MG	A204299	002	Jun 03, 2015	May NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

AB	BANNER LIFE SCIENCES	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

TYLENOL

@ J AND J CONSUMER INC 120MG

N017756 002

Aug CAHN

@ 650MG

N017756 001

Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

SUN PHARM INDS LTD 650MG

A078569 001 Dec 14, 2011

Apr CAHN

@ 650MG

A090205 001 Nov 18, 2009

Apr CAHN

TYLENOL

+ J AND J CONSUMER INC 650MG

N019872 001 Jun 08, 1994

Aug CAHN

+ 650MG

N019872 002 Jan 11, 2001

Aug CAHN

AVOEBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL

SHADE UVAGUARD

+ BAYER HEALTHCARE LLC 3%;7.5%;3%

N020045 001 Dec 07, 1992

Mar CAHN

BUDESONIDE

SPRAY, METERED;NASAL

RHINOCORT ALLERGY

+ ASTRAZENECA PHARMS 0.032MG/SPRAY

N020746 003 Mar 23, 2015

Mar NEWA

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

LOTRIMIN ULTRA

+ BAYER HEALTHCARE LLC 1%

N021307 001 Dec 07, 2001

Mar CAHN

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL

PEPCID COMPLETE

+ J AND J CONSUMER INC 800MG;10MG;165MG

N020958 001 Oct 16, 2000

Aug CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BANNER LIFE SCIENCES 5MG

N022429 001 Jul 23, 2009

Jan CAHN

+ 10MG

N022429 004 Jul 23, 2009

Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BANNER LIFE SCIENCES 5MG

N022429 003 Jul 23, 2009

Jan CAHN

+ 10MG

N022429 002 Jul 23, 2009

Jan CAHN

SYRUP;ORAL

CHILDREN'S ZYRTEC ALLERGY

+ J AND J CONSUMER INC 5MG/5ML

N022155 002 Nov 16, 2007

Aug CAHN

CHILDREN'S ZYRTEC HIVES RELIEF

+ J AND J CONSUMER INC 5MG/5ML

N022155 001 Nov 16, 2007

Aug CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA LTD 5MG

A090760 001 Aug 05, 2015

Jul NEWA

10MG

A090760 003 Aug 05, 2015

Jul NEWA

SUN PHARM INDS LTD 5MG

A077498 001 Dec 27, 2007

Apr CAHN

10MG

A077498 002 Dec 27, 2007

Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES

SUN PHARM INDS LTD 5MG

A077498 003 Dec 27, 2007

Apr CAHN

10MG

A077498 004 Dec 27, 2007

Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AUROBINDO PHARMA LTD 5MG

A090760 002 Aug 05, 2015

Jul NEWA

10MG

A090760 004 Aug 05, 2015

Jul NEWA

ZYRTEC ALLERGY

J AND J CONSUMER INC 5MG

N019835 003 Nov 16, 2007

Aug CAHN

+ 10MG

N019835 004 Nov 16, 2007

Aug CAHN

ZYRTEC HIVES RELIEF

J AND J CONSUMER INC 5MG

N019835 005 Nov 16, 2007

Aug CAHN

+ 10MG

N019835 006 Nov 16, 2007

Aug CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT GENERICS 5MG

A091116 001 Feb 19, 2015

Feb NEWA

10MG

A091116 002 Feb 19, 2015

Feb NEWA

SANDOZ 5MG

A078692 001 Feb 14, 2008

Feb CTNA

TABLET, CHEWABLE;ORAL					
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
+	10MG	A078692	002	Feb 14, 2008	Feb CTNA
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	JUBILANT GENERICS 5MG	A091116	003	Feb 19, 2015	Feb NEWA
	10MG	A091116	004	Feb 19, 2015	Feb NEWA
CHILDREN'S ZYRTEC ALLERGY					
@	J AND J CONSUMER INC 5MG	N021621	003	Nov 16, 2007	Aug CAHN
@	10MG	N021621	004	Nov 16, 2007	Aug CAHN
CHILDREN'S ZYRTEC HIVES RELIEF					
@	J AND J CONSUMER INC 5MG	N021621	005	Nov 16, 2007	Aug CAHN
@	10MG	N021621	006	Nov 16, 2007	Aug CAHN
TABLET, ORALLY DISINTEGRATING;ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
	PAR PHARM INC 10MG	A205490	001	Sep 02, 2015	Aug NEWA
ZYRTEC ALLERGY					
+	J AND J CONSUMER INC 10MG	N022578	001	Sep 03, 2010	Aug CAHN
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>					
TABLET, EXTENDED RELEASE;ORAL					
ZYRTEC-D 12 HOUR					
+	J AND J CONSUMER INC 5MG;120MG	N021150	002	Nov 09, 2007	Aug CAHN
<u>CHLORPHENIRAMINE MALEATE</u>					
TABLET, EXTENDED RELEASE;ORAL					
CHLOR-TRIMETON					
@	BAYER HEALTHCARE LLC 8MG	N007638	001		Mar CAHN
+	12MG	N007638	002		Mar CAHN
<u>CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE</u>					
TABLET, EXTENDED RELEASE;ORAL					
CHLOR-TRIMETON					
+	BAYER HEALTHCARE LLC 8MG;120MG	N018397	001		Mar CAHN
<u>CLEMASTINE FUMARATE</u>					
TABLET;ORAL					
CLEMASTINE FUMARATE					
@	ANI PHARMS INC 1.34MG	A073282	002	Dec 03, 1992	Jul CAHN
<u>CLOTTRIMAZOLE</u>					
CREAM;VAGINAL					
GYNE-LOTRIMIN					
+	BAYER HEALTHCARE LLC 1%	N018052	002	Nov 30, 1990	Mar CAHN
GYNE-LOTRIMIN 3					
+	BAYER HEALTHCARE LLC 2%	N020574	001	Nov 24, 1998	Mar CAHN
CREAM, TABLET;TOPICAL, VAGINAL					
GYNE-LOTRIMIN COMBINATION PACK					
+	BAYER HEALTHCARE LLC 1%,100MG	N020289	002	Apr 26, 1993	Mar CAHN
TABLET;VAGINAL					
GYNE-LOTRIMIN					
+	BAYER HEALTHCARE LLC 100MG	N017717	002	Nov 30, 1990	Mar CAHN
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN</u>					
TABLET, EXTENDED RELEASE;ORAL					
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE					
	ACTAVIS LABS FL INC 30MG;600MG	A091070	001	Aug 31, 2015	Aug NEWA
	60MG;1.2GM	A091070	002	Aug 31, 2015	Aug NEWA
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN</u>					
CAPSULE;ORAL					
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE					
	BANNER LIFE SCIENCES 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010	Jan CAHN
<u>FAMOTIDINE</u>					
TABLET;ORAL					
FAMOTIDINE					
	SUN PHARM INDS LTD 10MG	A090283	001	Nov 17, 2009	Apr CAHN
	20MG	A090283	002	Nov 17, 2009	Apr CAHN
PEPCID AC					
	J AND J CONSUMER INC 10MG	N020325	001	Apr 28, 1995	Jul CAHN

TABLET;ORAL							
PEPCID AC							
+	20MG			N020325	002	Sep 23, 2003	Jul CAHN
PEPCID AC							
	J AND J CONSUMER INC	10MG		N020902	001	Aug 05, 1999	Aug CAHN
TABLET, CHEWABLE;ORAL							
PEPCID AC							
@	J AND J CONSUMER INC	10MG		N020801	001	Sep 24, 1998	Aug CAHN
+	20MG			N020801	002	Dec 17, 2007	Aug CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL							
FEXOFENADINE HYDROCHLORIDE ALLERGY							
	SCIEGEN PHARMS INC	60MG		A204507	002	Sep 16, 2015	Aug NEWA
		180MG		A204507	003	Sep 16, 2015	Aug NEWA
FEXOFENADINE HYDROCHLORIDE HIVES							
	SCIEGEN PHARMS INC	60MG		A204507	004	Sep 16, 2015	Aug NEWA
		180MG		A204507	005	Sep 16, 2015	Aug NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL							
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
	SUN PHARMA GLOBAL	60MG;120MG		A090818	001	Jan 29, 2015	Jan NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL							
GUAIFENESIN							
	ACTAVIS LABS FL INC	1.2GM		A091009	002	Sep 03, 2015	Aug NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL							
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE							
	ACTAVIS LABS FL INC	600MG;60MG		A091071	001	May 27, 2015	May NEWA
		1.2GM;120MG		A091071	002	May 27, 2015	May NEWA

IBUPROFEN

CAPSULE;ORAL							
IBUPROFEN							
	BANNER LIFE SCIENCES	EQ 200MG FREE ACID AND POTASSIUM SALT		A078682	001	Mar 24, 2009	Jan CAHN
MIDOL LIQUID GELS							
+	BANNER LIFE SCIENCES	200MG		N021472	001	Oct 18, 2002	Jan CAHN
SUSPENSION;ORAL							
CHILDREN'S MOTRIN							
+	J AND J CONSUMER INC	100MG/5ML		N020516	001	Jun 16, 1995	Aug CAHN
SUSPENSION/DROPS;ORAL							
CHILDREN'S MOTRIN							
+	J AND J CONSUMER INC	40MG/ML		N020603	001	Jun 10, 1996	Aug CAHN
TABLET;ORAL							
IBUPROFEN							
>A>	@ ANI PHARMS INC	200MG		A071144	001	Jan 20, 1987	Oct CAHN
	@	200MG		A072901	001	Dec 19, 1991	Aug CAHN
	@	200MG		A072903	001	Dec 19, 1991	Aug CAHN
>D>	@ IVAX SUB TEVA PHARMS	200MG		A071144	001	Jan 20, 1987	Oct CAHN
JUNIOR STRENGTH MOTRIN							
	J AND J CONSUMER INC	100MG		N020602	001	Jun 10, 1996	Aug CAHN
MOTRIN IB							
+	J AND J CONSUMER INC	200MG		N019012	003	Dec 17, 1990	Aug CAHN
MOTRIN MIGRAINE PAIN							
+	J AND J CONSUMER INC	200MG		N019012	004	Feb 25, 2000	Aug CAHN
NUPRIN							
@	J AND J CONSUMER INC	200MG		N019012	001	May 18, 1984	Aug CAHN
@		200MG		N019012	002	Jul 29, 1987	Aug CAHN
TABLET, CHEWABLE;ORAL							
CHILDREN'S MOTRIN							
	J AND J CONSUMER INC	50MG		N020601	001	Nov 15, 1996	Aug CAHN
JUNIOR STRENGTH MOTRIN							
+	J AND J CONSUMER INC	100MG		N020601	003	Nov 15, 1996	Aug CAHN

IBUPROFEN SODIUM

TABLET;ORAL

IBUPROFEN SODIUM

PERRIGO R AND D

EQ 200MG BASE

A206581 001 Aug 03, 2015 Jul NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S MOTRIN COLD

+ J AND J CONSUMER INC 100MG/5ML;15MG/5ML

N021128 001 Aug 01, 2000 Aug CAHN

TABLET;ORAL

SINE-AID IB

J AND J CONSUMER INC 200MG;30MG

N019899 001 Dec 31, 1992 Aug CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

BAUSCH AND LOMB

EQ 0.035% BASE

N021996 002 Feb 11, 2015 Feb NEWA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

LOTUS PHARM CO LTD

1.5MG

A202246 001 Jun 05, 2015 May NEWA

OC PHARMA

1.5MG

A202380 001 May 29, 2015 May NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER LIFE SCIENCES

1MG

N021855 001 Aug 04, 2005 Jan CAHN

+ 2MG

N021855 002 Aug 04, 2005 Jan CAHN

SOLUTION;ORAL

IMODIUM A-D

+ J AND J CONSUMER INC 1MG/5ML

N019487 001 Mar 01, 1988 Aug CAHN

SUSPENSION;ORAL

IMODIUM A-D

+ J AND J CONSUMER INC 1MG/7.5ML

N019487 002 Jul 08, 2004 Aug CAHN

TABLET;ORAL

IMODIUM A-D

+ J AND J CONSUMER INC 2MG

N019860 001 Nov 22, 1989 Aug CAHN

TABLET, CHEWABLE;ORAL

IMODIUM A-D EZ CHEWS

+ J AND J CONSUMER INC 2MG

N020448 001 Jul 24, 1997 Aug CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC 2MG;125MG

N021140 001 Nov 30, 2000 Aug CAHN

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

SUN PHARM INDS LTD 2MG;125MG

A077500 001 Sep 06, 2006 Apr CAHN

TABLET, CHEWABLE;ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC 2MG;125MG

N020606 001 Jun 26, 1996 Aug CAHN

LORATADINE

CAPSULE;ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 10MG

N021952 001 Jun 16, 2008 Mar CAHN

SYRUP;ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 1MG/ML

N020641 002 Nov 27, 2002 Mar CAHN

CLARITIN HIVES RELIEF

@ BAYER HEALTHCARE LLC 1MG/ML

N020641 003 Nov 19, 2003 Mar CAHN

LORATADINE

TARO

1MG/ML

A201865 001 Jul 31, 2015 Jul NEWA

TABLET;ORAL

LORATADINE

SUN PHARM INDS LTD

10MG

A076134 001 Aug 18, 2003 Apr CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+ BAYER HEALTHCARE LLC 5MG

N021891 001 Aug 23, 2006 Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL									
CLARITIN REDITABS									
+	BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006	Mar	CAHN		
LORATADINE REDIDOSE									
	SUN PHARM INDS LTD	10MG	A077153	001	Apr 11, 2007	Apr	CAHN		
<u>LORATADINE; PSEUDOEPHEDRINE SULFATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
CLARITIN-D									
+	BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002	Mar	CAHN		
CLARITIN-D 24 HOUR									
+	BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002	Mar	CAHN		
LORATADINE AND PSEUDOEPHEDRINE SULFATE									
	SUN PHARM INDS LTD	10MG;240MG	A076557	001	Sep 22, 2004	Apr	CAHN		
<u>NAPROXEN SODIUM</u>									
CAPSULE;ORAL									
NAPROXEN SODIUM									
+	BANNER LIFE SCIENCES	EQ 200MG BASE	N021920	001	Feb 17, 2006	Jan	CAHN		
TABLET;ORAL									
NAPROXEN SODIUM									
	SUN PHARM INDS LTD	EQ 200MG BASE	A091183	001	May 20, 2011	Apr	CAHN		
<u>NICOTINE POLACRILEX</u>									
GUM, CHEWING;BUCCAL									
NICOTINE POLACRILEX									
@	IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880	001	Feb 18, 2009	Mar	DISC		
@		EQ 4MG BASE	A077850	001	Feb 18, 2009	Mar	DISC		
<u>OMEPRAZOLE MAGNESIUM</u>									
TABLET, DELAYED RELEASE;ORAL									
OMEPRAZOLE MAGNESIUM									
	PERRIGO R AND D	EQ 20MG BASE	A204152	001	Jul 30, 2015	Jul	NEWA		
<u>OMEPRAZOLE; SODIUM BICARBONATE</u>									
CAPSULE;ORAL									
ZEGERID OTC									
+	BAYER HEALTHCARE LLC	20MG;1.1GM	N022281	001	Dec 01, 2009	Mar	CAHN		
FOR SUSPENSION;ORAL									
ZEGERID OTC									
+	BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013	Mar	CAHN		
<u>OXYMETAZOLINE HYDROCHLORIDE</u>									
SOLUTION/DROPS;OPHTHALMIC									
OCUCLEAR									
	BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986	Mar	CAHN		
<u>POLYETHYLENE GLYCOL 3350</u>									
FOR SOLUTION;ORAL									
MIRALAX									
+	BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006	Mar	CAHN		
POLYETHYLENE GLYCOL 3350									
	RARITAN PHARMS INC	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Jan	CAHN		
<u>PSEUDOEPHEDRINE HYDROCHLORIDE</u>									
TABLET, EXTENDED RELEASE;ORAL									
PSEUDOEPHEDRINE HYDROCHLORIDE									
	SUN PHARM INDS LTD	120MG	A077442	001	Sep 28, 2005	Apr	CAHN		
SUDAFED 24 HOUR									
+	J AND J CONSUMER INC	240MG	N020021	002	Dec 15, 1992	Aug	CAHN		
<u>RANITIDINE HYDROCHLORIDE</u>									
TABLET;ORAL									
RANITIDINE HYDROCHLORIDE									
@	SUN PHARM INDS LTD	EQ 75MG BASE	A075132	001	Jan 14, 2000	Apr	CAHN		
@	WOCKHARDT	EQ 75MG BASE	A078884	001	Jul 31, 2008	Jan	DISC		

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2015

NO OCTOBER 2015 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO OCTOBER 2015 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977	001				D-147	Mar 23, 2018
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978	001				D-147	Mar 23, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551	001	6417191	Mar 28, 2016	DP U-1572		
		6417191*PED	Sep 28, 2016			
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652	001	6417191	Mar 28, 2016	DP U-257		
		6417191*PED	Sep 28, 2016			
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031	001	8980319	Dec 21, 2030	DP		
		8992975	May 16, 2032	DP		
		9050335	May 16, 2032	DP		
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450	001	9056100	Jul 07, 2020	DP U-1263		
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436	001	7223387	Jul 24, 2021	DP U-1006		
		7223387	Jul 24, 2021	DP U-1484		
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320	001	8936800	Dec 23, 2022	DP U-1078		
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917	001	8445543	Jul 12, 2027	U-1078	NP	Jul 15, 2018
		8703820	Mar 12, 2023	U-1078		
		8729127	Mar 12, 2023	U-1078		
		8785420	Dec 23, 2022	U-1078		
		8909305	Dec 23, 2022	U-1078		
		8936800	Dec 23, 2022	DP U-1078		
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636	001	6446627	Dec 18, 2017	DP	NP	Mar 12, 2018
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747	001	8733341	Dec 16, 2029	DP		
		9027967	Mar 31, 2027	DP		
<u>ALCAFTADINE - LASTACFT</u>						
N 022134	001	>A> 8664215	Dec 23, 2027	U-1493		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	001	8637079	Jun 04, 2029	DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	002	8637079	Jun 04, 2029	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	8637079	Jun 04, 2029	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8946262	Feb 12, 2030	U-1655			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 001	>A> 8377933	Dec 11, 2027	U-1754		>A> I-716	Oct 02, 2018
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	>A> 8377933	Dec 11, 2027	U-1754		>A> I-716	Oct 02, 2018
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	8778924	Dec 08, 2026	DS DP U-897			
<u>AMPHETAMINE - DYANA VEL XR</u>						
N 208147 001	>A> 8062667	Mar 29, 2029	DP		>A> NP	Oct 19, 2018
	>A> 8597684	Mar 15, 2027	DP			
	>A> 8747902	Mar 15, 2027	DP			
	>A> 8883217	Mar 15, 2027	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6967208	Feb 03, 2023	DS DP U-1167			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1502			
	6967208	Feb 03, 2023	DS DP U-1729			
	6967208	Feb 03, 2023	DS DP U-1730			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6413980	Dec 22, 2019	DS DP U-1301			
	6413980	Dec 22, 2019	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREPITANT - EMEND</u>						
N 021549 001	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
<u>APREPITANT - EMEND</u>						
N 021549 002	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
<u>APREPITANT - EMEND</u>						
N 021549 003	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-761			
	5006528*PED	Apr 20, 2015				
	6977257	Apr 24, 2022	DP			
	6977257*PED	Oct 24, 2022				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729	004				ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729	005				ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021866	001	5006528	Oct 20, 2014	DS DP U-543	ODE	Dec 12, 2021
		5006528	Oct 20, 2014	DS DP U-763		
		5006528*PED	Apr 20, 2015			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	001	5006528	Oct 20, 2014	DS DP U-543		
		5006528	Oct 20, 2014	DS DP U-1632		
		5006528*PED	Apr 20, 2015			
		8030313	Oct 19, 2024	U-543		
		8030313	Oct 19, 2024	U-1632		
		8338427	Mar 15, 2025	DP U-543		
		8338427	Mar 15, 2025	DP U-1633		
		8338428	Aug 06, 2023	DP U-543		
		8338428	Aug 06, 2023	DP U-1633		
		8399469	Jun 29, 2025	DS		
		8759351	Aug 06, 2023	DP U-1530		
		8759351	Aug 06, 2023	DP U-1633		
		8993761	Sep 25, 2022	DS		
		9089567	Jan 28, 2022	U-543		
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	002	5006528	Oct 20, 2014	DS DP U-543		
		5006528	Oct 20, 2014	DS DP U-1632		
		5006528*PED	Apr 20, 2015			
		8030313	Oct 19, 2024	U-543		
		8030313	Oct 19, 2024	U-1632		
		8338427	Mar 15, 2025	DP U-543		
		8338427	Mar 15, 2025	DP U-1633		
		8338428	Aug 06, 2023	DP U-543		
		8338428	Aug 06, 2023	DP U-1633		
		8399469	Jun 29, 2025	DS		
		8759351	Aug 06, 2023	DP U-1530		
		8759351	Aug 06, 2023	DP U-1633		
		8993761	Sep 25, 2022	DS		
		9089567	Jan 28, 2022	U-543		
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	003	5006528	Oct 20, 2014	DS DP U-543		
		5006528	Oct 20, 2014	DS DP U-1632		
		5006528*PED	Apr 20, 2015			
		8030313	Oct 19, 2024	U-543		
		8030313	Oct 19, 2024	U-1632		
		8338427	Mar 15, 2025	DP U-543		
		8338427	Mar 15, 2025	DP U-1633		
		8338428	Aug 06, 2023	DP U-543		
		8338428	Aug 06, 2023	DP U-1633		
		8399469	Jun 29, 2025	DS		
		8759351	Aug 06, 2023	DP U-1530		
		8759351	Aug 06, 2023	DP U-1633		
		8993761	Sep 25, 2022	DS		
		9089567	Jan 28, 2022	U-543		
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	004	5006528	Oct 20, 2014	DS DP U-543		
		5006528	Oct 20, 2014	DS DP U-1632		
		5006528*PED	Apr 20, 2015			
		8030313	Oct 19, 2024	U-543		
		8030313	Oct 19, 2024	U-1632		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	>A> 8431576	Oct 26, 2030	DS		>A> NCE	Oct 05, 2020
	>A> 8796276	Jun 24, 2030	U-543			
	>A> 9034867	Nov 07, 2032	DP U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	>A> 8431576	Oct 26, 2030	DS		>A> NCE	Oct 05, 2020
	>A> 8796276	Jun 24, 2030	U-543			
	>A> 9034867	Nov 07, 2032	DP U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	>A> 8431576	Oct 26, 2030	DS		>A> NCE	Oct 05, 2020
	>A> 8796276	Jun 24, 2030	U-543			
	>A> 9034867	Nov 07, 2032	DP U-543			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	9101637	Mar 23, 2022	U-1731			
	9101637	Mar 23, 2022	U-1732			
	9101637	Mar 23, 2022	U-1733			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 002	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 003	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 003	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 004	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352 001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
	5849911*PED	Dec 20, 2017			NPP	Sep 24, 2018
	6087383	Dec 21, 2018	DS DP		PED	Dec 02, 2017
	6087383*PED	Jun 21, 2019			PED	Mar 24, 2019
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
	8148374	Sep 03, 2029	DS DP U-1279			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-282			
	7612087	Nov 12, 2026	DP			
	8178554	Jul 24, 2021	DS DP U-282			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	6730288	Sep 08, 2019	DP		NP	Jul 29, 2018
	7700076	Sep 18, 2027	DP			
	8435498	Mar 01, 2024	U-1727			
	8722021	Oct 24, 2023	DP			
	8900554	Oct 24, 2023	DP			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001					NPP	Feb 20, 2018
					NPP	Feb 20, 2018
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
	8163723	Aug 29, 2023	U-81			
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-1667			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 001	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 002	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9066936	Mar 26, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	8895070	Jun 03, 2029	U-124			
	9078870	Jun 03, 2029	DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8937062	Nov 13, 2029	U-80			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	>A> 6753013	Jun 10, 2031	DP U-1761		>A> NP	Oct 16, 2018
	>A> 9119781	Jun 10, 2031	DP U-1761			
<u>BEXAROTENE - TARGRETIN</u>						
N 021055 001					M-164	Jul 29, 2018
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8933120	Mar 16, 2025	DP			
	8933127	Mar 16, 2025	DP			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	7351404	May 25, 2024	U-939	Y		
	7388029	Jan 21, 2022	U-938	Y		
	8541466	Jan 31, 2021	U-1217			
	8986715	Jan 15, 2023	U-1217			
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001	5780454	May 03, 2017	DS DP		D-141	Oct 08, 2017
	5780454*PED	Nov 03, 2017			D-142	Oct 08, 2017
	6713446	Jan 25, 2022	DS DP		I-695	Oct 08, 2017
	6713446*PED	Jul 25, 2022			M-139	Aug 08, 2017
	6958319	Jan 25, 2022	DS DP		M-165	Sep 14, 2018
	6958319*PED	Jul 25, 2022			ODE	Oct 08, 2021
					PED	Feb 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					PED	Mar 14, 2019
					PED	Apr 08, 2022
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	9044484	Oct 30, 2030	DP			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001 >A>	9144609	Jan 16, 2024	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	8877708	Jun 07, 2030	DP U-1706			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9132093	Sep 07, 2031	DP			
<u>BUDESONIDE - UCERIS</u>						
N 205613 001	5914122	Dec 19, 2015	DP			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001					>A> NP	Oct 23, 2018
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002					>A> NP	Oct 23, 2018
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003					>A> NP	Oct 23, 2018
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004					>A> NP	Oct 23, 2018
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005					>A> NP	Oct 23, 2018
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006					>A> NP	Oct 23, 2018
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007					>A> NP	Oct 23, 2018
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	8940330	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	8916195	Feb 02, 2030	U-1639			
	9107837	Jun 04, 2027	U-1639			
	>A> 9125868	Nov 08, 2027	U-1585			
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160 003	6875445	Jul 30, 2021	DP			
<u>CALCIUM ACETATE - PHOSLYRA</u>						
N 022581 001	9089528	Jul 20, 2027	U-1469			
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER</u>						
N 207026 001					ODE	Jan 13, 2022
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER</u>						
N 207026 002					ODE	Jan 13, 2022
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	6114313	Dec 11, 2017	DP U-1715		NCE	Jun 22, 2020
	6130208	Jun 29, 2018	DP U-1715			
	8680052	Mar 09, 2033	U-1715			
	8759316	May 13, 2029	U-1715			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - DUOPA</u>						
N 203952 001					NP ODE	Jan 09, 2018 Jan 09, 2022
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001					I-712	Jul 24, 2018
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	>A> 7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	>A> 7943621	Dec 16, 2028	DS DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	>A> 7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	>A> 7943621	Dec 16, 2028	DS DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	>A> 7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	>A> 7943621	Dec 16, 2028	DS DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	>A> 7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	>A> 7943621	Dec 16, 2028	DS DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
<u>CELECOXIB - CELECOXIB</u>						
A 076898 002					PC	Jun 02, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELECOXIB</u>						
A 076898	003				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898	004				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857	002				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857	003				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857	004				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562	002				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562	003				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562	004				PC	Jun 02, 2015
<u>CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE</u>						
N 206323	001	6248363	Nov 23, 2019	DP U-1716		
		6383471	Apr 06, 2019	DP U-1716		
		9066942	Jan 03, 2032	U-1716		
	>A>	9107921	Jan 03, 2032	DP		
<u>CHLORPHENIRAMINE POLYSTIREX; CODEINE POLYSTIREX - TUZISTRA XR</u>						
N 207768	001	8062667	Mar 29, 2029	DP		
		8790700	Mar 15, 2027	DP		
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	001				ODE	Mar 17, 2022
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	002				ODE	Mar 17, 2022
<u>CICLESONIDE - ALVESCO</u>						
N 021658	002	8371292	Feb 01, 2028	U-1355		
<u>CICLESONIDE - ALVESCO</u>						
N 021658	003	8371292	Feb 01, 2028	U-1355		
<u>CICLESONIDE - OMNARIS</u>						
N 022004	001	8371292	Feb 01, 2028	U-1356		
<u>CICLESONIDE - ZETONNA</u>						
N 202129	001	8371292	Feb 01, 2028	U-1357		
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537	001	>A> 9149486	Sep 13, 2022	DP U-1578		
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 090898	001				PC	Jul 01, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	8962000	Aug 31, 2025	DP U-1410			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	5843946	Dec 01, 2015	DP U-1660			
	5843946*PED	Jun 01, 2016				
	7470506	Jun 23, 2019	U-1660			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1660			
	RE43802*PED	Apr 19, 2017				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8981103	Oct 26, 2026	DS DP		I-704	Dec 17, 2017
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	8927607	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Aug 26, 2025	DS		M-163	Sep 14, 2018
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Aug 26, 2025	DS		M-163	Sep 14, 2018
<u>CROFELEMER - FULYZAO</u>						
N 202292 001	8962680	Oct 31, 2031	U-1319			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	>A> 9173851	Jun 17, 2034	DP		NPP	Aug 14, 2018
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	>A> 9173851	Jun 17, 2034	DP		NPP	Aug 14, 2018
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	>A> 9034822	Jan 20, 2031	U-1759			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	>A> 9034822	Jan 20, 2031	U-1759			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	8703781	Oct 15, 2030	DS DP U-1713			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	8703781	Oct 15, 2030	DS DP U-1713			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001					ODE	Jul 22, 2021
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001					M-157	Mar 11, 2018
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002					M-157	Mar 11, 2018
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	6037157	Jun 26, 2016	U-1635			
	6703403	Jun 26, 2016	U-1635			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1637			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1637			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	>A> 9139536	Nov 09, 2028	U-1753			
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 001	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			
<u>DEFERASIROX - JADENU</u>						
N 206910 002	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - JADENU</u>						
N 206910 003	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001	7049328	Jun 28, 2021	U-735			
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001	7049328	Jun 28, 2021	U-735		NCE	Oct 14, 2016
	8703156	Oct 29, 2029	DP U-735		ODE	Oct 14, 2016
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	7622130	Dec 10, 2027	U-1690			
	7754230	Dec 10, 2027	U-1690			
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025	U-1690			
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP U-1690			
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025	U-1690			
	8883770	Feb 21, 2028	DP			
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 001					PC	May 16, 2015
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 002					PC	May 16, 2015
<u>DESONIDE - VERDESO</u>						
N 021978 001	8962000	Aug 31, 2025	DP U-1412			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
	8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	8043628	Oct 20, 2020	U-1205			
	8088407	Oct 20, 2020	U-1205			
	9012437	Oct 20, 2020	U-1205			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9011926	Feb 24, 2026	DP			
	>A> 9145389	Jun 15, 2020	DS DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	9011926	Feb 24, 2026	DP			
	>A> 9145389	Jun 15, 2020	DS DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 002					PC	Aug 01, 2015
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 003					PC	Dec 19, 2015
<u>DICHLORPHENAMIDE - KEVEYIS</u>						
N 011366 002					ODE	Aug 07, 2022
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
	>A> 9173854	Apr 23, 2030	DP			
	>A> 9180096	Apr 23, 2030	DP			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
	>A> 9173854	Apr 23, 2030	DP			
	>A> 9180096	Apr 23, 2030	DP			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	8927604	Jun 16, 2026	U-436			
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396 001	6407079	Jun 18, 2019	DP			
	8946292	Mar 22, 2027	U-1659			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9066913	Oct 17, 2027	DP U-1488			
	9101591	Oct 17, 2027	DP U-1488			
	9132110	Oct 17, 2027	U-1488			
	>A> 9168304	Oct 16, 2027	DP			
	>A> 9168305	Oct 17, 2027	U-1488			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM</u>						
N 021393 001	>A> 9155718	Jan 17, 2022	DP			
<u>DOLUATEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001					M-166	Jul 30, 2018
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9107898	May 01, 2028	DP U-620			
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9107898	May 01, 2028	DP U-620			
<u>DOXYCYCLINE HYCLATE - DOXTERIC</u>						
N 050795 006	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425 001	9107900	Apr 16, 2029	U-1726			
	9107900	Apr 16, 2029	U-1728			
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090694 003					PC	Jan 11, 2016
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	9018192	Jun 13, 2026	U-750			
	9018192	Jun 13, 2026	U-1170			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-930			
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-930			
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-1575			
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-714			
	8062665	Aug 01, 2027	DP U-930			
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-1575			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-930			
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-1575			
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293*PED	Nov 21, 2023				
	8052995	Aug 01, 2027	DP U-1306			
	8052995	Aug 01, 2027	DP U-1575			
	8052995*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027 001	6280959	Oct 30, 2018	DS DP U-1736		D-149	Jun 11, 2018
	7160870	Nov 20, 2022	DS DP U-1736		I-711	Jun 11, 2018
	7332481	May 24, 2021	U-1736		ODE	Nov 20, 2015
	7452874	May 24, 2021	DS DP		PED	Dec 11, 2018
	7473686	May 24, 2021	DS DP U-1736		PED	Dec 11, 2018
	7547719	Jul 13, 2025	DS DP U-1736			
	7790704	May 24, 2021	U-1736			
	7795293	May 24, 2023	U-1736			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	8691860	Jul 07, 2028	DS U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	8981103	Oct 26, 2026	DS DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	8981103	Oct 26, 2026	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001					M-160 M-161	Jun 26, 2018 Jun 26, 2018
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002					M-160 M-161	Jun 26, 2018 Jun 26, 2018
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2024	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001 >A>	7125879	Aug 09, 2022	DS DP U-257			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	9126941	May 15, 2026	U-1588			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 001	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
>A>	9149579	Jul 19, 2025	U-1758			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 002	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
>A>	9149579	Jul 19, 2025	U-1758			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9119876	Mar 13, 2035	DP			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jul 20, 2023	DS			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1509			
	5714504*PED	Aug 03, 2015				
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1509			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1509			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810*PED	May 03, 2020				
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8945621	Oct 17, 2031	U-1661			
	>A> 9161920	May 31, 2022	U-1760			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8945621	Oct 17, 2031	U-1661			
	>A> 9161920	May 31, 2022	U-1760			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001					M-162	Sep 24, 2018
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001	9107912	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002	9107912	Sep 08, 2031	U-1346			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9078814	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9078814	Jan 08, 2024	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	6169920	Jan 02, 2018	DP U-736			
	6181963	Nov 02, 2019	DP			
	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	U-736			
	8428709	Jun 11, 2032	DP U-736			
	8781571	Mar 31, 2032	DP U-736			
	9095706	Jan 17, 2033	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	8901349	Feb 18, 2024	U-1577			
	9050316	Feb 18, 2024	U-1577			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317 001	6689275	Dec 31, 2016	U-1656			
	6779468	Dec 31, 2016	U-1656			
	7816404	Apr 17, 2029	DP U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	8933097	Aug 16, 2032	DP			
<u>FINAFLOXACIN - XTORO</u>						
N 206307 001	6133260	Apr 12, 2017	DS DP			
	6432948	Apr 12, 2017	DS DP			
	8536167	Aug 08, 2031	U-1679			
	9119859	Jul 02, 2030	U-1679			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLIBANSERIN - ADDYI</u>						
N 022526 001	7151103	May 09, 2023	U-1734		NCE	Aug 18, 2020
	7420057	Aug 01, 2022	DS DP			
	8227471	May 09, 2023	U-1734			
<u>FLUOROURACIL - TOLAK</u>						
N 022259 001 >A>	7169401	Jul 18, 2023	DP		NP	Sep 18, 2018
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	8916131	Sep 16, 2028	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	8916131	Sep 16, 2028	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	6537983	Aug 03, 2021	DP U-1401		I-708	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1401			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1691			
	8511304	Jun 14, 2027	DP U-1424			
	8511304	Jun 14, 2027	DP U-1691			
	RE44874	Mar 23, 2023	DS DP U-1548			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	5873360	Feb 23, 2016	DP		NP	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1691			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-1691			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152 001					NPP	Jan 16, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 001					M-155	Mar 27, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					M-155	Mar 27, 2018
<u>GEFITINIB - IRESSA</u>						
N 206995 001 >A>	5770599	May 05, 2017	DS DP U-1755		NP ODE	Jul 13, 2018 Jul 13, 2022
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	8969302	Aug 19, 2030	U-441			
	9155776	Aug 19, 2030	U-441			
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284 001	9095559	Mar 09, 2032	U-1383			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881	001				PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881	002				PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881	003				PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881	004				PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	001				M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	002				M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	003				M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	004				M-154	Mar 18, 2018
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	001	9132096	Sep 12, 2034		DP	
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	002	9132096	Sep 12, 2034		DP	
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	003	9132096	Sep 12, 2034		DP	
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	004	9132096	Sep 12, 2034		DP	
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	005	9132096	Sep 12, 2034		DP	
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	006	9132096	Sep 12, 2034		DP	
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	001	9023401	Oct 30, 2021		DP	
		9056052	Oct 30, 2021		DP	
		9060940	Oct 30, 2021		U-1556	
		9084816	Aug 24, 2027		DP	
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027		DP	
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	002	9023401	Oct 30, 2021		DP	
		9056052	Oct 30, 2021		DP	
		9060940	Oct 30, 2021		U-1556	
		9084816	Aug 24, 2027		DP	
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027		DP	
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	003	9023401	Oct 30, 2021		DP	
		9056052	Oct 30, 2021		DP	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8497277	Dec 28, 2026	U-1456		I-702	Jan 29, 2018
	8497277	Dec 28, 2026	U-1491		ODE	Jan 29, 2022
	8497277	Dec 28, 2026	U-1650			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
	9125889	Jun 03, 2031	U-1745			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8871810	Sep 30, 2029	U-1599			
	9012508	Sep 14, 2030	U-981			
	9114068	Sep 30, 2029	U-1735			
>A>	9138404	Sep 30, 2029	U-1756			
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150 001	5648333	Jul 15, 2019	DS DP	U-1187		
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	8138195	Apr 24, 2021	DS DP	U-1549		
	8865730	Mar 05, 2033	DS DP	U-1615		
	8980901	May 12, 2025		U-1678		
>A>	9149477	May 12, 2025		U-1757		
	RE44599	Jul 21, 2025		U-1558		
	RE44599	Jul 21, 2025		U-1615		
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	8138195	Apr 24, 2021	DS DP	U-1549		
	8865730	Mar 05, 2033	DS DP	U-1615		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	8980901	May 12, 2025	U-1678			
	>A> 9149477	May 12, 2025	U-1757			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
<u>LLOPERIDONE - FANAPT</u>						
N 022192 001	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>LLOPERIDONE - FANAPT</u>						
N 022192 002	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>LLOPERIDONE - FANAPT</u>						
N 022192 003	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>LLOPERIDONE - FANAPT</u>						
N 022192 004	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>LLOPERIDONE - FANAPT</u>						
N 022192 005	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>LLOPERIDONE - FANAPT</u>						
N 022192 006	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	8658673	Jun 02, 2020	DS DP U-1168			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	5866538	Jun 20, 2017	DP		NCE	Sep 25, 2020
	6899699	Jan 02, 2022	DP			
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	6899699	Jan 02, 2022	DP		NCE	Sep 25, 2020
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	6899699	Jan 02, 2022	DP		NCE	Sep 25, 2020
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
	7918833*PED	Mar 23, 2028				
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 205747 001	6034054	Jun 11, 2018	DP U-1707			
	6034054	Jun 11, 2018	DP U-1708			
	6551992	Jun 11, 2018	DP U-1707			
	6551992	Jun 11, 2018	DP U-1708			
	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001 >A>	8729019	Dec 26, 2028	DP			
	8912193	Jun 12, 2029	DP U-1538			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	7943572	Aug 10, 2026			U-1539	
	8424518	Oct 17, 2031	DP			
	8623817	Sep 18, 2029			U-1537	
>A>	8729019	Dec 26, 2028	DP			
	8912193	Jun 12, 2029	DP U-1538			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1697			
	8394414	May 15, 2015	DP U-1533			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
>A>	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527 001	8474447	Jan 17, 2030	DP			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001					>A> NP	Oct 22, 2018
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	DP U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	DP U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVACAFOTOR - KALYDECO</u>						
N 203188 001	8354427	Jul 06, 2026	U-1311		I-705	Dec 30, 2017
<u>IVACAFOTOR - KALYDECO</u>						
N 207925 001	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFOTOR - KALYDECO</u>						
N 207925 002	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFOTOR; LUMACAFOTOR - ORKAMBI</u>						
N 206038 001	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	8324242	Apr 18, 2027	U-1311		ODE	Jul 02, 2022
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Nov 08, 2026	DP U-1718			
	8741933	Nov 08, 2026	U-1717			
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028	U-1717			
	8993600	Dec 11, 2030	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	5952372	Sep 18, 2018	U-1631			
	6133310	Apr 26, 2019	U-1631			
	7550440	Apr 22, 2024	DP U-1631			
	8080530	Apr 22, 2024	DP U-1631			
	8093219	Apr 22, 2024	DP U-1631			
	8415311	Apr 22, 2024	DP U-1631			
	8470788	Apr 22, 2024	DP U-1631			
	8815816	Apr 22, 2024	DP U-1631			
	9089587	Mar 13, 2034	U-1631			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8946281	May 28, 2024	U-1662			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	8992952	Aug 05, 2024	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIIDRIA</u>						
N 205388 001	9066856	Oct 23, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMIVUDINE - LAMIVUDINE</u>						
A 203564 001					PC	Sep 01, 2015
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 001	5905082 5905082*PED	May 18, 2016 Nov 18, 2016	DS DP		D-147	Mar 23, 2018
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 003	5905082 5905082*PED	May 18, 2016 Nov 18, 2016	DS DP		D-147	Mar 23, 2018
<u>LAMIVUDINE - EPIVIR</u>						
N 020596 001	5905082 6004968 6004968*PED	May 18, 2016 Mar 20, 2018 Sep 20, 2018	DS DP DP U-248		D-147	Mar 23, 2018
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780 7217713 7435734 7754731 7820660	Oct 03, 2023 Oct 21, 2022 Oct 21, 2022 Mar 11, 2029 Apr 25, 2023	DS DP U-1663 U-1663 DS DP U-1663 DS			
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 001					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 002					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 003					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 004					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 004					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 005					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 006					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 002					M-159	May 18, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764	003				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764	004				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	001 >A>	9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	002 >A>	9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	003 >A>	9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	004 >A>	9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	005 >A>	9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	006 >A>	9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	001				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	002				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	003				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	004				M-159	May 18, 2018
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734	001	8980327	Dec 01, 2030	DP		
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734	002	8980327	Dec 01, 2030	DP		
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059	001	8821927	Sep 18, 2029	DS DP		
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834	001	9085573	Mar 21, 2028	DS DP U-1470		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	001	9056120	Apr 11, 2023	U-1215	I-706	Feb 17, 2018
		9101621	May 15, 2023	U-1216	ODE	Feb 17, 2022
		9101622	May 15, 2023	U-1216		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	002	9056120	Apr 11, 2023	U-1215	I-706	Feb 17, 2018
		9101621	May 15, 2023	U-1216	ODE	Feb 17, 2022
		9101622	May 15, 2023	U-1216		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS U-1211		I-706	Feb 17, 2018
	9056120	Apr 11, 2023	U-1215		ODE	Feb 17, 2022
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	7429559	Jan 13, 2019	DP			
	8815801	Jun 28, 2022	DP			
	8921326	Feb 05, 2031	DP U-1666			
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 001					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 002					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 003					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 004					M-151	Jan 22, 2018
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001					M-156	Mar 12, 2018
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	6471992	Feb 20, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	6471992	Feb 20, 2018	DP			
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 001					PC	Oct 20, 2015
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 002					PC	Oct 20, 2015
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001					NP	Feb 26, 2018
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 001	9006289	Oct 03, 2032	DP			
	>A> 9168238	Aug 29, 2032	DP			
	>A> 9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 002	9006289	Oct 03, 2032	DP			
	>A> 9168238	Aug 29, 2032	DP			
	>A> 9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 003	9006289	Oct 03, 2032	DP			
	>A> 9168238	Aug 29, 2032	DP			
	>A> 9168239	Aug 29, 2032	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8933030	Feb 17, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8933030	Feb 17, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	May 04, 2027		U-1503		
	8853156	Mar 05, 2031		U-1642		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	May 04, 2027		U-1503		
	>A> 9155705	May 21, 2030	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	May 04, 2027		U-1503		
	>A> 9155705	May 21, 2030	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	May 04, 2027		U-1503		
	>A> 9155705	May 21, 2030	DP			
<u>LINEZOLID - LINEZOLID</u>						
A 078061 001					PC	Dec 19, 2015
<u>LINEZOLID - LINEZOLID</u>						
A 200222 001					PC	Jul 04, 2015
<u>LINEZOLID - ZYVOX</u>						
N 021131 002	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINEZOLID - ZYVOX</u>						
N 021131 003	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	8846618	Jun 27, 2022	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	6268343	Aug 22, 2022	DS DP U-1255			
	6458924	Aug 22, 2017	DS DP U-1255			
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	7686786	Aug 03, 2026	DP			
	8114833	Aug 13, 2025	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 26, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	7105486	Feb 24, 2023		U-842		
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7105486	Feb 24, 2023	U-842		I-703	Jan 30, 2018
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7105486	Feb 24, 2023	U-842			
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007	7223735	Feb 24, 2023	DP		I-703	Jan 30, 2018
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2016	DS	U-1317	NCE	Dec 21, 2017
	6492365	Dec 10, 2019		U-1318	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
	8618135	Mar 07, 2025		U-1316		
<u>LORATADINE - CLARITIN</u>						
N 020641 002	6132758	Jun 01, 2018	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025		U-1252		
	8980881	Dec 20, 2025		U-1253		
	8980881	Dec 20, 2025		U-1254		
	8980881	Dec 20, 2025		U-1255		
	8999970	Feb 07, 2033		U-1688		
	8999970	Feb 07, 2033		U-1689		
	8999970	Feb 07, 2033		U-1692		
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	8955512	Oct 26, 2021	DP			
	8991387	May 21, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP	U-540		
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	RE45573	Jun 23, 2025	DS			
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778 001	9040088	Apr 22, 2024		U-755		
	9101540	Apr 22, 2024	DP	U-755		
	9101549	Apr 22, 2024		U-755		
	9107827	Apr 22, 2024		U-755		
<u>MELOXICAM - VIVLODEX</u>						
N 207233 001					>A> NP	Oct 22, 2018
<u>MELOXICAM - VIVLODEX</u>						
N 207233 002					>A> NP	Oct 22, 2018
<u>MESALAMINE - ASACOL HD</u>						
N 021830 001	9089492	Nov 15, 2021	DP			
<u>MESALAMINE - APRISO</u>						
N 022301 001	8940328	Apr 20, 2018	DP			
	8956647	Apr 20, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	9101660	Jan 22, 2027	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	9101660	Jan 22, 2027	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	9060941	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	9060941	Sep 19, 2023	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	8945063	Mar 19, 2030	DP U-1442			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8956649	Feb 15, 2031	DP U-1665			
	9040083	Feb 15, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	7893097	Feb 19, 2028	DP			
	8658678	Jun 27, 2028	U-1682			
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032	U-1664			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	8921348	Aug 27, 2028	U-1643			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9084802	May 12, 2031	U-282			
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781 001	7699609	Mar 29, 2022	DP			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002	6946120	Apr 20, 2019	DP U-702			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	8623418	Nov 07, 2029	U-1640			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	8623418	Nov 07, 2029	U-1640			
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	9114168	May 29, 2029	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001 >A>	9161914	Jan 31, 2033	U-540			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7056500	Jun 29, 2024	DP U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7056500	Jun 29, 2024	DP U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
>A>	9161937	May 10, 2022	DP U-1556			
>A>	9168252	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
>A>	9161937	May 10, 2022	DP U-1556			
>A>	9168252	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
>A>	9161937	May 10, 2022	DP U-1556			
>A>	9168252	May 10, 2022	DP U-1556			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 001	6060499	Aug 14, 2017	DP U-867			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-867			
	6586458*PED	Feb 14, 2018				
	7332183	Oct 02, 2025	DP U-867			
	7332183*PED	Apr 02, 2026				
	8022095	Aug 14, 2017	DP U-867			
	8022095*PED	Feb 14, 2018				
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 002	5872145	Aug 14, 2017	DP U-1719		NP	May 14, 2018
	5872145*PED	Feb 14, 2018			PED	Nov 14, 2018
	6060499	Aug 14, 2017	DP U-1719			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-1719			
	6586458*PED	Feb 14, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 002	7332183	Oct 02, 2025	DP U-1719			
	7332183*PED	Apr 02, 2026				
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	8921337	Mar 31, 2032	DP			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	8951969	Nov 18, 2030	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8940772	Apr 30, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8940772	Apr 30, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	7989474	Apr 06, 2024	U-1677			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	7989474	Apr 06, 2024	U-1677			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003					>A> M-167	Oct 09, 2018
<u>OLAPARIB - LYNPARZA</u>						
N 206162 001	7151102	Apr 29, 2022	DS DP		ODE	Dec 19, 2021
	7449464	Oct 11, 2024	DS DP			
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027			U-1634	
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031			U-1634	
	8912187	Mar 12, 2024			U-1634	
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	5964416	Oct 04, 2016	DP		NC	May 21, 2018
	6149054	Dec 19, 2016	DP		NCE	Jul 31, 2019
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP	U-1703		
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025	U-1702			
	8044046	Nov 10, 2023	U-1702			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP U-1702			
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	8791154	May 19, 2032	DP U-1680		NP PED	Jan 30, 2018 Jul 30, 2018
<u>OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE</u>						
N 207931 001	6037157	Jun 26, 2016	U-1635		NCE	Dec 19, 2019
	6037157*PED	Dec 26, 2016			NP	Jul 24, 2018
	6703403	Jun 26, 2016	U-1635			
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP			
	7364752*PED	May 10, 2021				
	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8420596	Apr 10, 2031	DS DP			
	8420596*PED	Oct 10, 2031				
	8642538	Sep 10, 2029	DS DP U-1638			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	9012501	Feb 07, 2025	DP U-1511			
	9050308	Jan 04, 2033	U-1511			
	9050309	Jan 04, 2033	DS			
	9132112	Feb 07, 2025	DP U-1511			
<u>OMEPRAZOLE - OMEPRAZOLE</u>						
N 022032 001	9023391	Aug 16, 2025	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 001	9095577	Jul 13, 2030	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 002	9095577	Jul 13, 2030	DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002	>A> 5763483	Aug 23, 2016	DS DP U-1113			
	>A> 5763483*PED	Feb 23, 2017				
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	8642079	Jul 09, 2028	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	9119791	Apr 13, 2027	U-1298			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	9119791	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	9119791	Apr 13, 2027	U-1298			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	8920392	Mar 26, 2031	U-1644			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9101543	Feb 21, 2026	U-1434			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 001	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 002	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 003	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 004	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9125905	Jan 30, 2024	DP			
	>A> 9173942	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9125905	Jan 30, 2024	DP			
	>A> 9173942	Jan 30, 2024	DP			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8946251	Aug 04, 2026	DS DP U-904			
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 001					>A> NCE	Oct 21, 2020
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 002					>A> NCE	Oct 21, 2020
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 003					>A> NCE	Oct 21, 2020
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002					I-710	Jun 19, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	003				I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	004				I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	005				I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	006				I-710	Jun 19, 2018
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580	001	9011905	Jun 09, 2028	DP		
		9011906	Jun 09, 2028		U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580	002	9011905	Jun 09, 2028	DP		
		9011906	Jun 09, 2028		U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580	003	9011905	Jun 09, 2028	DP		
		9011906	Jun 09, 2028		U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580	004	9011905	Jun 09, 2028	DP		
		9011906	Jun 09, 2028		U-1262	
<u>PIRFENIDONE - ESBRIET</u>						
N 022535	001	7696236	Dec 18, 2027		U-1601	
<u>POLIDOCANOL - VARITHENA</u>						
N 205098	001	RE40640	Oct 14, 2016	DS DP	U-1462	
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	001				I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	002				I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	003				I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	004				I-707	Apr 23, 2018
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469	001	9029533	Dec 22, 2026		U-836	
		9029533	Dec 22, 2026		U-1283	
		9029533	Dec 22, 2026		U-1699	
		9029533	Dec 22, 2026		U-1700	
		9029533	Dec 22, 2026		U-1701	
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469	002	9029533	Dec 22, 2026		U-836	
		9029533	Dec 22, 2026		U-1283	
		9029533	Dec 22, 2026		U-1699	
		9029533	Dec 22, 2026		U-1700	
		9029533	Dec 22, 2026		U-1701	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9023790	Jul 04, 2031	DP U-1698			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9040085	Apr 23, 2024	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9040085	Apr 23, 2024	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 003	9040085	Apr 23, 2024	U-1362			
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	9045519	Jun 22, 2019	DP			
	9085601	Feb 02, 2027	DP			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	8637553	Feb 16, 2031	DS DP			
	8680124	Jun 02, 2030	U-1506			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	6861053	Aug 11, 2019	U-1707		I-709	May 27, 2018
	6861053	Aug 11, 2019	U-1708			
	7452857	Aug 11, 2019	U-1707			
	7452857	Aug 11, 2019	U-1708			
	7605240	Aug 11, 2019	U-1707			
	7605240	Aug 11, 2019	U-1708			
	7718608	Aug 11, 2019	U-1707			
	7718608	Aug 11, 2019	U-1708			
	7915275	Feb 23, 2025	U-1707			
	7915275	Feb 23, 2025	U-1708			
	7935799	Aug 11, 2019	U-1707			
	7935799	Aug 11, 2019	U-1708			
	8193196	Sep 02, 2027	DS DP U-1707			
	8193196	Sep 02, 2027	DS DP U-1708			
	8309569	Jul 18, 2029	U-1707			
	8309569	Jul 18, 2029	U-1708			
	8741904	Feb 27, 2026	DS U-1526			
	8741904	Feb 27, 2026	DS U-1707			
	8741904	Feb 27, 2026	DS U-1708			
	8946252	Jul 24, 2029	U-1481			
	8969398	Oct 02, 2029	U-1481			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	>A> 7125879	Aug 09, 2022	DS DP U-1153		NPP	Aug 26, 2018
	>A> 7125879	Aug 09, 2022	DS DP U-1307			
	>A> 7125879	Aug 09, 2022	DS DP U-1740			
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 001					PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 002					PC	Nov 28, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132	003				PC	Nov 28, 2015
<u>RIVASTIGMINE - RIVASTIGMINE</u>						
A 204403	003				PC	Feb 29, 2016
<u>ROFLUMILAST - DALIRESP</u>						
N 022522	001	5712298	Jan 27, 2020	DS DP U-1115		
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500	001	7049230	Dec 08, 2023	DS DP U-1741	NCE	Sep 01, 2020
		7563801	Apr 04, 2027	DP		
		7981905	Apr 04, 2027	U-1741		
		7981905	Apr 04, 2027	U-1742		
		8178550	Apr 04, 2027	DS DP		
		8361500	Oct 09, 2029	DP		
		8404702	Oct 09, 2029	U-1741		
		8470842	Jan 18, 2029	U-1741		
		8796299	Dec 17, 2022	U-1741		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	001	9079912	Dec 12, 2026	U-1573		
		9079912	Dec 12, 2026	U-1721		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	002	9079912	Dec 12, 2026	U-1573		
		9079912	Dec 12, 2026	U-1721		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	003	9079912	Dec 12, 2026	U-1573		
		9079912	Dec 12, 2026	U-1721		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	004	9079912	Dec 12, 2026	U-1573		
		9079912	Dec 12, 2026	U-1721		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	005	9079912	Dec 12, 2026	U-1573		
		9079912	Dec 12, 2026	U-1721		
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620	001	7468390	Nov 27, 2023	DP	NCE	Jul 07, 2020
		8101659	Jan 14, 2023	DP		
		8404744	Jan 14, 2023	DP		
		8796331	Jan 14, 2023	U-1723		
		8877938	May 27, 2027	DS DP		
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620	002	7468390	Nov 27, 2023	DP	NCE	Jul 07, 2020
		8101659	Jan 14, 2023	DP		
		8404744	Jan 14, 2023	DP		
		8796331	Jan 14, 2023	U-1723		
		8877938	May 27, 2027	DS DP		
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620	003	7468390	Nov 27, 2023	DP	NCE	Jul 07, 2020
		8101659	Jan 14, 2023	DP		
		8404744	Jan 14, 2023	DP		
		8796331	Jan 14, 2023	U-1723		
		8877938	May 27, 2027	DS DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9040562	Jul 28, 2026	DS DP U-1467		>A> D-151 >A> I-717	Oct 05, 2018 Oct 05, 2018
<u>SIROLIMUS - RAPAMUNE</u>						
N 021083 001					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 001					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 002					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 003					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 004					ODE	May 28, 2022
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8952062	Dec 22, 2019	U-1101			
	8952062	Dec 22, 2019	U-1102			
	9050302	Mar 15, 2033	U-1532			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9085573	Mar 21, 2028	DS DP U-1470			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	5849700	Dec 15, 2015	U-1041			
	5849704	Dec 15, 2015	DS DP U-1041			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>SONIDEGIB PHOSPHATE - ODOMZO</u>						
N 205266 001	8063043	Sep 15, 2029	DS DP		NCE	Jul 24, 2020
	8178563	Feb 06, 2029	DS U-1722			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	8124630	Jan 12, 2020	U-1459			
	8841330	Jan 12, 2020	U-1696			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SPINOSAD - NATROBA</u>						
N 022408 001	6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	8983594	Nov 19, 2030	DP U-1328			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	>A> 8486993	Aug 30, 2024	DP U-1752			
	>A> 8586084	Aug 30, 2024	U-1752			
	>A> 8591946	Aug 30, 2024	DP			
	>A> 8617599	Aug 30, 2024	DP			
	>A> 8623410	Aug 30, 2024	DP			
	>A> 8623411	Aug 30, 2024	U-1752			
	>A> 8664239	May 30, 2028	U-1752			
	>A> 8685998	May 30, 2028	DP U-1752			
	>A> 8889185	Aug 30, 2024	U-1752			
	>A> 8889186	Aug 30, 2024	U-1752			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	>A> 8486993	Aug 30, 2024	DP U-1752			
	>A> 8586084	Aug 30, 2024	U-1752			
	>A> 8591946	Aug 30, 2024	DP			
	>A> 8617599	Aug 30, 2024	DP			
	>A> 8623410	Aug 30, 2024	DP			
	>A> 8623411	Aug 30, 2024	U-1752			
	>A> 8664239	May 30, 2028	U-1752			
	>A> 8685998	May 30, 2028	DP U-1752			
	>A> 8889185	Aug 30, 2024	U-1752			
	>A> 8889186	Aug 30, 2024	U-1752			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	>A> 8486993	Aug 30, 2024	DP U-1752			
	>A> 8586084	Aug 30, 2024	U-1752			
	>A> 8591946	Aug 30, 2024	DP			
	>A> 8617599	Aug 30, 2024	DP			
	>A> 8623410	Aug 30, 2024	DP			
	>A> 8623411	Aug 30, 2024	U-1752			
	>A> 8664239	May 30, 2028	U-1752			
	>A> 8685998	May 30, 2028	DP U-1752			
	>A> 8889185	Aug 30, 2024	U-1752			
	>A> 8889186	Aug 30, 2024	U-1752			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 001	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 002	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 003	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 004	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 005	8536130	Sep 22, 2028	U-1739			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9060995	Jan 25, 2033	U-1710			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2016	DS DP U-1320			
	9060992	Nov 01, 2025	U-1320			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	9125816	Aug 30, 2020	U-1103			
	9132089	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	9125816	Aug 30, 2020	U-1103			
	9132089	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	9125816	Aug 30, 2020	U-1103			
	9132089	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8435944	Sep 27, 2027	U-1390			
	8993520	Jun 02, 2026	U-1390			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001					I-714	Sep 03, 2018
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6251910	Jul 15, 2018	DS		>A> NCE	Jul 20, 2016
	6525060	Dec 02, 2019	DS DP U-1171		NS	Sep 03, 2018
	7250419	Dec 02, 2019	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1171			
	>A> 8425934	Apr 17, 2030	DP			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8975242	Oct 24, 2028	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	5964416	Oct 04, 2016	DP		NP	Sep 15, 2018
	6149054	Dec 16, 2016	DP			
	6176442	May 31, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	>A> 5744475	Mar 28, 2016	DS DP U-1751		NCE	Sep 22, 2020
	>A> 6479500	Mar 16, 2020	U-1751			
	>A> 7799783	Dec 16, 2026	U-1751			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	>A> 5744475	Mar 28, 2016	DS DP U-1751		NCE	Sep 22, 2020
	>A> 6479500	Mar 16, 2020	U-1751			
	>A> 7799783	Dec 16, 2026	U-1751			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9101545	Mar 19, 2033	DP			
<u>TRABECTEDIN - YONDELIS</u>						
N 207953 001					>A> NCE	Oct 23, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8957113	Mar 04, 2025	DP U-1182			
	9060939	Mar 04, 2025	DP			
<u>TRAVOPROST - IZBA</u>						
N 204822 001	8178582	Oct 10, 2029	DP			
	9144561	Mar 13, 2029	DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 001	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 002	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 003	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 004	8133893	Mar 13, 2029	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TRETINOIN - RETIN-A-MICRO</u>						
N 020475 003	5955109	Sep 21, 2016	DP U-134			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	>A> 8512745	Jun 02, 2030	DP			
	8962603	Jun 12, 2030	U-1657			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8511304	Jun 14, 2027	DP U-1476			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	>A> 6258795	Jul 10, 2018	DP		NCE ODE	Sep 04, 2020 Sep 04, 2022
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001					D-146	Mar 16, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003					D-146	Mar 16, 2018
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027		U-1668		
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 003					NPP	Jun 12, 2018
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 004					NPP	Jun 12, 2018

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>